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Esophageal cancer
Worldwide, esophageal cancer is the eighth most common cancer and 
the sixth most common cause of death from cancer, with an estimated 
456,000 new cases (3.2% of total) and 400,000 deaths (4.9% of total) in 
2012.1 Esophageal cancer has two main histological subtypes — eso-
phageal squamous cell carcinoma and esophageal adenocarcinoma. 
Esophageal squamous cell carcinoma accounts for approximately 90% 
of esophageal cancer cases worldwide. While historically esophageal 
adenocarcinoma has been rare, it has been associated with a rapid rise 
in incidence over the last decades, especially in Western countries.2-4 
Consequently, esophageal adenocarcinoma is now the most prevalent 
esophageal cancer subtype in Western European and North American 
countries. In The Netherlands, approximately 2,550 new cases of eso-
phageal cancer were reported in 2014, of which approximately 1,750 
(69%) cases were of the adenocarcinoma subtype.5 
Prognostication 
In the field of oncology, prognosis usually relates to the probability of 
survival or disease recurrence over a specific period, based on patient, 
tumor and treatment related characteristics. Therefore, prognostica-
tion deals with estimating how long a patient is expected to survive (or 
be without disease recurrence), given the presence (or absence) of cer-
tain prognostic characteristics. Medical prognostication and prognostic 
models are mainly used to inform patients and their treating physicians 
about the expected future course of their illness and to guide decisions 
on further treatment, if any.6
In patients with cancer of the esophagus or esophagogastric junction, 
several prognostic factors for long-term survival after primary surgical 
resection have been identified. Important, patient related prognostic 
factors include age7,8, gender8-11 and pretreatment weight loss12, 13. The 
extent of esophageal cancer progression is usually classified using the 
Union for International Cancer Control (UICC) tumor (T), node (N) and 
metastasis (M) staging system.14 Where the T-stage indicates the ex-
tent of the primary tumor depth of invasion in the esophageal wall, the 
N-stage indicates the number of tumor positive regional lymph nodes 
and the M-stage indicates the presence of distant dissemination to 
other organs. This categorization corresponds with a decreasing prob-
ability of survival (i.e. M1 is associated with a worse prognosis than N3, 
and N1 is associated with a worse prognosis than T3). The TNM-stage 
is used to direct treatment choices before start of treatment and to 
estimate the probability of survival after completion of treatment. 
An important treatment related prognostic factor is surgical radicali-
ty15-17, i.e. the completeness of surgical tumor removal. However, most 
of these well-established prognostic factors have been identified and 
validated in the era of primary surgical resection. 
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Results from the CROSS trial show that the addition of neoadjuvant 
chemoradiotherapy (carboplatin, paclitaxel and 41.4 Gy of concurrent 
radiotherapy) to surgery significantly increases survival as compared 
to surgery alone. Therefore, neoadjuvant chemoradiation plus surgery 
is now considered the standard of care in The Netherlands for poten-
tially curable esophageal cancer (cT2-4a N0-3 M0 and cT1 N1-3 M0, 
according to the UICC TNM classification, 7th ed.14) in patients fit to 
undergo this treatment.
New treatment strategy 
In subsequent analyses of secondary endpoints of the CROSS trial a 
striking finding was made.33 In the nCRT group 49% of patients with 
a squamous cell carcinoma and 23% of patients with an adenocarci-
noma had a pathologically complete response (pCR) in the resection 
specimen (i.e. no viable tumor cells were found at the site of the pri-
mary tumor or in the resected regional lymph nodes, as determined by 
conventional histological examination). Therefore, these results impose 
an ethical imperative to reconsider and study the necessity of standard 
esophagectomy, which is associated with severe postoperative morbid-
ity and a substantial impact on the quality of life23,25-27, in all patients 
after application of the CROSS-regimen. Under analogous conditions, 
a non-operative management in rectal cancer patients with a clinically 
complete response after nCRT has been shown feasible and safe, lead-
ing to organ-sparing treatment with low morbidity and mortality rates 
and favorable long-term survival in a subset of these rectal cancer 
patients.34-36
Outline of the thesis
The research in this thesis addresses issues concerning prognostication 
and a new treatment strategy for potentially curable esophageal or 
esophagogastric junction cancer. The thesis is divided into two parts. 
Part I focusses on the prediction of survival using conventional and 
more novel prognostic factors in patients with esophageal or junction-
al cancer. While Part II focusses on the long-term survival benefit of 
neoadjuvant chemoradiotherapy plus surgery (as compared to surgery 
alone) and on the feasibility of a new treatment strategy for a subset 
of patients with potentially curable esophageal or junctional cancer. 
Treatment of esophageal cancer
Presently, surgical resection is considered the cornerstone of inten-
tionally curative treatment in the Netherlands for patients eligible (i.e. 
stages cT1b-4aN0-3M0) to undergo surgical resection. In the inter-
national literature reported 5-year survival rates for patients treated 
with primary surgical resection range from 6 to 50%, but rarely exceed 
35%.18-22 However, esophageal resections are associated with periop-
erative mortality rates of 1-5% in high-volume centers, severe postop-
erative morbidity and a substantial impact on the quality of life.23-28 In 
order to improve the radicality of surgical resection and the long term 
survival after surgical resection many trials have been performed to 
study the additional value of (neo-) adjuvant chemo- and/or radiation 
therapy.29-32 One of the largest and most recent of these trials is the 
Dutch multicenter randomized CROSS trial (ChemoRadiotherapy for 
Oesophageal cancer followed by Surgery Study), which compared neo-
adjuvant chemoradiotherapy plus surgery to surgery alone.33 
The recently completed CROSS trial was a multicenter, randomized 
phase III trial,33 which started in March 2004 and included and ana-
lyzed 366 patients during a 5-year period. It included patients from 5 
academic and 2 non-academic high-volume teaching hospitals in The 
Netherlands. The study compared neoadjuvant chemoradiotherapy 
(nCRT) followed by surgery with surgery alone in patients with po-
tentially curable esophageal cancer (cT2-3 N0-1 M0 and cT1 N1 M0, 
according to the UICC TNM classification, 6th ed.33), with a planned 
inclusion of 175 patients per arm. The neoadjuvant regimen consisted 
of carboplatin (AUC=2) and paclitaxel (50 mg/m2) given by intravenous 
infusion on days 1, 8, 15, 22 and 29, combined with concurrent radi-
ation therapy delivered using a multiple field technique. A total dose 
of 41.4 Gy was given in 23 fractions of 1.8 Gy, 5 fractions per week, 
starting on the first day of the first cycle of chemotherapy. The aim 
of this trial was to compare overall survival between patients treated 
with nCRT followed by surgery and patients treated with surgery alone 
for potentially curable, esophageal adenocarcinoma or squamous cell 
carcinoma. The most common toxic effects in the chemoradiotherapy 
followed by surgery group were leukopenia (6%), anorexia (5%), fatigue 
(3%) and neutropenia (2%). Median overall survival of patients who 
received nCRT plus surgery was 49 months, compared to 24 months 
for those who received surgery alone. With a median follow-up of 32 
months, 70 patients had died in the nCRT group versus 97 in the sur-
gery-alone group. Three-year overall survival was superior in the nCRT 
arm (HR 0.66; 95% confidence interval 0.50-0.87; p=0.003).
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Part I
Prognostication for esophageal and junctional cancer
In patients with cancer of the esophagus or esophagogastric junction, 
several prognostic factors for long-term survival after primary surgical 
resection have been identified. These include age7,8, gender8-11, weight 
loss12,13, histological tumor subtype37,38, tumor location39-41, tumor 
length42-44, clinical TNM-stage45-47, tumor grade37,48, surgical radicali-
ty15-17 and pathological TNM-stage41,49. Prediction models have been 
developed to predict overall survival in individual patients, based on 
these prognostic factors.50,51 However, most of these well-established 
prognostic factors have been identified and validated in the era of pri-
mary surgical resection. In chapter 1 we quantify the impact of nCRT 
on these well-established prognostic factors, and develop and validate 
a prognostic model for patients treated with nCRT plus surgery for es-
ophageal or junctional cancer. In patients undergoing nCRT, pretreat-
ment stage can only be estimated using endoscopic ultrasonography 
(EUS), computed tomography (CT) and more recently positron emission 
tomography (PET) for the T- and N-stages and is known to be relative-
ly inaccurate, especially for the N-stage.52,53 In chapter 2 we introduce 
and validate a novel method of determining pretreatment tumor ex-
tent, based on the extent of regressional changes (e.g. fibrosis, mu-
cous lakes, keratin pearls, and/or foreign body giant cell reactions) and 
on the presence of residual tumor cells in the resection specimen. We 
determine the interobserver reproducibility of this new pretreatment 
pathological staging system, we compare this pretreatment patholog-
ical staging system with the pretreatment clinical staging system and 
we determine the value of this new pretreatment pathological stag-
ing system for posttreatment prognostication. As nCRT is known to 
frequently ‘sterilize’ regional lymph nodes, it is unclear whether extend-
ed lymphadenectomy after nCRT is still indicated for prognostic and 
therapeutic reasons. In chapter 3 we compare the prognostic impact 
of total number of resected nodes and the number of resected positive 
nodes between patients who underwent nCRT plus surgery or surgery 
alone for esophageal or junctional cancer. In chapter 4 we create and 
validate a small optimized panel of immunohistochemistry markers 
that could be used to segregate patients with esophageal adenocarci-
noma into different prognostic groups.
Part II
New treatment strategy for esophageal and junctional cancer
The CROSS trial compared nCRT plus surgery to surgery alone in squa-
mous cell carcinoma and adenocarcinoma of the esophagus or esoph-
agogastric junction. Initial results, after a median follow-up 45 months, 
showed an absolute increase in five-year overall survival of 13% in 
favor of the nCRT plus surgery group. In chapter 5 we report the long-
term results of the CROSS trial and we analyze secondary end-points, 
such as progression-free survival and recurrence patterns. It is ques-
tionable whether patients with a pathologically complete response 
(pCR) in the resection specimen after nCRT have sufficient addition-
al benefit to justify subsequent standard esophagectomy. Therefore, 
these high complete response rates impose a strong ethical impera-
tive to clinically identify patients with pCR after nCRT. Several studies 
have tried to identify patients with pCR after nCRT using convention-
al endoscopy with histological biopsies, endoscopic ultrasonography 
(EUS), computed tomography (CT) and positron emission tomography 
(PET)54-60. However, results from these studies have been mostly dis-
appointing. Before a watchful waiting policy can be safely considered 
in a subgroup of patients with esophageal cancer after nCRT, a better 
insight into the exact location of residual tumor in the  esophageal wall 
and regional lymph nodes is needed. Therefore, in chapter 6 we de-
scribe the exact location of residual tumor in the esophageal wall and 
resected lymph nodes after nCRT and we describe the tumor regres-
sion pattern of esophageal cancer as induced by nCRT. It remains un-
clear, however, whether time to surgery (TTS; i.e. the interval between 
the last day of nCRT and the day of surgery) has an impact on pCR 
rate, on short-term surgical outcome and on long-term survival. Theo-
retically, prolonged TTS might increase pCR rate and possibly improve 
disease-free survival because of a prolonged effect of nCRT. Converse-
ly, prolonged TTS might lead to residual tumor outgrowth, increased 
difficulty of surgical resection with a higher postoperative complication 
rate and possibly a worse overall survival. In chapter 7 we investigate 
the impact of TTS after nCRT on pCR rate, short-term surgical out-
come and disease-free and overall survival in a cohort of patients with 
potentially curable esophageal or junctional cancer, who underwent 
nCRT according to CROSS33 followed by surgical resection. Finally, in 
chapter 8, we describe the study protocol of a single arm diagnostic 
feasibility trial (preSANO, Dutch Trial Register NTR4834)61 which is cur-
rently running in several Dutch high volume centers and aims to deter-
mine the accuracy of clinically detecting or predicting the presence of 
residual disease after nCRT.
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Table 1 — Overview of studies in the thesis
RCT: randomized controlled trial
CROSS-I cohort: nCRT plus surgery, single center non-randomized feasibility trial62 
(n=51, 2001–2004) 
CROSS-II cohort: nCRT plus surgery or surgery alone, Dutch multicenter randomized 
controlled trial33 (n=178/188, 2004–2009)
post-CROSS cohort: nCRT plus surgery, standard of care, 2009–2013).
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Chapter
2
3
4
5
Chapter
6
7
8
Design
Retrospective cohort 
The Netherlands
Retrospective cohort 
Rotterdam and 
Amsterdam
RCT  
The Netherlands
Retrospective cohort 
Rotterdam, Pittsburgh 
and Cambridge
Design
RCT  
The Netherlands
Retrospective cohort  
Rotterdam
Retrospective cohort  
Rotterdam
Sample
Patients with esophageal 
or junctional cancer, 
treated with surgery 
alone or nCRT plus sur-
gery (CROSS-I, CROSS-II 
and post-CROSS)
Patients with esophageal 
or junctional cancer, 
treated with nCRT plus 
surgery (CROSS-II and 
post-CROSS)
Patients with esophageal 
or junctional cancer, 
treated with surgery 
alone or nCRT plus 
surgery, who under-
went surgical resection 
(CROSS-II)
Patients with esophageal 
or junctional adenocar-
cinoma, treated with 
surgery alone
Sample
Patients with esophageal 
or junctional cancer, 
treated with surgery 
alone or nCRT plus sur-
gery (CROSS-II)
Patients with esophageal 
or junctional cancer, 
treated with nCRT 
plus surgery (CROSS-I, 
CROSS-II and post-
CROSS)
Patients with esophageal 
or junctional cancer, 
treated with nCRT 
plus surgery (CROSS-I, 
CROSS-II and post-
CROSS)
Population
1.017
180
320
1.040
Population
366
102
325
Research focus
To determine the prog-
nostic value of patient, 
disease and treatment 
related characteristics
To determine the 
prognostic value of pre-
treatment pathological 
tumor extent 
To determine the 
prognostic value of 
number of lymph nodes 
resected and number 
of positive lymph nodes 
resected
To validate the prog-
nostic value of epi-
dermal growth factor 
receptor (EGFR), tripar-
tite motif-containing 44 
(TRIM44), and sirtuin 2 
(SIRT2) 
Research focus
To determine the 
long-term overall and 
progression-free surviv-
al benefit of nCRT plus 
surgery as compared to 
surgery alone
To describe the exact 
location of residual 
tumor in the esopha-
geal wall and resected 
lymph nodes after 
nCRT
To determine the im-
pact of time to surgery 
after nCRT on pCR rate, 
surgical outcome and 
survival
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Abstract
Background 
The value of conventional prognostic factors is unclear in the era of 
multimodality treatment for esophageal cancer. This study aimed to 
quantify the impact of neoadjuvant chemoradiotherapy (nCRT) on 
well-established prognostic factors and to develop and validate a prog-
nostic model.
Methods 
Patients treated with surgery alone or with nCRT plus surgery were 
included. Multivariable Cox modeling was used to identify prognostic 
factors for overall survival, with treatment included as an interaction. 
A prediction model for individual survival was developed using step-
wise backward selection in nCRT plus surgery patients. The model was 
internally and cross-validated and a nomogram was designed for use 
in clinical practice.
Results 
In total, 1017 patients were included, 391 in the surgery alone group 
and 626 in the nCRT plus surgery group. Independent prognostic fac-
tors in the surgery alone group were age, tumor histology, surgical 
approach, radicality, pT-stage and pN-stage. Whereas, in the nCRT plus 
surgery group, only cN-stage and pN-stage remained. Tumor histolo-
gy, surgical approach and pT-stage were significantly less prognostic, 
while cN-stage was significantly more prognostic in patients treated 
with nCRT plus surgery. The final prognostic model included cN-stage, 
pT-stage and pN-stage and had moderate discrimination (c-index at 
internal validation 0.63).
Conclusion 
In nCRT plus surgery patients, only pretreatment cN-stage and post-
treatment pN-stage remain as independent prognostic factors. The 
final prediction model, based on cN-stage, pT-stage and pN-stage, has 
moderate discriminatory ability. These results strengthen the need for 
new prognostic factors to improve survival prediction in the era of mul-
timodality treatment for esophageal cancer.
Introduction
In patients with cancer of the esophagus or esophagogastric junction, 
several pretreatment prognostic factors for long-term survival after 
primary surgical resection have been identified. These include age1,2, 
gender2-5, weight loss6,7, histological tumor subtype8,9, tumor loca-
tion10-12, tumor length13-15 and clinical TNM-stage16,17. Well-established 
prognostic factors which become available after esophagectomy in-
clude surgical approach18,19, surgical radicality20-22, tumor grade8,23 and 
pathological TNM-stage.12,24 Prediction models have been developed to 
predict overall survival in individual patients, based on these prognostic 
factors.25,26 However, most of these well-established prognostic fac-
tors have been identified and validated in the era of primary surgical 
resection. 
Recent studies show that the addition of neoadjuvant chemoradiother-
apy (nCRT) to surgery substantially improves locoregional control and 
long-term survival as compared to surgery alone.27,28 In many countries, 
nCRT plus surgery is now standard of care for these patients. Howev-
er, the value of conventional prognostic factors and the accuracy of 
models for individual survival prediction are still unclear in the context 
of current multimodality treatment strategies and have not yet been 
investigated in a large patient cohort.
We aim (I) to quantify the impact of nCRT on several well-established 
prognostic factors, and (II) to develop and validate a prognostic model 
in patients treated with nCRT plus surgery for esophageal or junctional 
cancer.
Methods
Patient selection
Patients were included, who were treated with surgery alone as stand-
ard of care (pre-CROSS, 1993–2001), with nCRT plus surgery as part 
of the single-center non-randomized CROSS-I trial29 (2001–2004), with 
surgery alone or nCRT plus surgery as part of the multicenter rand-
omized controlled CROSS-II trial28 (2004–2009), or with nCRT plus 
surgery as standard of care at the Erasmus MC, Rotterdam, The Neth-
erlands or at the Academic Medical Center, Amsterdam, The Nether-
lands (post-CROSS, 2009–2013). Both squamous cell carcinoma (SCC) 
and adenocarcinoma (AC) histologies were included. Patients who did 
not receive at least 80% of the planned dose of chemoradiotherapy, 
who received a different nCRT regimen or in whom surgical resection 
was not completed were excluded. Inclusion criteria of the randomized 
CROSS-II trial28 were retrospectively applied to patients treated with 
2322 Part I - Chapter 2
surgery alone as part of standard of care, i.e. only those patients were 
included, who underwent the complete staging protocol and who had 
locally advanced disease (cT2-T4a or cT1N+). 
Clinical staging
In all patients, pretreatment staging included endoscopy with biopsy, 
endoscopic ultrasonography (with fine needle aspiration [FNA] when 
indicated), CT scan of the neck, chest and abdomen and external ul-
trasonography of the neck (with FNA when indicated). PET scans were 
not routinely performed during this study period but were performed 
in some patients when available and indicated. Tumor location and 
tumor length were determined by pretreatment endoscopy. Clinical 
T-stage and N-stage were determined by endoscopic ultrasonography 
and CT-scanning with or without FDG-PET-scanning according to the 
Union for International Cancer Control (UICC) TNM Cancer Staging, 6th 
edition.30
Neoadjuvant and surgical treatment
Neoadjuvant chemoradiotherapy (nCRT) was given according to the 
CROSS regimen.28,29 For carcinomas at or above the level of the carina 
a transthoracic esophageal resection (TTE) with a two-field lymph node 
dissection was performed. For carcinomas located well below the level 
of the carina, either TTE with two-field lymph node dissection or a tran-
shiatal esophageal resection (THE) was performed depending on fitness 
of the patient and preference of the surgeon. For carcinomas involving 
the esophagogastric junction, THE was the preferred technique. In both 
the transthoracic and the transhiatal approach, an upper abdominal 
lymphadenectomy was performed, including resection of nodes along 
the hepatic artery, splenic artery and origin of the left gastric artery. 
Open- as well as minimally invasive techniques were used.
Pathological assessment
All histopathological parameters were prospectively collected. Tumor 
histology was determined based on the pretreatment biopsy, while 
tumor grade was determined in the resection specimen only. In the 
absence of residual tumor in the resection specimen, tumor grade was 
scored as ‘non determinable’ (Gx). A microscopically radical resec-
tion (R
0
) was defined as a tumor-free resection margin ≥1 mm. R
1
 was 
defined as a macroscopically radical resection, with a microscopically 
tumor-free resection margin <1 mm. Pathological T-stage and N-stage 
were (re)scored according to the UICC TNM Cancer Staging, 7th edi-
tion31. The tumor regression grade (TRG) was scored using the system 
as reported by Chirieac et al.32,33.
Follow-up and data collection
Clinical and surgical characteristics were collected from prospective-
ly maintained institutional databases. Survival was determined using 
hospital records and municipal registers. Survival was limited at five 
years to reduce the effect of death by other causes. 
Data analysis 
Data were described as medians with an interquartile range in case 
of continuous variables and frequencies with percentages in case of 
categorical variables. Grouped data were compared using Student’s 
t-test and Pearson’s chi-squared test. An advanced multiple imputa-
tion approach was used to impute missing data, resulting in five sep-
arate datasets.34 Categories with less than 20 cases were combined 
with related categories. Weight loss was truncated at 10 kilograms 
(=p95). During imputation pT0 was set to combine with TRG1 and Gx. In 
the total patient cohort, hazard ratios (HRs), with corresponding 95% 
confidence intervals (CIs) were calculated using a multivariable Cox 
proportional-hazards model, with treatment (i.e. surgery alone or nCRT 
plus surgery) included as an interaction in the analysis. The following 
characteristics were included: age, gender, weight loss, tumor histology, 
tumor location, tumor length, clinical T-stage (cT), clinical N-stage (cN), 
surgical approach, radicality of resection, tumor grade in the resec-
tion specimen, pathological T-stage (pT), pathological N-stage (pN) and 
tumor regression grade (TRG). Survival was calculated from the end of 
therapy (day of surgery in both treatment groups) until death or end of 
follow-up. Differences in prognostic impact of the various characteris-
tics were quantified by including statistical interaction terms for the two 
treatment groups (‘treatment interaction’), defined as the HR associat-
ed with a characteristic among patients undergoing nCRT plus surgery 
divided by the HR for the same characteristic among patients undergo-
ing surgery alone (i.e. HR
nCRT+S
/HR
S
). Significance was set to p<0.05. 
Development, validation and visualization of prognostic model 
A prognostic model was developed in the nCRT plus surgery group, us-
ing stepwise backward selection, where variables were excluded from 
the model in a stepwise manner, testing for the significance of elimi-
nation per variable35, until no further improvement was achieved. The 
prognostic model was internally validated by correcting for optimism 
and cross-validated by dividing the total nCRT plus surgery cohort 
into a cohort with patients from the Erasmus MC, Rotterdam, and a 
cohort with patients from all other centers. Where the prognostic was 
developed in one cohort and validated in the other, and vice versa. The 
model was tested for prognostic accuracy, using Harrell’s concord-
ance-index (c-index).36 The c-index determines for two randomly cho-
sen subjects the probability that the model predicts a higher risk for 
the subject with poorer outcome. Analyses were performed using the 
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following R-packages37: ‘multivariate imputation by chained equations’ 
(mice)34, ‘regression modeling strategies’ (rms)38. 
The prognostic strength of individual risk factors in the prognostic 
model were visualized in a nomogram. The weights for each category 
within an individual risk factor were calculated by multiplying the orig-
inal coefficients of the multivariable Cox model with ten and rounding 
the result to the lowest whole number. The total number of points de-
rived from all predictors was used to calculate the expected one-year 
and five-year overall survival rates. 
Results
Patient, tumor and treatment related characteristics
In total, 1017 patients were included, of whom 391 were treated with 
surgery alone and 626 were treated with nCRT plus surgery. Medi-
an age at diagnosis was 63 years (table 1). Most patients were male 
(79%), had an adenocarcinoma (77%), most often clinically staged as 
cT3 (77%). Significant differences were found between surgery alone 
patients and nCRT plus surgery patients for weight loss (p=0.001), 
tumor location (p=0.045) and clinical N-stage (p<0.001) (table 1). Also, 
a transhiatal approach was performed significantly more often in the 
surgery alone group as compared to the nCRT plus surgery group 
(p<0.001).
Prognostic factors in patients treated 
with surgery alone or nCRT plus surgery
In patients treated with surgery alone, independent prognostic factors 
for overall survival were age (HR per decade=1.21 95%CI 1.05–1.40 
p=0.009), tumor histology (HR SCC vs. AC=1.93 95%CI 1.36–2.75 
p<0.001), surgical approach (HR TTE or other vs. THE=0.74 95%CI 
0.55–0.98 p=0.036), radicality (HR R
1
-R
2
 vs. R
0
=1.63 95%CI 1.25–
2.13 p<0.001), pT-stage (HR pT3-pT4 vs. pT1=3.35 95%CI 1.64–6.85 
p=0.001) and pN-stage (HR pN1 vs. pN0=2.07 95%CI 1.41–3.04 
p<0.001, HR pN2 vs. pN0=2.99 95%CI 2.01–4.46 p<0.001 and pN3 vs. 
pN0=4.57 95%CI 3.01–6.95 p<0.001) (table 2). Whereas, in patients 
treated with nCRT plus surgery, the only independent prognostic fac-
tors were cN-stage (HR cN1 vs. cN0=1.46 95%CI 1.09–1.95 p=0.012) 
and pN-stage (HR pN1 vs. pN0=1.78 95%CI 1.32–2.39 p<0.001, HR 
pN2 vs. pN0=1.98 95%CI 1.29–3.02 p<0.001 and pN3 vs. pN0=4.34 
95%CI 2.38–7.93 p<0.001). Specifically, TRG was not prognostic for 
survival (HR TRG1 vs. TRG2=0.77 95%CI 0.52–1.12, HR TRG3 vs. 
TRG2=1.21 95%CI 0.85–1.72 and TRG4 vs. TRG2=1.03 95%CI 0.69–
1.54). This was also not the case when different groupings of TRG39-41 
were tested (data not shown).
A significant difference in prognostic value between the two treatment 
groups (i.e. treatment interaction) was identified for tumor histology 
(HR
nCRT
+S/HRS SCC vs. AC=0.40 95%CI 0.24–0.67, P
interaction
=0.001), 
indicating that tumor histology significantly decreased in prognos-
tic value in the nCRT plus surgery group (i.e. the HR between sub-
groups decreased). Significant treatment interaction was also identi-
fied for cN-stage (HR
nCRT
+S/HRS cN1 vs. cN0=1.55 95%CI 1.04–2.31, 
 P
interaction
=0.030), surgical approach (HR
nCRT
+S/HRS TTE vs. THE=1.56 
95%CI 1.04–2.33, P
interaction
=0.030) and pT-stage (HR
nCRT
+S/HRS pT3-pT4 
vs. pT1=0.34 95%CI 0.15–0.78, P
interaction
=0.011). These results indicate 
that clinical N-stage significantly improved in prognostic value in the 
nCRT plus surgery group, while surgical approach and pT-stage signifi-
cantly decreased in prognostic value. 
Prediction model for survival in patients treated 
with nCRT plus surgery
After stepwise backward selection, the final prediction model includ-
ed cN-stage, pT-stage and pN-stage. Discrimination of the prediction 
model was moderate (c-index at internal validation 0.63). Cross-vali-
dation between the Erasmus MC cohort (n=246) and the other centers 
(n=380) was comparable (c-index 0.62 and 0.63, resp.). Discrimination 
of the prediction model was higher in surgery alone patients (c-index 
0.66). Finally, a nomogram was constructed (figure 1) to allow for in-
dividual one-year and five-year overall survival estimations, based on 
the three variables included in the final prediction model. As an exam-
ple, patients with pretreatment suspicion of nodal disease (cN1) and a 
complete response in the resection specimen (pT0, pN0) would have a 
total of two points, which corresponds with an estimated one-year and 
five-year survival rate of 88% and 62%, respectively. 
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Discussion
In this large and comprehensive study on patients with esophageal 
or junctional cancer, only clinical N-stage (cN-stage) and pathological 
N-stage (pN-stage) remained as independent prognostic factors in pa-
tients treated with neoadjuvant chemoradiotherapy (nCRT) plus surgery. 
Pathological T-stage (pT-stage) was added to the final prediction model 
for these patients after backward selection. Tumor histology, surgical 
approach and pT-stage were significantly less prognostic, while cN-stage 
was significantly more prognostic in patients treated with nCRT plus sur-
gery as compared to patients who underwent surgery alone. 
By using a single statistical model, which included both treatment 
groups, specific effects of nCRT on prognostic factors could be deter-
mined, independent from the effects of surgery. Results indicate an 
overall decrease in significance and in number of independent prog-
nostic factors in patients treated with nCRT plus surgery. Interesting-
ly, there was no overlap in significant independent prognostic factors 
between the two treatment groups, except for pN-stage, confirming 
previous reports42,43, and thus underlining the continued significance of 
pN-stage as an important prognostic factor in the era of multimodality 
treatment.42-45 
Surprisingly, pretreatment clinical N-stage (cN-stage) increased in 
prognostic value in patients treated with nCRT plus surgery. In patients 
treated with surgery alone, cN-stage and pathological N-stage (pN-
stage) are different estimations of the same disease state (i.e. pre-
treatment clinical estimation and posttreatment pathological estima-
tion, resp.). Clinical N-stage is known to be relatively inaccurate46,47 and 
therefore has little additional prognostic value (on top of pN-stage) in 
patients treated with surgery alone. However, in patients treated with 
nCRT plus surgery, cN-stage is no longer necessarily similar to pN-
stage. By definition, cN-stage is an estimation of nodal involvement be-
fore nCRT, while pN-stage is an estimation of nodal involvement after 
nCRT. Therefore, cN-stage and pN-stage represent different disease 
states in these patients and cN-stage, although relatively inaccurate, 
had additional prognostic value, as was seen in these analyses. 
Another important finding is that surgical approach lost prognostic 
value in patients treated with nCRT plus surgery. In patients treat-
ed with surgery alone, a transthoracic approach was associated with 
a significantly more favorable prognosis as compared to a transhi-
atal approach, whereas in patients treated with nCRT plus surgery, a 
transthoracic approach was associated with a non-significantly less 
favorable prognosis. These findings suggest that in patients treated 
with nCRT plus surgery, the benefit of a transthoracic approach is at 
best limited and the necessity for maximization of surgical lymph node 
retrieval should be questioned. However, only a new randomized trial, 
comparing these two surgical approaches (with their inherent differ-
ences in extent of lymphadenectomy) after neoadjuvant treatment will 
offer a more definitive answer.
 
The final prognostic model had moderate discriminatory ability in 
patients treated with nCRT plus surgery, which is lower than what 
is generally reported for other tumor types after neoadjuvant treat-
ment.48-50 Interestingly, the model (although developed in patients who 
underwent nCRT plus surgery) performed better in patients who un-
derwent surgery alone. This indicates that from a prognostic perspec-
tive, neoadjuvant chemoradiotherapy has a strong equalizing effect on 
patients, making individual survival predictions in the era of nCRT less 
reliable.
 
Unfortunately, this study could not identify any additional factors out-
side of the already well-established TNM-staging system that might 
contribute to more accurate prognostication in the era of multimo-
dality treatment. Even the much studied and widely applied tumor 
regression grading (TRG) systems32,33,39-41 were not significantly associ-
ated with survival in this large and homogeneous patient cohort, thus 
questioning the usefulness of TRG as an independent prognostic factor 
in esophageal or junctional cancer patients. These results, therefore, 
strengthen the need for new prognostic factors, such as genetic and 
molecular markers, to improve the accuracy of individual survival 
prediction in the era of multimodality treatment for esophageal and 
junctional cancer.
Limitations
Although this study only included parameters that have been col-
lected prospectively, the time period was relatively long (1993-2013), 
which might have caused bias in the comparison of patients treated 
with surgery alone or with nCRT plus surgery despite the selection of 
all patients according to the same inclusion criteria as applied in the 
CROSS-I and CROSS-II trials. A further limitation is that not all rec-
ognized prognostic factors in esophageal and junctional cancer could 
be included in this study, such as extracapsular lymph node involve-
ment51-53, signet cell features in esophageal adenocarcinomas54,55 and 
genetic and molecular markers.56,57
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Conclusions
Most conventional prognostic factors lose their prognostic significance 
in patients with potentially curable esophageal or junctional can-
cer, when treated with neoadjuvant chemoradiotherapy (nCRT) plus 
surgery. In the era of nCRT, clinical N-stage and pathological N-stage 
remain as independent prognostic factors. Surgical approach, which 
is of prognostic relevance in patients treated with surgery alone, loses 
its prognostic significance after nCRT, thus questioning the necessity 
of maximization of surgical lymph node retrieval. Furthermore, tumor 
regression grading is not independently associated with survival in pa-
tients treated with nCRT plus surgery. The final prediction model, based 
on clinical N-stage, pathological T-stage and pathological N-stage, has 
moderate discriminatory ability. These results strengthen the need for 
new prognostic factors to improve survival prediction in the era of mul-
timodality treatment for esophageal and junctional cancer.
Table 1 — Clinical, surgical and histopathological characteristics in 
1017 patients with potentially curable carcinoma of the esophagus 
or esophagogastric junction, treated with surgery alone or 
neoadjuvant chemoradiotherapy (nCRT) plus surgery.
Total
(n=1017)
1993 – 2013
n (%)*
63 (56 – 69)
212 (21)
805  (79)
 
3 (0 – 6)
42 (4)
 
 
224 (22)
783 (77)
10 (1)
 
 
1 (0)
12 (1)
129 (13)
653 (65)
211 (21)
11 
5 (3 – 6)
85 (9)
 
20 (2)
193 (20)
757 (77)
16 (2)
31
387 (39)
599 (61)
31 
Surgery alone
(n=391)
1993 – 2009
n (%)*
63 (55 – 69)
78 (20)
313 (80)
 
2 (0 – 5)
23 (6)
 
 
85 (22)
302 (77)
4 (1)
 
 
1 (0)
9 (2)
48 (13)
240 (63)
86 (22)
7 
4 (3 – 6)
38 (10)
 
8 (2)
80 (21)
281 (75)
6 (2)
16
205 (55)
169 (45)
17
nCRT plus surgery
(n=626)
2001 – 2013
n (%)*
63 (56 – 69)
129 (22)
451 (78)
 
3 (0 – 6)
19 (3)
 
 
139 (22)
481 (78)
6 (1)
 
 
– –
3 (1)
81 (13)
413 (66)
125 (20)
4 
5 (3 – 6)
47 (8)
 
12 (2)
113 (19)
476 (78)
10 (2)
15
182 (30)
430 (70)
14
p**
0.275
0.578
0.001
0.866
0.045
0.262
0.739
<0.001
Age [years]
Median (p25 – p75)
Gender
Female
Male
Weight loss [kg]
Median (p25 – p75)
Missing (%)
Tumor histology€
Squamous cell carcinoma
Adenocarcinoma
Undeterminable
Tumor location§
Cervical
Upper third esophagus
Middle third esophagus
Lower third esophagus
Esophagogastric junction
Missing
Tumor length§ [cm]
Median (p25 – p75)
Missing (%)
cT-stage‡
cT1
cT2
cT3
T4
Missing
cN-stage‡
cN0
cN1
Missing
31
Legend table 1
*  Data presented as median (interquartile range) or number (%). Percentages may not 
add up to 100 due to rounding. 
**  Data were compared between the surgery alone and nCRT plus surgery groups 
using Student’s t-test for continuous variables and Pearson’s chi-squared test for 
categorical variables.
€  Tumor histology was determined in the pretreatment biopsy.
§  Tumor location and tumor length were determined by endoscopy.
‡   Clinical T-stage and N-stage were determined by endoscopic ultrasonography 
and CT-scanning with or without FDG-PET-scanning according to the Union for 
International Cancer Control (UICC) TNM Cancer Staging, 6th edition.30 cT1: (sub)
mucosal involvement, cT2: proper muscle layer involvement, cT3: surrounding stroma 
involvement.
◊  R
0
 was defined as a tumor-free resection margin ≥ 1 mm. R
1
 was defined as a 
macro scopically radical resection, with a microscopically tumor-free resection 
 margin < 1 mm.
£  Tumor grade was determined in the resection specimen only. Histological tumor 
grade was not determined in the pretreatment biopsy.
∆   Pathological T-stage and N-stage, as measured in the resection specimen were 
(re)scored according to UICC TNM Cancer Staging, 7th edition31; pT1: (sub)mucosal 
involvement, pT2: proper muscle layer involvement, pT3: surrounding stroma involve-
ment; pN0: no lymph node positivity, pN1: 1-2 lymph nodes positive, pN2: 3-6 lymph 
nodes positive, pN3: ≥7 lymph nodes positive.
¥  Tumor regression grade was scored as defined by Chirieac et al.32,33 : TRG1: no 
residual tumor cells found; TRG2: 1-10% residual tumor cells; TRG3: 11-50% residual 
tumor cells; TRG4: > 50% residual tumor cells.
Total
(n=1017)
1993 – 2013
n (%)*
487 (48)
525 (52)
5 (1)
851 (84)
163 (16)
3 (0)
 
171 (20)
40 (5)
327 (38)
313 (37)
166 
187 (19)
128 (13)
169 (17) 
518 (51)
9 (1)
6
523 (52)
247 (24)
149 (15)
93 (9)
5 
187 (30)
135 (22)
175 28)
124 (20)
5 
Surgery alone
(n=391)
1993 – 2009
n (%)*
263 (67)
128 (33)
– –
 
 
262 (67)
126 (32)
3 (1)
 
 
– –
31 (8)
194 (51)
155 (41)
11 
 
 
– –
39 (10)
63 (16)
278 (72)
5 (1)
6 
 
 
123 (32)
101 (26)
89 (23)
73 (19)
5 
 
 
– –
– –
– –
– –
– 
 
nCRT plus surgery
(n=626)
2001 – 2013
n (%)*
6224 (36)
397 (63)
5 (1)
 
 
589 (94)
37 (6)
– –
 
 
171 (36)
9 (2)
133 (28)
158 (34)
155 
 
187 (30)
89 (14)
106 (17)
240 (38)
4 (1)
– 
 
 
400 (64)
146 (23)
60 (10)
20 (3)
– 
 
 
187 (30)
135 (22)
175 (28)
124 (20)
5 
p**
<0.001
<0.001
<0.001
<0.001
<0.001
–
Surgical approach
Transhiatal approach
Transthoracic approach
Other
Radicality◊
R
0
R
1
R
2
Tumor grade£
Gx (undeterminable)
G1
G2
G3
Missing
pT-stage∆
pT0
pT1, includes pTis
pT2
pT3
pT4
Missing
pN-stage∆ 
pN0
pN1
pN2
pN3
Missing
Tumor regression 
grade¥ (TRG)
TRG1
TRG2
TRG3
TRG4
Missing
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Table 2 — Prognostic factors for overall survival in 1017 
patients with potentially curable carcinoma of the esophagus or 
esophagogastric junction, treated with surgery alone or neoadjuvant 
chemoradiotherapy (nCRT) plus surgery.
Age [per 10 years]
Gender
Female
Male
Weight loss (per kg)
Tumor histology
Squamous cell 
carcinoma
Adenocarcinoma
Tumor location
Cervical-to-middle  
third esophagus
Lower third esophagus
Esophagogastric 
junction
Tumor length [per cm]
cT–stage
cT1 – cT2
cT3 – cT4
cN–stage
cN0
cN1
Surgical approach
Transhiatal approach
Transthoracic  
approach or other
Radicality
R
0
R
1
 – R
2
Tumor grade
Gx
G1
G2
G3
pT-stage
pT0
pT1
pT2
pT3 – pT4
pN-stage
pN0
pN1
pN2
pN3
Tumor regression 
grade*
TRG1
TRG2
TRG3
TRG4
HR
1.21
0.80
1 (ref)
1.01
1.93
1 (ref)
1 (ref)
1.05
0.79
1.00
1 (ref)
0.90
1 (ref)
0.94
1 (ref)
0.74
1 (ref)
1.63
–
1 (ref)
1.47
1.66
HR
–
1 (ref)
1.87
3.35
1 (ref)
2.07
2.99
4.57
–
–
–
–
95% CI
(1.05 – 1.40)
(0.57 – 1.13)
–
(0.97 – 1.05)
(1.36 – 2.75)
–
–
(0.69 – 1.61)
(0.48 – 1.31)
(0.95 – 1.05)
–
(0.63 – 1.29)
–
(0.71 – 1.24)
–
(0.55 – 0.98)
–
(1.25 – 2.13)
–
–
(0.72 – 3.00)
(0.80 – 3.46)
95% CI
–
–
(0.87 – 4.03)
(1.64 – 6.85)
–
(1.41 – 3.04)
(2.01 – 4.46)
(3.01 – 6.95)
–
–
–
–
p
0.009
0.198
–
0.617
<0.001
–
–
0.807
0.359
0.942
–
0.566
–
0.653
–
0.036
–
<0.001
–
–
0.289
0.176
p
–
–
0.110
0.001
–
<0.001
<0.001
<0.001
–
–
–
–
HR
1.12
0.77
1 (ref)
1.01
0.77
1 (ref)
1 (ref)
0.93
0.72
0.97
1 (ref)
1.16
1 (ref)
1.46
1 (ref)
1.15
1 (ref)
1.35
1.94
1 (ref)
2.78
2.80
HR
0.76
1 (ref)
1.02
1.15
1 (ref)
1.78
1.98
4.34
0.77
1 (ref)
1.21
1.03
95% CI
(0.98 – 1.28)
(0.55 – 1.08)
–
(0.98 – 1.05)
(0.53 – 1.12)
–
–
(0.60 – 1.44)
(0.42 – 1.23)
(0.92 – 1.04)
–
(0.81 – 1.67)
–
(1.09 – 1.95)
–
(0.87 – 1.52)
–
(0.85 – 2.15)
(0.36 – 8.61)
–
(0.58 – 13.25)
(0.67 – 11.74)
95% CI
(0.49 – 1.17)
–
(0.64 – 1.61)
(0.76 – 1.73)
–
(1.32 – 2.39)
(1.29 – 3.02)
(2.38 – 7.93)
(0.52 – 1.12)
–
(0.85 – 1.72)
(0.69 – 1.54)
p
0.099
0.129
–
0.462
0.173
–
–
0.740
0.232
0.414
–
0.415
–
0.012
–
0.333
–
0.202
0.385
–
0.202
0.159
p
0.318
–
0.945
0.499
–
<0.001
<0.001
<0.001
0.173
–
0.302
0.895
HRnCRT+S / 
HRS
0.93
0.96
1 (ref)
1.00
0.40
1 (ref)
1 (ref)
0.88
0.92
0.98
1 (ref)
1.29
1 (ref)
1.55
1 (ref)
1.56
1 (ref)
0.83
–
1 (ref)
1.89
1.69
HRnCRT+S / 
HRS
–
1 (ref)
0.54
0.34
1 (ref)
0.86
0.66
0.95
–
–
–
–
95% CI
(0.76 – 1.13)
(0.59 – 1.56)
–
(0.95 – 1.06)
(0.24 – 0.67)
–
–
(0.48 – 1.62)
(0.44 – 1.90)
(0.90 – 1.06)
–
(0.78 – 2.14)
–
(1.04 – 2.31)
–
(1.04 – 2.33)
–
(0.48 – 1.41)
–
–
(0.36 – 9.93)
(0.35 – 8.13)
95% CI
–
–
(0.22 – 1.33)
(0.15 – 0.78)
–
(0.53 – 1.40)
(0.37 – 1.18)
(0.46 – 1.97)
–
–
–
–
Pint
0.444
0.879
–
0.872
0.001
–
–
0.681
0.812
0.579
–
0.325
0.030
–
0.030
–
0.486
–
–
0.454
0.514
Pint
–
–
0.182
0.011
–
0.538
0.161
0.890
–
–
–
–
Surgery alone Surgery alone
(n=391) 
1993 – 2009
(n=391) 
1993 – 2009
nCRT plus surgery nCRT plus surgery
(n=626) 
2001 – 2013
(n=626) 
2001 – 2013
Legend table 2
HR: hazard ratio.
HR
nCRT+S
/HR
S
: HR associated with a characteristic among patients undergoing nCRT 
plus surgery divided by the HR for the same characteristic among patients undergoing 
surgery alone.
CI: confidence interval.
P
int
: p-value for the treatment interaction (HR
nCRT+S
/ HR
S
).
* Also different groupings of TRG were tested: TRG1 vs. TRG2-439, TRG1 vs. TRG2-3 vs. 
TRG441 and TRG1-2 vs. TRG3-440 (data not shown). None of these groupings showed a 
significant independent effect.
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Figure 1 — Nomogram for overall survival as developed in 626 
patients with potentially curable carcinoma of the esophagus 
or esophagogastric junction, treated with neoadjuvant 
chemoradiotherapy (nCRT) plus surgery.
Legend figure 1
From the total points axis, a straight line down through the survival axes shows survival 
probabilities at one-and five years. Clinical N-stage according to UICC TNM Cancer 
Staging, 6th edition30; cN0: no clinical suspicion of pretreatment lymph node involvement, 
cN1: clinical suspicion of pretreatment lymph node involvement. Pathological T-stage 
according to UICC TNM Cancer Staging, 7th edition31; pT0: no residual tumor at the 
primary tumor site, pT1: (sub)mucosal involvement, pT2: proper muscle layer involve-
ment, pT3: surrounding stroma involvement. Pathological N-stage according to UICC 
TNM Cancer Staging, 7th edition31; pN0: no lymph node positivity, pN1: 1-2 lymph nodes 
positive, pN2: 3-6 lymph nodes positive, pN3: ≥7 lymph nodes positive.
Clinical N-stage
Pathological T-stage
Pathological N-stage
Total points
One-year survival (%)
Five-year survival (%)
cN0 cN1
points0 2
0 2 4 6 8 10 12 14 16
91 88 85 81 75 68 60 51 41
70 62 53 43 33 23 14 7 3
ypT0 ypT1/pT2
points0 2 4
ypT3
ypN1 ypN2 ypN3
points0 4 5 10
ypN0
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Abstract
Objective
We aimed to determine pretreatment pathological tumor extent in the 
resection specimen after neoadjuvant chemoradiotherapy (nCRT) and 
to assess its prognostic value in patients with esophageal cancer.
Methods
Patients with esophageal cancer, treated with nCRT plus surgery were 
included (2003 -2011). Pretreatment pathological T-stage (prepT-
stage) and N-stage (prepN-stage) were estimated based on the ex-
tent of regressional changes and residual tumor cells in the resection 
specimen. Interobserver agreement was determined between three 
pathologists. The prognostic performance of prepT-stage and prepN-
stage was scored using the difference in Akaike’s information criterion 
(ΔAIC). PrepN-stage and posttreatment pathological N-stage (ypN-
stage) were combined to determine the effect of nodal sterilization on 
prognosis.
Results
Overall concordance for prepT-stage and prepN-stage was 0.69 and 
0.84, respectively. Prognostic strength of prepT-stage was similar to 
cT-stage and worse compared to ypT-stage (ΔAIC 1.3 vs. 2.0 and 8.9, 
resp.). In contrast, prognostic strength of prepN-stage was better than 
cN-stage and similar to ypN-stage (ΔAIC 17.9 vs. 6.2 and 17.2, resp.). 
PrepN+ patients who become ypN0 after nCRT have a worse survival 
compared to prepN0 patients, with a five year overall survival of 51% 
vs. 68%, p=0.019, respectively. 
Conclusions
PrepT-stage and prepN-stage can be estimated reproducibly. Prog-
nostic strength of prepT-stage is comparable to cT-stage, while prepN-
stage is better than cN-stage. PrepN+ patients who become ypN0 
after nCRT have a worse survival compared to prepN0 patients. Pre-
treatment pathological staging, should be considered useful as a new 
staging parameter for esophageal cancer and could also be of interest 
for other tumor types.
Introduction
An important indicator of prognosis in esophageal cancer is the TNM-
stage.1-3 The TNM-staging system consists of three categories which 
classify the depth of invasion of the primary tumor (T), the number of 
involved lymph nodes (N) and the presence of distant dissemination 
(M). The TNM-staging system has been validated extensively in litera-
ture for many tumor types treated with surgery alone, based on meas-
urements in the surgical resection specimens, classified as the patho-
logical TNM-staging (pTNM).2,3 
In recent years, potentially curative treatment of esophageal cancer 
has shifted to include neoadjuvant therapy prior to surgical resection.4-6 
Unfortunately, in a post-neoadjuvant therapy setting, the pTNM-stag-
ing system, based on the residual disease in the resection specimen 
(ypTNM), largely loses its prognostic strength.7-9 However, the percent-
age of residual viable tumor cells in the resection specimen after neo-
adjuvant therapy was found to be of prognostic value which resulted in 
several tumor regression grading (TRG) systems.10-13 
Consequently, in patients undergoing neoadjuvant therapy, the con-
ventional pretreatment stage can only be estimated using clinical 
evaluation criteria during initial clinical work-up. This pretreatment 
clinical TNM-staging (cTNM) relies on endoscopic ultrasonography 
(EUS), computed tomography (CT) and more recently positron emission 
tomography (PET) for the T- and N-stages and is known to be relatively 
inaccurate, especially for the N-stage.14,15 Therefore, an updated TNM 
staging system is necessary, suited for the era of neoadjuvant treat-
ment. More specifically, an improved estimation of the pretreatment 
stage is needed. 
In the present study we introduce and validate a novel method of 
determining pretreatment pathological tumor extent, based on the 
extent of regressional changes (e.g. fibrosis, mucinous lakes, keratin 
pearls, and/or foreign body giant cell reactions) and on the presence of 
residual tumor cells in the resection specimen. We aim (I) to determine 
the interobserver reproducibility of this new pretreatment pathological 
staging system, (II) to compare this pretreatment pathological staging 
system with the pretreatment clinical staging system and (III) to deter-
mine the value of this new pretreatment pathological staging system 
for posttreatment prognostication.
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Methods
Patient selection and clinical staging
Patients were included with potentially curable esophageal or junc-
tional cancer, who were treated with neoadjuvant chemoradiotherapy 
(nCRT) plus surgery according to the CROSS regimen at the Erasmus 
MC – University Medical Center, Rotterdam or at the Academic Med-
ical Center, Amsterdam, The Netherlands, between 2003 and 2011. 
Both squamous cell carcinoma (SCC) and adenocarcinoma (AC) tumor 
types were included. Patients who did not receive at least 80% of the 
planned dose of chemoradiotherapy, who received a different nCRT 
regimen or in whom surgical resection could not be completed, were 
excluded. 
Clinical staging and treatment
In all patients, pretreatment work-up included endoscopy with histo-
logical biopsy, endoscopic ultrasonography (with fine needle aspiration 
when indicated), CT scan of the neck, chest and abdomen, external 
ultrasonography of the neck (with fine needle aspiration when indi-
cated) and more recently FDG-PET-CT. Pretreatment clinical T-stage 
and N-stage were determined by endoscopic ultrasonography and 
CT-scanning and/or FDG-PET-CT scanning according to the Union for 
International Cancer Control (UICC) TNM Cancer Staging, 7th edition.1 
The neoadjuvant treatment regimen according to the CROSS regimen 
has been described before in detail.6 Esophagectomy was performed 
either via a transthoracic approach (with two-field lymph node dis-
section) or a transhiatal approach. In both the transthoracic and the 
transhiatal approach, an upper abdominal lymphadenectomy was 
performed, including removal of nodes along the hepatic artery, splenic 
artery and origin of the left gastric artery.
Conventional pathological assessment 
The resection specimens (primary tumor and all resected lymph nodes) 
were processed according to a standardized protocol.16 Pathological 
T-stage and N-stage were scored according to the UICC TNM Cancer 
Staging, 7th edition1, with N0: no nodes positive; N1: 1-2 lymph nodes 
positive; N2: 3-6 lymph nodes positive; N3: ≥7 lymph nodes positive. The 
tumor regression grade (TRG) was scored using the system as reported 
by Mandard et al.10, TRG1: no residual tumor cells found; TRG2: 1-10% 
residual tumor cells; TRG3: 11-50% residual tumor cells; TRG4: >50% 
residual tumor cells; TRG5: no signs of tumor regression.
Pretreatment pathological assessment 
The original tumor area —before nCRT— was estimated based on the 
extent of regressional changes (e.g. fibrosis, mucinous lakes, keratin 
pearls, and/or foreign body giant cell reactions) plus the presence of 
residual tumor cells in the resection specimen, as was previously de-
scribed in patients with rectal cancer.17-20 The evaluating pathologists 
(KB, GJAO, FJWtK, SLM) carefully examined all slides of all cases. The 
extent of regressional changes in the esophageal wall and peri-esoph-
ageal stroma was included in the interpretation of the ‘pretreatment 
pathological T-stage’ (prepT-stage), reflecting the estimated original 
invasion depth of the primary tumor. Pretreatment T4a tumors were 
categorized as prepT3, in order to prevent a staging category with 
very few patients, which could give unreliable results. The presence of 
such regressional changes in lymph nodes in addition to lymph nodes 
containing vital tumor cells was used for interpretation of the ‘pretreat-
ment pathological N-stage’ (prepN-stage), reflecting the estimated 
number of originally involved lymph nodes. 
Follow-up and data collection
Clinical characteristics were collected from prospectively maintained 
databases. Survival was determined using hospital records and munic-
ipal registers. All patients were regularly evaluated in the outpatient 
clinic during the first five postoperative years. Overall survival was cal-
culated from the day of surgery and was limited at five years to reduce 
the effect of death by other causes. 
Data analysis 
Data were described as medians with an interquartile range (IQR) in 
case of continuous variables and frequencies with percentages in case 
of categorical variables. Grouped data were compared using Student’s 
t-test and Pearson’s chi-squared test. A value of p<0.05 (two-sided) 
was considered statistically significant. Statistical analysis was per-
formed with SPSS 21 for Windows (SPSS, Chicago, IL, USA).
Interobserver agreement
In order to determine the reproducibility of prepT-staging and 
prepN-staging, the interobserver agreement was quantified in a sub-
group of 90 consecutive patients from the Erasmus MC, Rotterdam. The 
interobserver agreement was determined between three independent-
ly scoring upper-GI pathologists (KB, GJAO, FJWtK) for prepT-stage, 
ypT-stage, prepN-stage, ypN-stage and TRG using the weighted kappa 
statistic (κ
w
)21,22 per pair of scorers and using the intraclass correlation 
coefficient (ICC)23 to quantify the overall concordance. In case of disa-
greement, the median score was used for further analyses. A κ
w
 or ICC 
of 0.0 or less was considered to represent poor agreement, 0.01–0.20 
slight, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80 substantial and 
0.81–1.00 near-perfect agreement.24 PrepN-stage and ypN-stage were 
correlated as both ordinal variables and continuous variables. 
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Comparison of staging systems
Survival was calculated by the Kaplan–Meier method and differenc-
es between groups were assessed by the log-rank test. Prognostic 
strength of a model was measured by the likelihood ratio chi-squared 
statistic (LR χ2) of the corresponding Cox proportional hazards model 
minus two times the degrees of freedom (df). This corresponds to the 
difference between Akaike’s information criterion (AIC) of the mod-
el and the null-model (ΔAIC).25 A higher ΔAIC value indicates better 
prognostic ability, adjusted for the statistical complexity of the model 
fit. PrepN-stage and ypN-stage were analyzed as ordinal variables and 
as continuous variables. For models with continuous variables, restrict-
ed cubic splines with three knots (corresponding with two degrees of 
freedom) were used. 
Combining pretreatment and posttreatment N-staging systems
Pretreatment pathological N-stage (prepN-stage) was considered to 
represent the estimated lymph node involvement before neoadjuvant 
chemoradiotherapy, based on the presence of residual tumor plus 
regressional changes in resected lymph nodes. Nodes that showed 
regressional changes, without the presence of residual tumor were 
considered to have been sterilized by neoadjuvant chemoradiotherapy. 
Using both the pretreatment pathological N-stage (prepN) and post-
treatment pathological N-stage (ypN), patients were categorized into 
three groups: I) patients who never had nodal involvement, II) patients 
who had nodal involvement pretreatment, but became node-negative 
after nCRT and III) patients who remained node positive after nCRT. 
Results
Clinical and histopathological characteristics
Some 206 patients were evaluated, of whom 24 were excluded be-
cause they did not undergo surgical resection and two additional 
patients were excluded because they received less than 80% of the 
planned nCRT regimen. In total, 180 patients were included. Medi-
an age at diagnosis was 61 years (table 1). Most patients were male 
(76%), had an adenocarcinoma (77%), most often clinically staged as 
cT3 (75%) and cN+ (68%). Patients were most often staged as prepT3 
(77%) and prepN+ (56%) (table 2). The median (IQR) number of resect-
ed lymph nodes was 18 (13-23).
 
Interobserver agreement 
In 90 of 180 patients, the resection specimens were independently 
scored by three upper-GI pathologists. We found high concordance with 
intraclass correlation coefficients (ICC) between 0.7 to 0.9 (table 2). 
Comparison of prepT-stage to cT-stage and ypT-stage 
Some 43 of 180 patients (24%) had non-concordant pretreatment 
T-stages (table 4a). Of these 43 patients, 21 had a more advanced and 
22 had a less advanced prepT-stage compared to the cT-stage. The 
overall survival curves according to cT-stage, prepT-stage and ypT-
stage are shown in figure 1. Prognostic strength of prepT-stage was 
comparable to cT-stage and worse compared to ypT-stage (ΔAIC 1.3 
vs. 2.0 and 8.9, resp., table 3).
 
Comparison of prepN-stage to cN-stage and ypN-stage
Some 96 of of 180 patients (53%) had non-concordant pretreatment 
N-stages (table 4b). Of these 96 patients, 39 had a more advanced and 
57 had a less advanced prepN-stage compared to cN-stage, More spe-
cifically, out of 57 clinically node negative patients, 22 patients (39%) 
showed pathological signs of pretreatment nodal involvement. Con-
versely, out of 123 clinically node positive patients, 45 patients (37%) 
showed no pathological signs of pretreatment nodal involvement in the 
resection specimen. The overall survival curves according to cN-stage, 
prepN-stage and ypN-stage are shown in figure 2. Prognostic strength 
of prepN-stage was better than cN-stage and similar to ypN-stage 
(ΔAIC 17.9 vs. 6.2 and 17.2, resp., table 3). Counting of involved lymph 
nodes further improved prognostic strength of prepN-stage, but not 
for ypN-stage (ΔAIC 22.2 and 13.1, resp.). 
Combining prepN-stage and ypN-stage 
As shown in figure 3, the group of patients who never had nodal in-
volvement (i.e. no residual tumor and no regressional changes) had 
a better survival compared to patients who had nodal involvement 
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pretreatment, but became node-negative after nCRT and compared to 
patients who remained node positive after nCRT. The five year overall 
survival was 68% vs. 51%, p=0.019 and 68% vs. 36%, p<0.001, respec-
tively. Patients who had nodal involvement pretreatment, but became 
node-negative after nCRT had a (statistically not significant) better 
five year overall survival compared to patients who remained node 
positive after nCRT (51% vs. 36% p=0.282). Finally, combining prepN-
stage and ypN-stage in a multivariable model did not improve the 
prognostic strength of the univariable prepN-stage model (ΔAIC 18.8 , 
table 3).
Discussion 
We found that the pathological estimations of pretreatment primary 
tumor extent (prepT) and especially pretreatment nodal involvement 
(prepN) in the resection specimen were highly reproducible in pa-
tients with esophageal or junctional cancer, treated with neoadjuvant 
chemoradiotherapy (nCRT) followed by surgery. 
Clinical T-stage, based on EUS and CT, had comparable prognostic 
strength to prepT-stage. This might be explained by the relatively high 
accuracy of EUS for determining depth of tumor invasion, which is well 
above 80%26 and increases to over 90% for locally more advanced tu-
mors27 (i.e. tumors invading the peri-esophageal stroma; pT3). The com-
parable strength of cT-stage to prepT-stage might be further explained 
by the distorting effect of the desmoplastic reaction (i.e. tumor-stro-
ma interaction), which is frequently present at the invasive front and 
cannot easily be distinguished from therapy-induced fibrosis. There-
by, possibly, overestimating the percentage of tumors invading into 
the peri-esophageal stroma. Prognostic strength of prepN-stage was 
better than for cN-stage. Meaning, prepN-stage gave a more reliable 
estimation of nodal involvement. Estimation of nodal involvement by 
EUS and CT is known to be unreliable, with reported accuracies ranging 
from 70% to 80% and from 59% to 75%, respectively.14,15 
Interestingly, prognostic strength of prepN-stage was also better than 
that of ypN-stage. Thus, indicating that prepN-stage was better at sep-
arating patients with good prognosis from patients with worse prognosis 
than ypN-stage. Several previous studies have emphasized the impor-
tance of continued node positivity after neoadjuvant chemoradiother-
apy.7,28-31 Also, the present study confirms the importance of ypN-stage 
(as expressed by its high ΔAIC). However, it appears that an accurate 
pathological estimation of pretreatment nodal involvement is even more 
informative than posttreatment pathological nodal involvement. Con-
ceptually this is understandable, since most patients die from distant 
disease recurrence after nCRT plus surgery and the risk of systemic 
dissemination is expected to be correlated more with pretreatment than 
with posttreatment nodal positivity.32,33 This also explains that patients 
who had no residual disease in the resected lymph nodes (ypN0), but 
who did have pretreatment nodal involvement (prepN+) had a worse 
prognosis, as compared to patients who did not have any pretreatment 
nodal involvement (prepN0). Whether improvement in survival after 
nCRT is caused by the actual sterilization of lymph nodes, or whether a 
good nodal response is simply a marker of more favorable tumor biology 
cannot be concluded from the present data. 
Finally, the kappa values found for prepT-stage (κ
w
 range: 0.59–0.78) 
and prepN-stage (κ
w
 range: 0.84–0.84) were comparable to the kappa 
values found for tumor regression grade (TRG; κ
w
 range: 0.84–0.93) 
and were generally higher than normally found for other diagnos-
tic modalities, such as endoscopic ultrasonography (EUS; T-stage, κ
w
 
range: 0.29–0.69 and N-stage, κ
w
 range: 0.49–0.56)34 and computed 
tomography (CT; T-stage, κ
w
 range: 0.15–0.68 and N-stage, κ
w
 range: 
0.03–0.45)35. This suggests that these new histopathological parame-
ters could indeed have clinical applicability. 
Currently, we can only speculate on additional treatment options for 
patients with (pretreatment) nodal involvement. Primarily, a need exists 
for an effective systemic treatment, which could be given adjuvantly 
(based on prepN-staging in the resection specimen) with the purpose 
of sterilizing distant (micro)metastases. The benefit of such additional 
treatment should then be studied for different prepN-stages. 
In patients undergoing neoadjuvant therapy, the conventional pretreat-
ment stage can only be estimated using clinical evaluation criteria dur-
ing initial clinical work-up. However, clinical staging and especially clini-
cal N-staging, is known to be relatively inaccurate. The relevance of the 
proposed prepN staging system is that this method allows for the exact 
histopathological correlation with ypN stage at the level of individual 
lymph nodes. In this study it has allowed us to address the biological 
significance of pretreatment node positivity in patients treated with 
nCRT plus surgery. This novel pretreatment pathological staging, which 
has also been recently described by Nieman et al.36 should be validat-
ed in a larger, independent group of patients. If proven valid, pretreat-
ment pathological staging, and especially pretreatment pathological 
N-staging, should be considered a useful new staging parameter for 
esophageal and junctional cancers and could also be of interest for 
other tumor types that are treated by neoadjuvant therapy followed 
by surgical resection. 
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Conclusions
The pretreatment pathological T-stage (prepT-stage) and pretreatment 
pathological N-stage (prepN-stage) can be reproducibly estimated in 
the resection specimen. Prognostic strength of prepT-stage is com-
parable to pretreatment clinical T-stage (cT-stage), while prognostic 
strength of prepN-stage is better than pretreatment clinical N-stage 
(cN-stage). Furthermore, prepN-stage better predicts overall survival 
than posttreatment pathological N-stage (ypN-stage). Patients who 
have pretreatment nodal involvement, but become node-negative after 
nCRT have a worse survival compared to patients without pretreat-
ment nodal involvement. If proven valid, pretreatment pathological 
staging, and especially pretreatment pathological N-staging, should be 
considered a useful new staging parameter for esophageal and junc-
tional cancers and could also be of interest for other tumor types that 
are treated by neoadjuvant therapy followed by surgical resection. 
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Age [years]
median (p25 – p75)
Gender
female 
male
Tumor type
squamous cell carcinoma
adenocarcinoma
cT-stage○
cT1
cT2
cT3
cN-stage○
cN0
cN1
cN2
cN3
prepT-stage◊
prepT1
prepT2
prepT3
prepN-stage◊
prepN0
prepN1
prepN2
prepN3
Number of nodes 
resected
median (p25 – p75)
ypT-stage∆
ypT0
ypT1
ypT2
ypT3
ypN-stage∆
ypN0
ypN1
ypN2
ypN3
Tumor regression 
grade¥ (TRG)
TRG1
TRG2
TRG3
TRG4
TRG5
Table 1 — Clinical and histopathological characteristics in 180 
patients with esophageal or junctional cancer treated with 
neoadjuvant chemoradiotherapy plus surgical resection.
Complete cohort
(n=180)
n (%)*
(n=180)
n (%)*
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Table 2 — Interobserver agreement between three pathologists for 
pretreatment T-stage (prepT-stage), pretreatment N-stage (prep N-
stage), posttreatment T-stage (ypT-stage), posttreatment N-stage 
(ypN-stage) and tumor regression grade (TRG) in the resection 
specimen of 90 patients with esophageal or junctional cancer treated 
with neoadjuvant chemoradiotherapy plus surgical resection.
Data type
ordinal
ordinal
ordinal
ordinal
ordinal
1 to 2
κw
0.78
0.92
0.84
0.95
0.84
1 to 3
κw
0.59
0.89
0.84
0.92
0.86
2 to 3
κw
0.71
0.93
0.84
0.93
0.93
Overall
ICC
0.69
0.92
0.84
0.93
0.88
prepT-stage◊ 
ypT-stage∆ 
prepN-stage◊ 
ypN-stage∆ 
TRG¥
Legend table 2 
◊  Pretreatment pathological T-stage (prepT-stage) and N-stage (prepN-stage) repre-
sent the estimated extent of tumor before neoadjuvant chemoradiotherapy, based 
on the location of residual tumor plus regressional changes in the esophageal wall 
and resected lymph nodes. These regressional changes include fibrosis, mucous 
lakes, keratin pearls and foreign body giant cell reactions. Both prepT and prepN 
categories were staged according to the pT- and pN-stages as defined by the 7th 
edition of the TNM staging manual1.
∆   Posttreatment pathological T-stage (ypT-stage) and N-stage (ypN-stage), as mea-
sured in the resection specimen were (re)scored according to UICC TNM Cancer 
Staging, 7th edition1; pT1: (sub)mucosal involvement, pT2: proper muscle layer involve-
ment, pT3: surrounding stroma involvement; N0: no lymph node positivity, N1: 1-2 
lymph nodes positive, N2: 3-6 lymph nodes positive, N3: ≥7 lymph nodes positive.
Legend table 1
*  Data presented as median (interquartile range) or number (%). Percentages may not 
add up to 100 due to rounding. 
○  Clinical T-stage and N-stage were determined by endoscopic ultrasonography and/
or CT-scanning and/or FDG-PET-scanning according to the Union for International 
Cancer Control (UICC) TNM Cancer Staging, 7th edition1.
◊  Pretreatment pathological T-stage (prepT-stage) and N-stage (prepN-stage) repre-
sent the estimated extent of tumor before neoadjuvant chemoradiotherapy, based 
on the location of residual tumor plus regressional changes in the esophageal wall 
and resected lymph nodes. These regressional changes include fibrosis, mucous 
lakes, keratin pearls and foreign body giant cell reactions. Both prepT and prepN 
categories were staged according to the pT- and pN-stages as defined by the 7th 
edition of the TNM staging manual1.
∆   Posttreatment pathological T-stage (ypT-stage) and N-stage (ypN-stage), as mea-
sured in the resection specimen were (re)scored according to UICC TNM Cancer 
Staging, 7th edition1; pT1: (sub)mucosal involvement, pT2: proper muscle layer involve-
ment, pT3: surrounding stroma involvement; N0: no lymph node positivity, N1: 1-2 
lymph nodes positive, N2: 3-6 lymph nodes positive, N3: ≥7 lymph nodes positive.
¥  The tumor regression grade (TRG) was scored using the system as reported by Man-
dard et al.10; TRG1: no residual tumor cells found, TRG2: 1-10% residual tumor cells, 
TRG3: 11-50% residual tumor cells, TRG4: > 50% residual tumor cells, TRG5: no signs 
of tumor regression.
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Table 4 — Interobserver agreement between three pathologists for 
pretreatment T-stage (prepT-stage), pretreatment N-stage (prep N- 
stage), posttreatment T-stage (ypT-stage), posttreatment N-stage 
(ypN-stage) and tumor regression grade (TRG) in the resection 
specimen of 90 patients with esophageal or junctional cancer treated 
with neoadjuvant chemoradiotherapy plus surgical resection.
Table 3 — Prognostic stratification of 180 patients with esophageal 
or junctional cancer treated with neoadjuvant chemoradiotherapy 
plus surgical resection based on pretreatment clinical T-stage (cT-
stage), pretreatment pathological T-stage (prepT-stage), and post-
treatment pathological T-stage (ypT-stage), and pretreatment clinical 
N-stage (cN-stage), pretreatment pathological N-stage (prepN-stage) 
and posttreatment pathological N-stage (ypN-stage).
Legend table 4
○   Pretreatment clinical T-stage (cT-stage) and N-stage (cN-stage) were determined by 
endoscopic ultrasonography and/or CT-scanning and/or FDG-PET-scanning and (re)
scored according to the Union for International Cancer Control (UICC) TNM Cancer 
Staging, 7th edition1.
◊  Pretreatment pathological T-stage (prepT-stage) and N-stage (prepN-stage) repre-
sent the estimated extent of tumor before neoadjuvant chemoradiotherapy, based 
on the location of residual tumor plus regressional changes in the esophageal wall 
and resected lymph nodes. These regressional changes include fibrosis, mucous 
lakes, keratin pearls and foreign body giant cell reactions. Both prepT and prepN 
categories were staged according to the pT- and pN-stages as defined by the 7th 
edition of the TNM staging manual1.
cT - stage○
Total
cT - stage○
Total
1
2
3
0
1
2
3
1
2
7
3
12
1
15
36
10
2
63
0
35
26
19
0
80
2
3
15
12
30
2
7
9
12
0
28
3
2
16
120
138
3
0
3
5
1
9
Total
7
38
135
180
Total
57
74
46
3
180
prepT - stage◊
prepN - stage◊
B
A
T-staging
Data type
ordinal
ordinal
ordinal
Data type
ordinal
ordinal
ordinal
continuous
continuous
continuous
LR χ2
6.0
5.3
14.9
LR χ2
12.2
23.9
23.2
26.2
17.1
26.8
df
2
2
3
df
3
3
3
2
2
4
ΔAIC
2.0
1.3
8.9
ΔAIC
6.2
17.9
17.2
22.2
13.1
18.8
cT-stage○
prepT-stage◊
ypT-stage∆ 
cN-stage○
prepN-stage◊
ypN-stage∆ 
prepN-stage◊
ypN-stage∆
prepN-stage◊ + 
ypN∆ 
N-staging
Legend table 3 
○   Pretreatment clinical T-stage (cT-stage) and N-stage (cN-stage) were determined by 
endoscopic ultrasonography and/or CT-scanning and/or FDG-PET-scanning and (re)
scored according to the Union for International Cancer Control (UICC) TNM Cancer 
Staging, 7th edition1. 
◊  Pretreatment pathological T-stage (prepT-stage) and N-stage (prepN-stage) repre-
sent the estimated extent of tumor before neoadjuvant chemoradiotherapy, based 
on the location of residual tumor plus regressional changes in the esophageal wall 
and resected lymph nodes. These regressional changes include fibrosis, mucous 
lakes, keratin pearls and foreign body giant cell reactions. Both prepT and prepN 
categories were staged according to the pT- and pN-stages as defined by the 7th 
edition of the TNM staging manual1.
∆   Posttreatment pathological T-stage (ypT-stage) and N-stage (ypN-stage), as mea-
sured in the resection specimen were (re)scored according to UICC TNM Cancer 
Staging, 7th edition1; pT1: (sub)mucosal involvement, pT2: proper muscle layer involve-
ment, pT3: surrounding stroma involvement; N0: no lymph node positivity, N1: 1-2 
lymph nodes positive, N2: 3-6 lymph nodes positive, N3: ≥7 lymph nodes positive.
LR χ2: likelihood ratio chi-squared statistic 
df: degrees of freedom 
ΔAIC: difference between Akaike’s information criterion25 of the model and the null- 
model. This measure represents the prognostic strength of a model and is calculated by 
the likelihood ratio chi-squared statistic (LR χ2) of the corresponding Cox proportional 
hazards model minus two times the degrees of freedom (df). A higher ΔAIC value indi-
cates better prognostic ability, adjusted for the statistical complexity of the model fit.
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Figure 1 — Overall survival according to pretreatment clinical 
T-stage (cT-stage), pretreatment pathological T-stage (prepT-stage) 
and posttreatment pathological T-stage (ypT-stage).
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Figure 2 — Overall survival according to pretreatment clinical 
N-stage (cN-stage), pretreatment pathological N-stage (prep - 
N-stage) and posttreatment pathological N-stage (ypN-stage).
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Figure 3 — Overall survival according to combined scoring of pre-
treatment pathological N-stage (prepN) and posttreatment patho-
logical N-stage (ypN).
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Abstract
Objectives
We aimed to examine the association between total number of resect-
ed nodes and survival in patients after esophagectomy with and with-
out neoadjuvant chemoradiotherapy (nCRT). 
Background Data
Most studies concerning the potentially positive effect of extended 
lymphadenectomy on survival have been performed in patients who 
underwent surgery alone. As nCRT is known to frequently ‘sterilize’ 
regional nodes, it is unclear whether extended lymphadenectomy after 
nCRT is still useful.
Methods
Patients from the randomized CROSS-trial who completed the entire 
protocol (i.e. surgery alone or chemoradiotherapy plus surgery) were 
included. With Cox regression models we compared the impact of 
number of resected nodes as well as resected positive nodes on surviv-
al in both groups.
Results
161 patients underwent surgery alone and 159 patients received mul-
timodality treatment. Median (interquartile range) number of resected 
nodes was 18(12-27) and 14(9-21), with 2(1-6) and 0(0-1) resected 
positive nodes respectively. Persistent lymph node positivity after nCRT 
had a greater negative prognostic impact on survival as compared to 
lymph node positivity after surgery alone. Total number of resected 
nodes was significantly associated with survival for patients in the sur-
gery alone arm (hazard ratio (HR) per 10 additionally resected nodes, 
0.76; p=0.007), but not in the multimodality arm (HR 1.00; p=0.98). 
Conclusions
The number of resected nodes had a prognostic impact on survival in 
patients after surgery alone, but its therapeutic value is still controver-
sial. After nCRT, number of resected nodes was not associated with 
survival. These data question the indication for maximization of lym-
phadenectomy after nCRT. 
Introduction
Esophageal cancer is associated with early and chaotic lymphatic dis-
semination to both the neck, chest and abdomen1, 2. The lymphadenec-
tomy accompanying esophagectomy is the main oncological factor 
that can be influenced by the surgeon, besides a complete resection 
of the primary tumor. Many investigators have previously attempted 
to explore the potential benefits of extended lymphadenectomy which 
include more accurate disease staging, better locoregional disease 
control, and perhaps even improved long-term survival. For staging 
purposes a more extended lymphadenectomy is intuitively superior to 
a more limited nodal dissection3, 4. The therapeutic impact of extended 
lymphadenectomy in esophageal cancer surgery, however, has re-
mained controversial. Some authors state that surgery has reached 
its maximum therapeutic impact with limited lymphadenectomy, while 
others believe that the course of the disease can be influenced favora-
bly by aggressive surgery with a more extended lymphadenectomy5,6. 
Although most studies have concluded that lymph node retrieval is 
associated with improved survival, the majority of these studies have 
been performed in patients undergoing surgery alone, which has led 
to recommendations regarding the optimal extent of lymphadenecto-
my ranging from 6-30 nodes7,8. Other studies investigated designated 
fields of dissection3,4. Prospective trials have been performed compar-
ing survival after transhiatal and transthoracic esophagectomy9, but a 
recent meta-analysis did not show any difference in survival between 
limited transhiatal and extended transthoracic operations10. 
Especially after publication of the randomized controlled CROSS trial11, 
neoadjuvant chemoradiotherapy (nCRT) has become standard of care 
for esophageal cancer patients in many countries. As nCRT is known 
to frequently ‘sterilize’ regional nodes, it is unclear whether extend-
ed lymphadenectomy after nCRT is still indicated for prognostic and 
therapeutic reasons. The aim of the present study was, therefore, to 
examine the association between the total number of resected nodes 
and survival in patients with esophageal cancer undergoing surgical 
resection with and without nCRT. 
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Methods
Study population and follow-up 
The study population consisted of patients who participated in the 
randomized CROSS-trial from March 2004 through December 200811. 
Patients with histologically confirmed, potentially curable carcinoma of 
the esophagus or esophagogastric junction were randomly assigned to 
receive surgery alone or neoadjuvant chemoradiotherapy followed by 
surgery. The randomization process was stratified for histological tumor 
type, center and clinical N-stage. Patients were excluded who under-
went exploratory thoracotomy or laparotomy only. Follow-up took place 
at regular intervals with a minimal follow-up of 24 months. 
Clinical and pathological staging
Pretreatment clinical staging included endoscopy (and ultrasonography) 
with biopsy and CT of the neck, chest, and upper abdomen; and exter-
nal ultrasonography of the neck, with fine-needle aspiration of suspect-
ed cervical lymph nodes. The surgical resection specimen was processed 
according to a standardized protocol. The clinical and pathological 
staging were based on the 6th and 7th edition of the TNM staging system 
respectively12. Tumor regression after nCRT was classified in the resec-
tion specimen as major response: ≤10% viable tumor cells and minor 
response: >10% viable tumor cells.
Neoadjuvant treatment and surgical approach
Patients randomized to neoadjuvant treatment underwent weekly admin-
istration of carboplatin (doses titrated to achieve an area under the curve 
of 2 mg/ml/min) and paclitaxel (50 mg/m2) for 5 weeks and concurrent ra-
diotherapy (41.4 Gy in 23 fractions, 5 days/week), followed by surgery. 
For esophageal carcinomas at or above the level of the carina a tran-
sthoracic esophagectomy (TTE) with two-field lymph node dissection was 
performed. For carcinomas located well below the level of the carina, 
either a TTE with two-field lymph node dissection or a transhiatal eso-
phagectomy(THE) was performed. THE encompassed en bloc dissection 
of the primary tumor and its adjacent lymph nodes under direct vision 
through the widened diaphragmatic hiatus up to the level of the inferior 
pulmonary vein. Dissected lymph nodes in the upper abdomen included 
the paracardial, lesser curvature, left gastric artery, celiac trunk, common 
hepatic artery, and splenic artery nodes. TTE included en bloc dissection 
of the azygos vein, thoracic duct, ipsilateral pleura, and all peri-esopha-
geal tissue in the posterior mediastinum. Compared to THE, the resection 
specimen after TTE additionally included the middle mediastinal, subcari-
nal, paratracheal and aortopulmonary window lymph nodes. In the pres-
ent study, ‘extended’ lymphadenectomy was defined in terms of numbers 
of lymph nodes retrieved.
Statistical analysis
Descriptive statistics included median and interquartile range for 
continuous variables and percentages for categorical variables. 
Mann-Whitney, Chi-square, and log-rank tests were used to assess 
statistical significance (p<0.05, two-sided). Overall survival was defined 
as the time interval between day of randomization and day of cen-
soring or death and analysed with Kaplan-Meier and Cox regression 
analysis. Scatter plots of number of resected nodes versus number of 
resected positive nodes were constructed separately for both random-
ization arms. In these scatter plots, lines were fitted representing equal 
probabilities of death as calculated with Cox regression models. All 
analyses were performed using SPSS version 19.0 (SPSS Inc, Chicago, 
IL, USA) and R (version 2.14, R foundation for statistical computing, 
Vienna, Austria). 
Results
Patient and tumor characteristics
Of 368 patients enrolled in the original CROSS trial, 180 were randomly 
assigned to nCRT+surgery, and 188 to surgery alone. In the nCRT+sur-
gery group 161 patients actually underwent resection, of whom two 
patients were excluded from the present analysis because of missing 
values on the exact number of resected nodes. In the surgery alone 
group 161 actually underwent resection. In both groups, two out of three 
patients had signs of lymph node involvement during pretreatment in-
vestigations (table 1). Both groups were similar in the surgical approach-
es that were chosen. nCRT resulted in clear downstaging; in almost forty 
percent of patients no vital tumor cells were identified in the esophageal 
wall after nCRT (ypT0). R
0
 resection rate increased from 69% in the sur-
gery alone group to 93% in the nCRT+surgery group (p<0.01).
Impact of nCRT on number of resected nodes and number of 
resected positive nodes 
The distribution of the number of resected nodes for both randomiza-
tion groups is presented in figure 1, showing a leftward shift (i.e. fewer 
resected nodes) in the nCRT+surgery group. Median number (interquar-
tile range) of resected nodes was 18(12-27) for the surgery alone group 
and 14(9-21) for the nCRT+surgery group (table 1). Mean difference in 
number of resected nodes between the surgery alone and nCRT+surgery 
group was 4.3 (p<0.001). Number of resected nodes was not associated 
with radicality of resection in both groups (data not shown).
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Median number (interquartile range) of resected positive nodes for the 
surgery alone and nCRT +surgery group was 2(1-6) and 0(0-1) respec-
tively (table 1), resulting in a leftward shift in the 7th TNM N-stage dis-
tribution of the nCRT+surgery group (Supplementary figure 1). Fewer 
positive nodes (mean difference, 3.4 nodes; p<0.001), but a compa-
rable number of negative nodes (mean difference, 1.0 nodes; p=0.37) 
were resected in the nCRT+surgery group as compared to the surgery 
alone group (Supplementary figure 2).
Impact of number of resected nodes on number of resected  
positive nodes 
In the surgery alone group a positive association was identified be-
tween number of resected nodes and number of resected positive 
nodes. This association was absent in the nCRT+surgery group (figure 
2). The mean number of resected positive nodes in patients who un-
derwent surgery alone ranged from 2.4 in patients with 0-10 resected 
nodes to 5.9 in patients ≥25 resected nodes. 
Impact of number of resected (positive) nodes on survival 
For surviving patients, the median follow-up was 48.7 months (range 
25.5-80.9). The overall survival rate at 5 year was 44%, with 37% in the 
surgery alone group as compared to 50% in the nCRT+surgery group 
(p=0.004). 
 
At univariable analysis, age, ypT-stage, resection margin involvement 
and number of resected positive nodes tended to be associated with 
survival in both groups (table 2). In multivariable Cox regression anal-
ysis, the number of resected nodes was significantly associated with 
survival (HR 0.76 per every 10 additionally resected nodes; p<0.01) in 
patients who underwent surgery alone. However, in the nCRT+surgery 
group, number of resected nodes was not associated with survival (HR 
1.00, p=0.87), nor was it associated with survival within ypN0, ypN1 or 
ypN1-ypN3 patients (data not shown). The number of resected posi-
tive nodes was associated with survival in both groups, but lymph node 
positivity after nCRT was associated with a more negative impact on 
survival compared to lymph node positivity after surgery alone (HR 
1.18 vs HR 1.12 per every additionally resected positive node, respec-
tively), especially in combination with a minor pathological response to 
nCRT (HR 1.38, p<0.05; data not shown). Additionally, a stratified anal-
ysis for histological tumor type showed that the significant impact of 
number of resected nodes observed in adenocarcinoma patients treat-
ed by surgery alone (every 10 additionally resected nodes HR=0.71; 
p<0.05) disappeared after nCRT (HR=1.06; n.s.). In the group of squa-
mous cell carcinoma patients there was a similar (smaller) effect after 
nCRT, but sample sizes were probably too small to reach significance 
(surgery alone: HR=0.73; n.s. vs. nCRT+surgery: HR=0.84; n.s.). 
In figure 3 scatter plots are shown that depict the same correlation 
between number of resected nodes and number of resected positive 
nodes as is visualized in figure 2, but now for all individual patients. At 
a given number of resected positive nodes, the probability of death in 
the surgery alone group will become lower when the number of resect-
ed nodes increases (figure 3A), but will remain unchanged and will even 
tend to become higher in the nCRT+surgery group (figure 3B).
 
Discussion
After nCRT, the number of resected nodes and number of resect-
ed positive nodes were significantly decreased, as compared to the 
surgery alone group. Also, the positive correlation between number of 
resected nodes and number of resected positive nodes, which was sig-
nificant in the surgery alone group, was not present in the nCRT+sur-
gery group. The number of resected nodes was an independent prog-
nostic factor for survival in patients who underwent surgery alone, but 
not in patients treated with nCRT followed by surgery. The addition of 
nCRT to surgery resulted in a significantly reduced number of resected 
positive nodes, but after this multimodality treatment node positivity 
was more strongly inversely associated with survival than after surgery 
alone.
Prognostic implications of number of resected nodes
Identifying positive nodes is informative for a patients prognosis. In 
the present study, the decreased number of nodes retrieved in the 
nCRT+surgery group resulted exclusively from a reduction in number of 
resected positive nodes, while the number of resected negative nodes 
was similar in both groups (Supplementary figure 2). This might be 
because many positive nodes are sterilized by nCRT13. Therefore, many 
initially positive nodes will contribute to the node negative category 
in the resection specimen after nCRT. The overall decrease in nodes 
resected after nCRT might therefore be compensated in the node neg-
ative category by the addition of formerly positive (i.e. sterilized) nodes. 
Interestingly, not only did the number of resected nodes and number 
of resected positive nodes decrease upon addition of nCRT to surgery, 
also the ‘upstaging’ effect of number of resected nodes on number of 
resected positive nodes disappeared (figure 2). This (absent) correlation 
suggests that the number of resected positive nodes found after nCRT 
is less dependent on sampling compared to resected positive nodes 
found after surgery alone. 
In patients treated with surgery alone, the number of resected nodes 
was not correlated with overall survival in univariable analysis. How-
ever, in multivariable analysis, after correction for the number of 
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resected positive nodes, the number of resected nodes did show an 
independent association with overall survival (table 2). The difference 
in association from univariable to multivariable analysis is most like-
ly caused by the dominant and confounding effect of resected posi-
tive nodes. Thus, after correction for the number of resected positive 
nodes, the smaller but significant prognostic effect of number of re-
sected nodes is revealed. 
For patients undergoing nCRT plus surgery, however, neither in univar-
iable analysis, nor in multivariable analysis an association was found 
between the number of resected nodes and overall survival. Apparent-
ly, the prognostic value of the total number of resected nodes for sur-
vival is lost in patients treated with nCRT + surgery, even after correc-
tion for the number of resected positive nodes.
In the CROSS trial, the favorable effect of nCRT on lymph node positiv-
ity has been clearly shown: in the surgery alone group 76% of patients 
were pathologically node positive, versus 32% in the nCRT+surgery 
group. However, lymph node positivity in the nCRT+surgery group in 
itself tended to have a stronger negative prognostic impact on survival 
as compared to that in the surgery alone group. Apparently, persistent 
lymph node positivity after nCRT reflects a biologically unfavorable tu-
mor biology, which is in line with previous publications14-17. 
Therapeutic considerations
After correction for the number of resected positive nodes, the num-
ber of resected nodes was significantly associated with survival in the 
surgery alone group (table 2). Removal of negative nodes might hence 
have not only a prognostic impact, but also a therapeutic impact in this 
group. The most important hypothesis supporting such genuine survival 
benefit of an extended lymphadenectomy is the clearance of microme-
tastases that can be present in up to 50% of histology-negative nodes 
and are associated with a poor outcome18-20. 
Some previous studies have shown that increasing the number of re-
sected nodes is still relevant after nCRT21-23, while other studies have 
concluded that it is not.16, 24-26 In the present data, within the nCRT+-
surgery group, no such prognostic impact of the number of resected 
nodes could be identified, let alone any therapeutic impact on survival. 
This could possibly be explained by the sterilization of micrometastases 
after chemoradiotherapy.27 
Some authors question any therapeutic impact of extended lymphad-
enectomy. In their view, lymph node metastases are simply markers 
of systemic disease and removal of the primary lesion plus the easily 
accessible peritumoral nodes alone will yield a similar survival28. Their 
alternative explanation is that the suggested therapeutic effect is 
based on stage migration. Stage migration occurs when positive nodes 
in the extended part of the dissection change N-stage to a higher 
category (surgery alone group in figure 2), but at the same time have 
a more favorable prognosis than patients with a similar number of pos-
itive nodes from a more limited dissection (the so-called ‘Will Rogers 
phenomenon’29). This ‘stage purification’ leads to unreliable stage-by-
stage comparisons of survival. 
In the present study, ‘extended lymphadenectomy’ was defined in 
terms of numbers of lymph nodes retrieved, which is a more reliable 
variable to study compared to surgical approach, which is not always 
synonymous with extent of lymph node stations sampling. Unfortu-
nately, data on the exact location of lymph node stations from which 
individual lymph nodes were retrieved were not available. The strength 
of the present study is that patients were randomized. Therefore, the 
described difference in impact of the number of resected nodes on 
survival between both arms can be attributed to neoadjuvant chemo-
radiotherapy specifically. The multicenter design is both a strength 
(because of great variability and therefore generalizability) and a limi-
tation (since there was no strict protocol for surgical approach nor for 
extent of lymph node stations sampling). To properly address the im-
pact of surgical approach on lymph node retrieval and survival, a new 
randomized trial should be performed comparing a transhiatal and 
transthoracic approach after nCRT. Finally, the relatively small number 
of patients per randomization arm limited the statistical power. 
In conclusion, lymph node positivity, especially if persistent after nCRT, 
is a strong negative prognostic factor for overall survival. The number 
of resected lymph nodes has an independent prognostic impact on 
survival in patients who undergo surgery alone. The therapeutic value 
of extended lymphadenectomy, however, remains questionable in this 
group. After nCRT, the number of resected nodes is not associated with 
survival. These data question the indication for maximization of lymph 
node dissection after nCRT for staging purposes as well as for thera-
peutic reasons. 
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Table 1 — Clinical and tumor characteristics of 320 patients with 
esophageal or junctional cancer who underwent surgical resection 
with or without neoadjuvant chemoradiotherapy (nCRT) in the 
CROSS trial11. 
60 (54-66)
129 (80.1)
37 (23.0)
121 (75.2)
3 (1.9)
3 (1.9)
16 (9.9)
123 (76.4)
18 (11.2)
1 (0.6)
11 (6.8)
73 (45.3)
69 (42.2)
8 (5.0)
53 (32.9)
100 (62.1)
8 (5.0)
87 (54.0)
72 (44.7)
2 (1.2)
n/a
-
13 (8.1)
19 (11.8)
126 (78.3)
3 (1.9)
111 (68.9)
49 (30.4)
1 (0.6)
39 (24.2)
43 (26.7)
41 (25.5)
38 (23.6)
18 (12-27)
2 (1-6)
60 (55-67)
121 (76.1)
37 (23.3)
119 (74.8)
3 (1.9)
2 (1.3)
24 (15.1)
111 (69.8)
22 (13.8)
-
5 (3.1)
50 (31.4)
68 (42.8)
36 (22.6)
56 (35.2)
101 (63.5)
2 (1.3)
88 (55.3)
71 (44.7)
47 (29.6)
62 (39.0)
15 (9.4)
32 (20.1)
48 (30.2)
1 (0.6)
1 (0.6)
147 (92.5)
12 (7.5)
108 (67.9)
35 (22.0)
11 (6.9)
5 (3.1)
14 (9-21)
0 (0-1)
Legend table 5
* Clinical lymph-node (N) stage was assessed by means of endoscopic ultrasonogra-
phy, CT, or 18F-fluorodeoxyglucose positron-emission tomography and was classified 
according to 6th edition of the UICC TNM classification; ‡TTE=transthoracic esophagec-
tomy; THE=transhiatal esophagectomy; †Pathologic TNM stage was classified according 
to the 7th edition of the UICC TNM staging system; ∞R
0
=resection margin microscopically 
tumor-free, ≥ 1mm; R
1
=resection margin macroscopically tumor-free, but microscopically 
<1mm; оPathologic node category according to 7th TNM-staging system: N0 (no positive 
nodes), N1 (1-2 positive nodes), N2 (3-6 positive nodes) and N3 (>6 positive nodes).
Age – median [years] (interq. range)
Male sex – no. (%)
Tumor type –no. (%)
Squamous cell carcinoma
Adenocarcinoma
Other 
Tumor location –no. (%)
Proximal third esophagus 
Middle third esophagus
Distal third esophagus 
Esophago-gastric junction
Not specified
Differentiation grade in biopsy –no. (%)
Well differentiated
Moderately differentiated
Poorly differentiated
Not specified
Clinical N-stage (TNM6)* –no. (%)
cN0
cN1
Not specified
Operative approach‡ –no. (%)
TTE
THE
Other
Complete pathological response –no. (%)
(y)pT stage (TNM7†)
0/is
1
2
3
4
Not specified
Resection margin involvement∞ –no. (%)
R
0
R
1
Not specified
(y)pN stage (TNM7о) –no. (%)
0
1
2
3
Number of resected nodes – 
median no. (interq. range)
Number of resected positive nodes – 
median no. (interq. range)
Surgery alone
(n=161)
Surgery alone
(n=161)
nCRT + Surgery
(n=159 )
nCRT + Surgery
(n=159 )
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Table 2 — Hazard ratios (HR) for overall survival from univariable and 
multivariable Cox-regression analysis in 320 esophageal or junction-
al cancer patients who underwent surgical resection with or without 
neoadjuvant chemoradiotherapy (nCRT) in the CROSS trial 11.
Category
Every 10 additional years 
0/in situ
ypT1
ypT2
ypT3
ypT4
R
0
R
1
 
Every 10 additionally  
resected nodes 
Every additionally 
resected positive node
Category
Every 10 additional years 
0/in situ
ypT1
ypT2
ypT3
ypT4
R
0
R
1
 
Every 10 additionally  
resected nodes 
Every additionally 
resected positive node
Surgery alone
1.28 (1.03-1.60)
n/a
0.12 (0.03-0.50)
0.56 (0.30-1.06)
1 (ref)
0.28 (0.04-2.04)
1 (ref)
1.34 (0.90-2.00)
0.95 (0.79-1.14)
1.11 (1.08-1.15)
Surgery alone
1.20 (0.94-1.52)
n/a
0.14 (0.03-0.59)
0.80 (0.42-1.54)
-
0.25 (0.03-1.69)
-
1.42 (0.93-2.10)
0.76 (0.61-0.95)
1.12 (1.08-1.16)
nCRT+surgery
1.16 (0.90-1.51)
0.48 (0.29-0.81)
0.64 (0.28-1.44)
0.55 (0.31-1.01)
-
7.11 (0.92-54.84)
-
1.62 (0.78-3.38)
1.02 (0.84-1.25)
1.15 (1.06-1.25)
nCRT+surgery
1.26 (0.93-1.70)
0.55 (0.32-0.95)
0.64 (0.28-1.51)
0.44 (0.23-0.85)
-
5.44 (0.62-47.74)
-
1.20 (0.53-2.73)
1.00 (0.84-1.25)
1.18 (1.07-1.29)
Age
(y)pT stage
Resection margin  
involvement
Number of resected nodes 
Number of resected 
positive nodes 
Age
(y)pT stage
Resection margin  
involvement
Number of resected nodes 
Number of resected 
positive nodes 
Univariable analysis (HR (95% CI))
Multivariable analysis (HR (95% CI))
Figure 1 — Distribution of number of resected lymph nodes as 
assessed in the resection specimen of patients who underwent 
surgery alone (n=161) or neoadjuvant chemoradiotherapy (nCRT) 
followed by surgery (n=159). Compared to the surgery alone group, 
a leftward shift (i.e. fewer resected nodes) was observed in the 
nCRT+surgery group.
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Figure 3 — Correlation between number of resected nodes 
and number of resected positive nodes in individual patients 
who underwent surgery alone (A: n=161) or neoadjuvant 
chemoradiotherapy (nCRT) followed by surgery (B: n=159). Open 
circles indicate patients who were alive at end of follow-up; closed 
circles indicate patients who had died at end of follow-up.
Legend figure 3
Lines represent equal probabilities of death as can be calculated by the proportion 
of closed (dead) and open (alive) circles. In both groups (A and B), an increase in the 
number of resected positive nodes results in a higher probability of death. In the pa-
tients who underwent surgery alone, lines are sloped i.e. at a given number of resected 
positive nodes more resected nodes in the specimen are associated with a decreased 
probability of death (A). In patients in the nCRT+surgery group, the probability lines 
have a more horizontal course, i.e. at a given number of resected positive nodes more 
resected nodes are not associated (and even tend to be positively associated) with 
probability of death (B). 
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Figure 2 — Correlation between number of resected nodes 
(quartiles) and mean number (95% confidence interval) of resected 
positive nodes in patients who underwent surgery alone (n=161) or 
chemoradiotherapy (nCRT) followed by surgery (n=159). 
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Supplementary figure 1 — Pathological N-stage according to 
7th edition of TNM staging system as assessed in patients who 
underwent surgery alone (n=161) or neoadjuvant chemoradiotherapy 
(nCRT) followed by surgery (n=159). Data indicate a leftward shift 
(i.e. fewer resected positive nodes) in the nCRT+surgery group. 
N0=no positive lymph nodes;  
N1=1-2 positive lymph nodes;  
N2=3-6 positive lymph nodes;  
N3=more than 6 positive lymph nodes. 
Supplementary figure 2 — Comparison of mean number of positive 
and negative lymph nodes as assessed in the resection specimen 
of patients who underwent surgery alone (n=161)or neoadjuvant 
chemoradiotherapy (nCRT) followed by surgery(n=159).
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Extra discussions
of the study, as unknown factors affect 
survival. Factors known to affect survival, 
such as metastatic lymph nodes, need to 
be stratified. In your study, you stratified 
tumor histology, the center in which the 
operation was performed and the number 
of metastatic lymph nodes based on clinical 
staging. It would be difficult to stratify for 
metastatic lymph nodes by a clinical stag-
ing, when it had, according to my calcula-
tions, a 73% error rate, compared to the 
pathologic staging in the surgical alone arm 
of the study. Would you agree with this, and 
if not, do you have any way of confirming 
that there was an even distribution of met-
astatic lymph nodes in the 2 arms of the 
study, when using a clinical staging process 
with a 73% error rate?
Third, your question of the benefits of the 
en bloc esophagectomy to maximize lymph 
node resection after neoadjuvant chemo-
radiotherapy is in conflict with the expe-
riences of others, of whom I am one, who 
have reported that en bloc esophagectomy 
provides a significantly better survival rate 
than THE for patients who have a complete 
response or who have had residual disease 
after neoadjuvant chemoradiotherapy. Is 
there any way you can reconcile these pos-
itive findings against your rather negative 
suggestions?
Response From K. Talsma, J. van Lanschot 
(Rotterdam, The Netherlands): 
Thank you, Professor Demeester, for your 
questions. I will start with your first ques-
tion, in which you refer to the surgical 
approach, which is heterogeneous in our 
population. At the end of the day, I think 
that what the reader would perhaps like 
to know is whether a more limited surgical 
Discussants 1
T. R. Demeester (Los Angeles, CA):
To Dr Talsma and the members of the 
CROSS trial, I want to congratulate you on 
a very carefully done and impeccably ana-
lyzed study. You have shown us that lymph 
nodes containing metastatic tumors have 
a prognostic impact on survival and can be 
destroyed through neoadjuvant chemora-
diotherapy. You have also shown us that as 
the surgical therapy increases the number 
of nodes removed, survival also increases. 
But, this does not hold true for surgery after 
neoadjuvant chemoradiotherapy. And you 
have shown us that involved lymph nodes 
not destroyed by neoadjuvant chemora-
diotherapy have a greater negative im-
pact on survival than unexposed involved 
nodes. Based on these observations, you 
question, in your manuscript, the benefit 
of an en bloc esophagectomy to maximize 
lymph node resection to improve survival 
after neoadjuvant chemoradiotherapy. Your 
question is reasonable if the 2 assumptions 
are correct. The first assumption is that the 
surgical resections done in the study, tran-
shiatal and transthoracic esohagectomy, 
were similar to the number of lymph nodes 
removed. The second assumption is that 
the stratification of involved lymph nodes 
was equal in the 2 arms of the study.
I have 3 questions for you: First, were the 
operations performed, whether transhiatal 
or transthoracic esophagectomies, simi-
lar in the number of nodes removed? If so, 
what was the basis for this conclusion, and 
if not, how did you adjust this factor?
Second, randomization is designed to be 
evenly distributed between the 2 arms 
approach after chemoradiotherapy would 
be acceptable. But, for us, it is impossible to 
answer this question with the present data. 
I agree that there were no strict instruc-
tions for surgical approach or extended 
lymphadenectomy. There were no instruc-
tions, in terms of the locations of nodes, so 
that they could be sampled or removed. 
But, we think that these specific surgical 
center preferences will be equally distrib-
uted in both randomization arms because 
this was stratified for each surgical center, 
and therefore, for surgical approach, and 
perhaps, surgical effort or aggressiveness. 
We are aware that defining extended lym-
phadenectomy only in terms of the num-
ber of nodes is a simplification. Extended 
lymphadenectomy is also about location, of 
course, and approach. However, we decid-
ed to use numbers because we think that 
they are more reliable and robust than 
surgical approach alone, as a transthorac-
ic approach might in some cases even be 
less aggressive than a transhiatal ap-
proach; however, it is not synonymous with 
extended lymphadenectomy. In response 
to your question of whether a more limit-
ed approach is acceptable after chemo-
radiotherapy, thiswould really need a new 
HIVEX-type of randomized trial in the era of 
chemoradiation. 
Your second question refers to the rand-
omization process, which is used to stratify 
for unknown confounders. I fully agree that 
you should not correct things, which you 
are actually really interested in, such as the 
clinical stage you mentioned. Up until now, it 
is still very disappointing how poorly we can 
predict what the N stage actually is before 
surgery and neoadjuvant treatment. You 
mentioned that the error rate is also very 
high in the surgical alone group, if you com-
pare the clinical N stage with the patho-
logical data on lymph node involvement. Ac-
tually, we did a stratified analysis for clinical 
N stage and there was no difference. This 
is probably because it is just determined by 
the flip of a coin, or the chance that lymph 
nodes are involved during clinical staging. 
The chance that, at baseline, the actu-
al number of positive nodes was different 
between the 2 randomization arms is as 
high as it is for the other confounders to 
be different, and we know that all of these 
were symmetrically distributed between 
the 2 groups. The third question refers to 
the other studies published. I am aware of 
the paper you mentioned. In patients with 
a complete pathological response, it was 
shown that there was still an increased 
survival for extended lymphadenectomy. 
But, I think that it was also mentioned in 
the paper that patients who really bene-
fited from this extended surgical approach 
were nonresponders in the T-stage and had 
persistent nodal disease. So, these are the 
patients who depend more on the surgical 
part of the treatment than others. It still 
corroborates our hypothesis that there is a 
local clearance effect on the surgical field 
because of chemoradiation, and patients 
with persistent nodal disease depend more 
on surgical treatment.
81
Discussants 2
R. van Hillegersberg (Utrecht,  
The Netherlands): 
Thank you very much for your interest-
ing results. You mentioned that you think 
that the number of nodes is lower in the 
chemoradiotherapy group, due to the fact 
that the positive nodes cannot be identified 
anymore; they have been destroyed by the 
chemoradiotherapy. How did you conclude 
this, as I think that you did not show any
evidence for this?
Another comment is that you also showed 
that there are still positive nodes, even in 
patients with complete tumor response to 
chemoradiotherapy. So, I think it would be 
too early to conclude that we could omit 
the lymphadenectomy in esophageal re-
section. There is no reliable diagnostic tool 
available to preoperatively identify patients 
with positive nodes after chemoradiation. 
So, even if you performed a restaging with 
biopsies, which did not show a viable tumor 
in the esophagus, I think we cannot omit an 
extended lymphadenectomy based on the 
results of this study.
Response From K. Talsma, J. van Lanschot 
(Rotterdam, The Netherlands): 
We do not actually think that there is 
preferential sterilization of positive nodes. 
However, it has been shown that there is 
lymphocytic stroma fibrosis after radiation. 
Some lymph nodes really disappeared, and 
both positive and negative lymph nodes will 
disappear. However, the reduction in neg-
ative nodes will have been compensated 
by positive nodes, which became negative. 
Actually, if you imagine that this is a glass 
of Guinness (see Supplemental figure 2 in 
the manuscript), the foam will go down into 
the beer a little bit. So, in both groups, there 
is not a preferential sterilization with either 
positive or negative nodes, but the negative 
nodes were just compensated by the nodes 
that were positive before. Finally, I also 
agree that it is too early to omit an extend-
ed lymphadenectomy after this study. 
Discussants 3
J. Reynolds (Dublin, Ireland):
Can I ask you whether, based on your data, 
the proponents of the value of lymph node 
ratio should reconsider this position, particu-
larly in patients who have had neodjuvant 
chemoradiation? It really is all about the 
number of involved nodes; this numerator 
is key as long as the denominator is a large 
enough sample size. This is certainly my 
opinion—the number of positive nodes out-
weighs a ratio, which is impacted by neoad-
juvant therapy. What is your view on this?
Response From K. Talsma, J. van Lanschot
(Rotterdam, The Netherlands): We deliber-
ately decided to use positive and negative 
nodes, and not the lymph node ratio, as this 
would be difficult to use. If 68% of patients 
will become lymph node negative, then the 
nominator will be, for the biggest part, 0. We 
also think that it is easier to interpret the 
data if you just stick to positive and negative 
nodes.
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Abstract
Purpose
Esophageal adenocarcinoma (EAC) is a highly aggressive disease with 
poor long-term survival. Despite growing knowledge of its biology, no 
molecular biomarkers are currently used in routine clinical practice to 
determine prognosis or aid clinical decision making. Hence, this study 
set out to identify and validate a small, clinically applicable immunohis-
tochemistry (IHC) panel for prognostication in patients with EAC.
Patients and Methods
We recently identified eight molecular prognostic biomarkers using two 
different genomic platforms. IHC scores of these biomarkers from a 
UK multicenter cohort (n=374) were used in univariate Cox regression 
analysis to determine the smallest biomarker panel with the greatest 
prognostic power with potential therapeutic relevance. This new panel 
was validated in two independent cohorts of patients with EAC who 
had undergone curative esophagectomy from the United States and 
Europe (n=666).
Results
Three of the eight previously identified prognostic molecular biomark-
ers (epidermal growth factor receptor [EGFR], tripartite motif-contain-
ing 44 [TRIM44], and sirtuin 2 [SIRT2]) had the strongest correlation 
with long-term survival in patients with EAC. Applying these three bio-
markers as an IHC panel to the validation cohort segregated patients 
into two different prognostic groups (p=0.01). Adjusting for known 
survival covariates, including clinical staging criteria, the IHC panel 
remained an independent predictor, with incremental adverse overall 
survival (OS) for each positive biomarker (hazard ratio, 1.20; 95% CI, 
1.03 to 1.40 per biomarker; p=0.02).
Conclusion
We identified and validated a clinically applicable IHC biomarker panel, 
consisting of EGFR, TRIM44, and SIRT2, that is independently associat-
ed with OS and provides additional prognostic information to current 
survival predictors such as stage.
Introduction
Esophageal adenocarcinoma (EAC) is a highly lethal cancer with a 
rapidly increasing incidence in the western world.1 Despite advances 
in clinical care, the prognosis for EAC remains dismal with less than 
20% of patients surviving 5 years.2 Currently, standard staging algo-
rithms based on tumor depth (T-stage), the presence and number of 
regional nodes with metastatic disease (N-stage), and the presence 
or absence of distant metastasis (M-stage) are used to predict sur-
vival for these patients.3 This approach, however, does not take into 
account the biology and molecular features of each individual tumor, 
which may explain the widely varying 5-year overall survival, rang-
ing from 11 to 41%, within groups of patients who otherwise appear 
similar by these standard staging algorithms.4 It is increasingly evident 
that tremendous heterogeneity between patients exists in the biology 
underlying esophageal adenocarcinoma; and hence the ideal staging 
system would take into account the biology and molecular features 
of each individual tumor and correlate prognosis with patient-specific 
tumor biomarkers.5,6 Importantly, advancing knowledge of the molec-
ular characteristics of the tumor would also enable the application of 
targeted therapies to improve selective killing of cancer cells.7-9
Our group has previously described two independent methods to identi-
fy molecular prognostic markers in EAC using gene expression analysis 
and array-comparative genomic hybridization arrays.10,11 These two in-
dependent studies identified eight biologically relevant molecular targets 
(TRIM44, SIRT2, EGFR, PAPPS2, NEIL2, WT1, MTMR9, DCK) which could 
be screened via immunohistochemistry (IHC) to help prognosticate pa-
tients with EAC. However, testing for multiple biomarkers via IHC would 
decrease clinical applicability and also, not all identified targets appear 
to have equal prognostic or therapeutic value. Therefore, to facilitate 
clinical utility, we aimed to create a small optimized panel of IHC mark-
ers selected from these eight potential molecular targets that can be 
used to segregate patients into different prognostic groups.
Methods
Study population used in generation and validation of best 
prognostic targets
Our original study cohort from six tertiary centers (OCCAMS study 
group) in the United Kingdom used to identify the eight molecular prog-
nostic markers in EAC has previously been described.10,11 Briefly, this 
cohort consisted of 374 patients with esophageal and gastroesoph-
ageal junction adenocarcinomas who underwent potentially curative 
surgery at one of the six OCCAMS centers.
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For independent validation of the refined IHC biomarker panel, two 
independent retrospective cohorts of EAC patients (where paraffin 
material is available) from the University of Pittsburgh Medical Centre 
(UPMC) and the Erasmus MC, University Medical Center Rotterdam 
(EMC) were used. Following approval by the relevant institutional re-
view boards, the clinical data from both centers were combined into a 
single database and reviewed for consistency. All patients had patho-
logically confirmed adenocarcinoma of the esophagus or gastroesoph-
ageal junction (GEJ), underwent esophagectomy with curative intent, 
and were followed up at their respective centers. In total, 363 patients 
from University of Pittsburgh Medical Center (UPMC; 1996-2009) in 
Pittsburgh, Pennsylvania and 314 patients from Erasmus Medical 
Center (EMC; 1995-2006) in Rotterdam were included as a combined 
validation cohort (n=677). 
Clinical characteristics of patients from both validation centers are de-
tailed in table 1. As expected, most patients who underwent surgery in 
both centers were male. However, there are some notable differences 
in clinical characteristics between the 2 centers. Patients from Pitts-
burgh were slightly older (67.0 versus 64.7 years old p<0.001) and had 
a shorter follow up time (24.5 versus 24.2 months p=0.039). More pa-
tients in the Pittsburgh cohort had an R
0
 resection (94.4 versus 70.1 % 
p<0.001); accompanied by a lower rate of recurrence (36.8 versus 64.0 
per cent p<0.001). More patients from the Pittsburgh cohort also had 
earlier T-stage and correspondingly fewer patients from Pittsburgh 
had neoadjuvant chemotherapy compared to patients from Rotterdam 
(2.5 versus 14.8 % p<0.001). 
Generation and validation of a biomarker panel 
to prognosticate EAC patients
To generate a new IHC biomarker panel from the previously identified 
eight molecular prognostic targets, a Cox proportional hazards mod-
el was used to evaluate the hazard ratio for each molecular target in 
order to rank their prognostic importance. Molecular targets with the 
highest hazard ratios were selected and brought forward for validation 
in the above mentioned cohorts of EAC patients. 
For validation of the three selected molecular targets as a prognostic 
IHC panel, archival slides from each tumor specimen from UPMC and 
EMC were reviewed by an expert pathologist who marked out are-
as representative of the tumor, accounting for tumor heterogeneity. 
Cores (0.6 mm) from 3 areas were then removed from paraffin blocks 
and TMAs constructed. IHC was performed on a Bond System (Leica 
Microsystems (UK) Ltd, Milton Keynes, UK) according to manufactur-
er’s recommendations. Antibody sources, conditions used for IHC and 
scoring criteria are detailed in supplementary materials and methods. 
Clinical End Points and Statistical analysis
The primary clinical end point in the validation study is overall surviv-
al (OS), defined as the time from surgery to death resulting from any 
cause. Patients who died within one month of surgery were deemed to 
have post-operative mortality and were excluded from further analy-
sis. In total, 666 patients were included in the survival analysis. Death 
beyond 5 years was censored. To compare differences in demograph-
ic and clinical factors between the two validation cohorts, Student’s 
t-test or Mann-Whitney test was used for continuous variables and 
the chi-square test was used for categorical variables. Kaplan-Meier 
curves were plotted to compare the five-year survival by the number 
of dysregulated molecular targets in the IHC panel. A multivariate Cox 
proportional hazards model was used to estimate the independent 
association between the IHC panel and prognosis after adjusting for 
demographic and clinical factors. A p-value of < 0.05 was considered 
statistically significant. All analyses were done using SPSS version 19.0 
(SPSS Company, Chicago, IL).
Results
Generation of the revised prognostic biomarker panel
Using univariate Cox regression, IHC scores for each of the eight mo-
lecular prognostic targets were analyzed together for the first time in 
the original OCCAMS cohort (n=374). A significantly increased haz-
ard for death was identified with dysregulation of EGFR, TRIM44 and 
SIRT2. (Supplementary table 1) Dysregulation of PAPPS2, NEIL2 and 
MTMR9 were associated with a non-significant increased hazard ratio 
for death, whereas WT1 and DCK were associated with a non-sig-
nificant decreased hazard ratio for death. The biomarkers that were 
statistically significantly associated with differential hazard for death 
(TRIMM44, SIRT2 and EGFR) were then selected for inclusion into a 
combined biomarker panel for validation. 
Validation of the revised prognostic biomarker panel
Validation of the new biomarker panel comprising TRIMM44, SIRT2 and 
EGFR began with internal validation using the OCCAMS study group. 
(Supplementary figure 2) In the OCCAMS study patients, median sur-
vival time for patients with 0, 1, 2 and 3 dysregulated molecular mark-
ers is 44.7, 18.2, 14.0, and 7.0 months respectively (p=0.002). For every 
one additional dysregulated molecular marker, the HR increases by 
1.44 (95% CI 1.18 to 1.75). After adjusting for age, sex, T stage, N stage, 
neoadjuvant chemotherapy, and tumor differentiation (grade), the 
hazard for death for each additional dysregulated molecular biomarker 
increased by 1.35 (95%CI 1.09 to 1.68). 
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External validation of the IHC 3-biomarker panel was then performed 
on the cohort of patients from UPMC and EMC (table 2). When pa-
tients in the validation cohorts were grouped according to the total 
number of dysregulated markers, there was no difference in the overall 
survival of patients with 0 or 1 dysregulated markers (median survival 
time=38.8 months versus 29.8 months respectively, p=0.48). These two 
groups of patients were hence combined into one prognostic group. 
Due to the small number of patients with 3 dysregulated markers, 
these patients were also combined with patients with 2 dysregulated 
markers to facilitate clinical utility of the IHC panel. Patients with 2 or 
3 dysregulated markers had a much poorer prognosis compared with 
patients with 0 or 1 dysregulated marker (Median survival 22.0 months 
versus 31.4 months respectively, p=0.004) (figure 1). The relative haz-
ard ratios with dysregulation for each individual target are shown in 
Supplementary table 2. Representative examples of dysregulated and 
non-dysregulated IHC expression of TRIMM44, SIRT2 and EGFR per-
formed on the validation cohorts from Pittsburgh and Rotterdam are 
shown in figure 2. The results of the IHC panel for each of the individual 
validation cohorts are shown in Supplementary figure 3.
Determining the independent prognostic value of the 3-biomarker 
IHC panel
Having demonstrated that the 3-biomarker panel had significant 
and additive predictive value for long-term survival, multivariate Cox 
regression analysis was performed to determine whether the IHC 
panel provided additional prognostic information independent of 
clinco-pathological features known to affect prognosis. Adjusting for 
centre, pathological T stage, N stage, age, sex, resection margin status, 
tumor differentiation and treatment with neoadjuvant chemotherapy, 
the results of the IHC panel remain significant in the multivariate cox 
regression model. (table 3) As seen from table 3, the hazard ratio for 
death increases by 1.20 (95% CI 1.03 to 1.40) for each increase on the 
IHC panel. The prognostic value of combined pathologic stage and in-
creasing number of molecular markers was then assessed. Stratifying 
patients with both stage and number of molecular markers showed a 
clear separation of the entire cohorts into distinct prognostic groups in 
the validation cohorts (figure 3, p<0.001). The breakdown of all pa-
tients in various stages of the disease and number of molecular marker 
dysregulated are detailed in Supplementary table 3. Patients in stage 
I disease cannot be further stratified with the IHC panel. However, 
patients in stage II and III disease can be prognosticated based on the 
number of markers dysregulated. Patients with stage II disease have 
an increased hazard ratio for death of 1.376 (95% CI 1.018 to 1.860) 
for each increase on the IHC panel while patients with stage III disease 
similarly have an increased risk of death for every increase in number 
of dysregulated marker (HR 1.215, 95% CI 1.031 to 1.433).
Discussion
This present study demonstrates that a IHC panel consisting of a com-
bination of three molecular markers generated and validated on 1040 
EAC patients can be used to aid prognosis prediction in EAC patients. 
Furthermore, this IHC panel is independent of clinical features known 
to influence prognosis and can serve as an adjunct to current staging 
systems. 
Reducing mortality from advanced esophageal adenocarcinoma 
remains the greatest challenge in the field.12,13 To achieve this aim, 
accurate prognostication, development of better surgical care and 
chemo-radiotherapeutic regimes as well as identification of novel ther-
apeutics are key areas to address.5,6,12,14-16 
Previous studies have attempted to better determine prognosis for 
EAC patients using nomograms based on clinical features.17-19 There 
have also been a large number of studies correlating molecular mark-
ers, identified by either a candidate gene approach or by a gene ex-
pression microarray approach, to prognosis in this disease.5,20,21 Howev-
er, none of these molecular panels have reached clinical utility, largely 
because these biomarkers or prognostic signatures are generated in 
underpowered cohorts. To best determine prognosis, we envision that a 
combination of clinical features and well-validated prognostic mark-
ers will be required to stratify EAC patients into clinically meaningful 
prognostic subgroups. Importantly, the molecular markers used must 
be independent of clinical features and ideally should account for the 
biology of these tumors rather than being purely molecular ‘passen-
gers’. This strategy formed the basis of this study to identify an in-
dependently prognostic IHC signature to be used in conjunction with 
current staging modalities.
The primary goal of this study was to identify a panel of biomarkers 
that could be readily implemented into clinical practice and provided 
improved prognostication for patients with this disease. This alone is 
of value to patients and their providers as it will facilitate more ac-
curate discussions about long-term survival when compared to the 
discussion using current clinico-pathologic features alone. The ultimate 
goal, however, would be to use these molecular biomarkers to guide 
therapeutic interventions. Unlike other cancer types such as breast 
cancer, colorectal cancer and non-small cell lung cancer where target-
ed therapies are already in clinical use,22 targeted therapy for EAC is 
still in its infancy. Biomarker targets with prognostic significance and 
biologic importance in tumor development would be the ideal clinical 
panel. Based on our own work and that of other investigators, the 3 
biomarkers in our panel may provide both prognostic significance and 
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aid in identification of patient subgroups in whom targeted therapy 
may be useful. For example, EGFR is currently being evaluated as a 
potential target for therapy in this disease.23,24 SIRT2 is a gene with 
known tumour suppressor and oncogenic functions in different tumour 
subtypes. In EAC, our data strongly suggest SIRT2 to be a tumour sup-
pressor. A recent report highlighted SIRT2 to be a tumour suppressor in 
hepatocellular carcinoma and breast cancers by regulating mitosis and 
genome integrity25. Importantly, the authors report that SIRT2 deficien-
cy causes increased levels of Aurora-A and Aurora-B (mitotic regula-
tors) which results in promotion of tumour growth. Inhibitors targeting 
Aurora-A and Aurora-B are already being evaluated in clinical trials 
with promising results26-28. The next step would be to evaluate if SIRT2 
deficient EAC would respond to targeted therapy with Aurora inhibitors 
in clinical studies. Lastly, TRIM44 belongs to a large family of TRIM pro-
teins and recent scientific advances have identified this class of pro-
teins to have the potential for pharmacological inhibition in cancer.29,30 
Although TRIM44 has previously unknown functions, recent data from 
our laboratory have demonstrated that EAC and breast tumours with 
high TRIM44 levels are highly susceptible to mTOR inhibition in vitro and 
in vivo, highlighting the fact that TRIM44 expression levels could serve 
as a biomarker for sensitivity to mTOR inhibitors.31 
A major strength of our study is the use of a simple IHC panel consist-
ing of three molecular markers as a tool to help prognosticate EAC pa-
tients. These 3 molecular targets were identified as the most prognos-
tic targets out of the 8 previously identified targets from our previous 
publications.10,11 Consistently, the combined panel of these 3 marker 
could be used to predict prognosis in EAC patients independently of 
current staging algorithms. Existing pathology services can easily 
adopt the IHC panel as a routine test to determine the status of these 
three molecular prognostic targets. The determination of whether 
a tumor is dysregulated or not for these markers is also straightfor-
ward and can be done in the same setting when a pathologist reviews 
the slides for staging. This is in contrast to using other more sophis-
ticated platforms that are often not available or appropriately opti-
mized in many clinical settings. A prime example of a molecular target 
being utilized in the clinic due to ease of detection with IHC is HER2/
NEU. HER2/NEU is a molecular target screened in breast cancers with 
IHC and fluorescent in-situ hybridization (FISH); patients with tumors 
overexpressing HER2/NEU have been shown to benefit from treatment 
with trastuzumab.32 Because our biomarkers have been optimized in 
IHC using paraffin-embedded tissues, we were able to capitalize on 
the large stores of EAC specimens in pathology repositories at two 
high volume centers to perform our validation. This provided a large 
number of patients from each center and made the validation process 
significantly more robust; importantly, this allowed for multivariate Cox 
regression to dissect the role of various known prognostic factors. In 
addition, the fact that the biomarker panel worked in both cohorts of 
patients provided evidence that this IHC biomarker panel was gener-
ally applicable to patients with EAC independent of the differences in 
clinical practices. Lastly, the IHC panel could potentially be applied to 
preoperative biopsies in order to prognosticate patients pre-operative-
ly. This will circumvent problems from using other techniques where the 
availability of sufficient tissue for extraction of DNA, RNA or proteins 
can be problematic.
As with all other studies, there are limitations to our current study, 
including the retrospective design. However, we rationalized that in 
order for a prospective study to successfully validate any molecu-
lar signature, it must be robust and easily applicable. This led us to 
streamline our panel of eight molecular prognostic targets, identified 
from our previous studies, to three of our most promising targets for 
further work. In addition, we wanted to evaluate whether our IHC panel 
could prognosticate patients from different centers with different pa-
tient populations, different treatment regimens and different surgical 
approaches. A prospective trial to evaluate our three-gene IHC pan-
el, similar to the MINDACT trial for the Mammaprint®, will be the next 
step.33 The second limitation of this study is that the IHC panel cannot 
supercede the TNM staging and should be used in conjunction with 
TNM preoperatively to inform clinical decisions. Our IHC panel hence 
provides a useful and objective adjunct to current staging criteria that 
incorporates the heterogeneity that exists in the biology of EAC We 
have shown that combining TNM staging criteria with our IHC panel 
allows segregation of stage II and III patients into distinct prognos-
tic groups. There is minimal effect in applying the IHC panel in stage 
I patients as these patients are diagnosed early and are very likely to 
have a good prognosis regardless (68.0% 5 year survival). In addition, 
surgery performed for these patients are also likely to be curative and 
complete removal of a biologically aggressive tumour which has not 
metastasized is probably sufficient to confer a good prognosis. The pa-
tients with no abnormal markers in the Cambridge cohort had a better 
prognosis compared to those with 1 marker dysregulated. This was 
not the case in the validation cohorts largely due to the small number 
of patients in these subgroups and individuals with dysregulation of 1 
molecular marker had differences in early disease stages between the 
geographical cohorts. The third limitation to this study is that although 
IHC is easily applicable to standard clinical pathology laboratories the 
scoring of each target using IHC is subjective; however this problem 
can be minimized with standard staining intensity pictures to allow for 
accurate classification of the staining pattern.
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In conclusion, our study confirms that a simple IHC panel of three mo-
lecular biomarkers can provide prognostic information in EAC patients 
independently of clinical prognostic variables and is applicable to pa-
tient cohorts from different continents. These data support the notion 
that distinct molecular features govern the clinical phenotypes of this 
disease. Using the IHC panel as an adjunct to current staging systems 
could be of particular relevance in the pre-operative setting where 
staging data is less accurate or in selected populations of patients for 
which the optimal therapeutic approach could be influenced by mo-
lecular prognostic information. Although identification of patients in 
a very poor prognosis group would not necessarily dictate withdraw-
al of chemotherapy or the choice of curative surgery, this study has 
also identified novel molecular targets which should be investigated to 
determine whether they can offer more tailored therapeutic options to 
EAC patients.
Table 1 — Clinical demographics of patients in the two validation 
cohorts.
*Data shown reflect median (range), or number (percentage); Sum of numbers may not 
add up to the size of patients in cohort due to missing data
Pittsburgh
356
67.0 (23-91)
24.5 (0.49-156.50)
297 (83.4%)
59 (16.6%)
131 (36.8%)
335 (94.4%)
20 (5.6%)
30 (8.5%)
150 (42.4%)
174 (49.2%)
155 (43.5%)
37 (10.4%)
159 (44.7%)
5 (1.4%)
152 (42.8%)
201 (56.6%)
2 (0.6%)
342 (96.1%)
14 (3.9%)
9 (2.5%)
347 (97.5%)
161 (45.2%)
Rotterdam
310
64.7 (33-90)
24.2 (1.08-191.41)
268 (86.5%)
42 (13.5%)
183 (64.0%)
216 (70.1%)
92 (29.9%)
15 (4.9%)
132 (43.4%)
157 (51.6%)
45 (14.6%)
54 (17.5%)
207 (67.0%)
3 (1.0%)
102 (33.0%)
167 (54.0%)
40 (12.9%)
250 (80.9%)
59 (19.1%)
46 (14.8%)
264 (85.2%)
90 (29.0%)
p
<0.01
0.04
0.28
<0.01
<0.01
0.20
<0.01
<0.01
<0.01
<0.01
<0.01
Number of patients
Age at surgery 
Follow up time 
Gender
Male
Female
Recurrence
Radicality
R
0
R
1
Histology grade
Well
Moderately
Poorly
Pathological T stage
T1
T2
T3
T4
Pathological N stage
N0
N1
N2
Pathological M stage
M0
M1
Chemotherapy
Yes
No
Alive
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Table 2 — IHC panel gene dysregulation frequency in the validation 
cohorts. 
Table 3 — Univariate and multivariate survival analysis in the 
combined validation cohorts.
HR
Ref
3.14
3.66
Ref
1.45
3.60
9.04
1.01 
Ref
1.15
Ref
2.75
Ref
3.01
5.67
Ref
0.64
Ref
1.22
1.30
95%CI
2.48 to 3.97
2.50 to 5.36
0.99 to 2.11
2.77 to 4.68
4.31 to 18.94
1.00 to 1.02
0.87 to 1.52
2.19 to 3.46
1.59 to 5.71
3.01 to 10.68
0.43 to 0.94
1.00 to 1.48
1.12 to 1.50
p
<0.01
<0.01
0.06
<0.01
<0.01
0.03
0.31
<0.01
<0.01
<0.01
0.02
0.05
<0.01
p
<0.01
<0.01
0.92
<0.01
<0.01
<0.01
0.87
<0.01
0.10
<0.01
0.04
0.56
0.02
HR
Ref
1.79
1.99
Ref
1.02
1.93
7.01
1.02
Ref
1.02
Ref
1.64
Ref
1.73
2.80
Ref
0.63
Ref
0.93
1.20
95%CI
1.36 to 2.37
1.29 to 3.06
0. 68 to 1.54
1.39 to 2.69
2.96 to 16.56
1.01 to 1.03
0.77 to 1.37
1.26 to 2.14
0.89 to 3.35
1.45 to 5.43
0.41 to 0.98
0.73 to 1.18
1.03 to 1.40
Pittsburgh
47 (13.5%)
203 (58.5%)
89 (25.6%)
8 (2.3%)
133 (38.0%)
217 (62.0%)
323 (91.5%)
30 (8.5%)
187 (53.0%)
166 (47.0%)
Rotterdam
20 (6.6%)
169 (55.4%)
101 (33.1%)
15 (4.9%)
80 (26.2%)
225 (73.8%)
240 (77.4%)
70 (22.6%)
186 (60.0%)
124 (40.0%)
p
<0.01
<0.01
<0.01
0.07
Number of dysregulated 
molecular markers
0
1
2
3
TRIM44
Non-dysregulated
Dysregulated
EGFR
Non-dysregulated
Dysregulated
SIRT2
Non-dysregulated
Dysregulated
N stage
N0
N1
N2
T stage
T1
T2
T3
T4
Age (per year increase)
Gender 
Female
Male
Radicality
R
0
R
1
Histology grade
Well-differentiated
Moderately-differentiated
Poorly-differentiated
Chemotherapy
No
Yes
Study Centre
Pittsburgh
Rotterdam
IHC panel (per score 
increase)
Univariate Multivariate
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Figure 1 — The IHC panel is highly prognostic. Application of the IHC 
panel to all validation cohort patients segregated patients into two 
main prognostic groups (p=0.004).
Figure 2 — Representative examples of dysregulated and non-
dysregulated IHC expression of EGFR, SIRT2 and TRIM44 on the 
tissue microarrays. Overexpression of EGFR and TRIM44 constitutes 
dysregulation while loss of SIRT2 constitutes dysregulation based on 
their effect on prognosis and known biologic role.
Non-dysregulated
EGFR
TRIM44
SIRT2
Dysregulated
327
130
10
230
92
6
164
60
3
126
37
2
100
34
2
Patients at risk
Dysregulation of 
0 or 1 molecular markers
Dysregulation of 
2 molecular markers
Dysregulation of 3
molecular markers
439
190
23
Survival time (months)
C
u
m
u
la
ti
ve
 s
u
rv
iv
a
l
100
50
0
n=439
n=190
n=23
0 12 24 36 48 60
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Figure 3 — The IHC panel adds to current staging criteria in 
prognosticating patients. Combination of stage and the IHC panel 
separated patients into distinct prognostic groups (p<0.001).
Supplemental Materials and Methods
Scoring criteria
Scoring for each of the selected targets was based on intensity of 
staining in tumor epithelial cells. For each marker a core was scored 
on a scale from 0 (no staining) to 3 (strong staining) if at least 10% of 
tumor epithelial cells stained positive. For SIRT2 and TRIM44 positive 
staining was cytoplasmic and for EGFR positive staining was mem-
branous. For scoring of SIRT2, each core was scored independently by 
two scorers blinded to clinical outcomes and the scores were averaged. 
For scoring of EGFR and TRIM44 staining, the maximum score for each 
individual case (comprising of 3 cores) was used. All scores differing by 
more than 1 were reviewed and a consensus was reached. The ration-
ale of doing so is that we noted that staining of the 3 targets on whole 
paraffin sections of EAC demonstrated that TRIM44 and EGFR can 
have heterogenous staining while decreased exoression or loss of SIRT2 
staining tends to be homogenous. This is also to simplify scoring from 
a clinical perspective as the maximum intensity of staining for EGFR 
and TRIM44 on whole tissue sections should be used to determine the 
status of the staining. 
The determination of whether a marker is dysregulated is based on the 
known biology of the molecular targets based on our previous study. 
SIRT2 is a known tumor suppressor and EGFR and TRIM44 have been 
shown to confer an oncogenic effect when overexpressed. Hence, a 
score of 0 or 1 is considered dysregulated while a score of 2 or 3 is 
considered non-dysregulated in the case of SIRT2. Conversely, a score 
of 0 or 1 is considered non-dysregulated while a score of 2 or 3 is con-
sidered dysregulated in the case of EGFR and TRIM44. The final scores 
were then checked by an expert GI pathologist for 12.5% (1/8) of all 
cores for each validation target to confirm that the consensus score 
was accurate. 
143
43
77
50
218
119
145
49
81
54
227
127
124
44
67
41
145
64
62
23
22
9
19
10
104
41
50
28
80
37
90
34
31
18
47
19
Stage I & 0-1 marker
Stage I & 2-3 markers
Stage II & 0-1 marker
Stage II & 2-3 markers
Stage III & 0-1 marker
Stage IIII & 2-3 markers
Patients at risk
Survival time (months)
C
u
m
u
la
ti
ve
 s
u
rv
iv
a
l
100
50
0
n=81
n=145
n=49
n=54
n=227
n=127
0 12 24 36 48 60
101100 Part I - Chapter 5
Supplementary Table 1 — Hazard ratios of each molecular marker 
derived via univariate cox regression analysis in the original OCCAMS 
cohort.
Supplementary table 2 — Hazard ratios of each dysregulated 
molecular marker in the validation cohorts.
 
95% CI
1.31 (1.01-1.70)
1.31 (1.03-1.67)
1.52 (1.03-2.26)
1.24 (0.96-1.61)
1.12 (0.87-1.43)
0.71 (0.39-1.30)
1.14 (0.87-1.51)
0.98 (0.75-1.28)
p
0.04
0.03
0.04
0.10
0.39
0.27
0.34
0.86
TRIM44
SIRT2
EGFR
PAPPS2
NEIL2
WT1
MTMR9
DCK
Intensity Score
0
1
2
3
3
2
1
0
0
1
2
3
HR
Ref
1.46
1.59
1.94
Ref
1.69
1.81
1.37
Ref
0.83
1.41
0.94
p
0.14
0.07
0.02
0.02
<0.01
0.08
0.10
0.02
0.80
95% CI
0.89
0.96
1.09
1.10
1.24
0.96
0.66
1.05
0.58
2.44
2.63
3.44
2.60
2.64
1.97
1.04
1.91
1.52
Molecular marker
TRIM44
SIRT2
EGFR
Supplementary Table 3 — Prognostic effect of the IHC panel in 
different stages of patients in all three cohorts.
1.47
2.28
9.03
1.79
3.22
3.61
8.96
1.67
2.41
2.62
4.97
1.45
2.06
2.54
24.91
1.78
3.74
4.15
25.54
1.86
2.06
2.21
5.18
1.43
stage
I
II
III
p
0.33
0.94
0.41
0.46
0.03
0.02
0.13
0.03
<0.01
<0.01
<0.01
<0.01
p
0.88
0.98
0.10
0.52
0.09
0.07
0.01
0.04
0.12
0.10
<0.01
0.02
n
241
214
537
No of MM 
dysregulated
0 
1 
2 
3 
Per 1 MM
0 
1
2 
3 
Per 1 MM
0 
1 
2 
3 
Per 1 MM
HR
Ref
0.69
0.97
1.92
1.17
Ref
1.84
1.99
2.59
1.31
Ref
1.66
1.77
2.78
1.26
HR
Ref
0.94
1.01
4.37
1.15
Ref
1.85
1.97
6.30
1.38
Ref
1.38
1.43
2.73
1.22
95% CI
0.32
0.41
0.41
0.77
1.05
1.10
0.75
1.03
1.15
1.20
1.56
1.09
95% CI
0.43
0.40
0.77
0.75
0.92
0.94
1.55
1.02
0.92
0.93
1.44
1.03
Univariate analysis Multivariate analysis*
*Adjusted for age, sex, study centre, N stage, T stage, radicality, 
tumour grade, and chemo therapy.
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Supplementary figure 1 — antibody sources and conditions used for 
IHC. 
Product number 
NCL-L-EGFR
ab69307
HPA011165
Antibody source
Novocastra, Leica, 
Milton Keynes, UK
Abcam Plc, 
Cambridge, UK
Atlas Antibodies AB, 
Stockholm, Sweden 
Normal control tissues
Positive - Normal squamous
Negative - Heart tissue
Positive control - Liver
Negative - Normal squamous
Positive - Parotid
Negative - Normal squamous 
*Note positively staining glands 
next to negative control tissue
IHC conditions
1/10 dilution 
IHC protocol F
HIER Epitope 
Retrieval
Solution 1 for 30 min 
1/100 dilution 
IHC protocol F
HIER Epitope 
Retrieval
Solution 2 for 30 min 
1/100 Dilution
IHC protocol F
HIER Epitope 
Retrieval 
Solution 2 for 30 
minutes
Target
EGFR
TRIM44
SIRT2
Supplementary figure 2 — Internal validation of TRIM44, SIRT2 and 
EGFR as a combined IHC panel to prognosticate EAC patients in the 
original OCCAMS cohort. 
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Supplementary figure 3 — Application of the IHC panel to all 
patients segregated patients into three prognostic groups in both 
centers (Pittsburgh: p=0.003; Rotterdam: p=0.021). 
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Dysregulation of 
2 molecular markers
Dysregulation of 
3 molecular markers
Dysregulation of 
0 or 1 molecular markers
Dysregulation of 
2 molecular markers
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Patients at risk Patients at risk
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100
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n=250
n=89
n=8
n=189
n=101
n=15
250
89
8
189
101
15
186
57
3
141
73
7
129
42
2
101
50
4
37
9
0
63
25
2
81
25
1
83
35
2
54
11
0
72
26
2
107
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Abstract
Background
The CROSS trial compared neoadjuvant chemoradiotherapy (nCRT) 
plus surgery to surgery alone in squamous cell carcinoma and adeno-
carcinoma of the oesophagus or oesophago-gastric junction. Initial 
results, after a median follow-up 45 months, showed an absolute in-
crease in five-year overall survival of 13% in favour of the nCRT plus 
surgery group. Here, we report long-term results after a minimal fol-
low-up of five years.
Methods 
Patients with clinically resectable oesophageal or junctional cancer (cT-
1N1M0 or cT2-3N0-1M0, TNM 6th ed.) were randomly assigned to receive 
weekly administration of carboplatin (AUC=2 mg/ml per min) and pacl-
itaxel (50 mg/m2 of body-surface area) for 5 weeks with concurrent ra-
diotherapy (41.4 Gy given in 23 fractions, 5 days per week), followed by 
surgery, or surgery alone. The primary endpoint was overall survival and 
analyses were performed on an intention-to-treat basis. Randomisation 
was performed centrally, according to computer-generated randomisa-
tion lists for each stratum, with random block sizes of 4 or 6. This trial is 
registered with the Netherlands Trial Register, number NTR487.
Findings 
Between March 30, 2004 and December 2, 2008, 368 patients were 
enrolled in this study, of whom 366 patients were analysed, 178 in the 
nCRT plus surgery group and 188 in the surgery alone group. The nCRT 
regimen was completed by 95% (162/171) of patients who received any 
nCRT in the multimodality group. Some 8% (13/171) and 11% (18/171) 
of patients experienced grade 3 or higher haematological- and non-hae-
matological toxicity, respectively. After a median follow-up for surviving 
patients of 84.1 months (range, 61.1–116.8), median survival was 49 
months in the nCRT plus surgery group and 24 months in the surgery 
alone group. Five-year overall and progression-free survival rates were 
47% and 44% in the nCRT plus surgery group and 33% and 27% in the 
surgery alone group, respectively. Five-year overall and progression-free 
survival were significantly higher in the nCRT plus surgery group in both 
squamous cell carcinoma (61% vs. 30%, p=0.008 and 58% vs. 28%, 
p=0.006, respectively) and adenocarcinoma (43% vs. 33%, p=0.038 and 
41% vs. 27%, p=0.010, respectively). Patients in the nCRT plus surgery 
group developed significantly less locoregional and distant progression, 
which was already observed within the first year after randomisation, 
as compared to patients in the surgery alone group (HR 0.45 95%CI 
0.30–0.66 and HR 0.63 95%CI 0.46–0.86, respectively).
Interpretation
Long-term follow-up confirms the overall and progression-free survival 
benefits for neoadjuvant chemoradiotherapy when added to surgery 
in resectable oesophageal or junctional cancer patients. This improve-
ment is statistically significant and clinically relevant for both squa-
mous cell carcinoma and adenocarcinoma subtypes. Therefore, neo-
adjuvant chemoradiotherapy according to CROSS followed by surgical 
resection should be considered a standard of care for resectable locally 
advanced oesophageal or junctional cancer patients.
Funding
Funded by the Dutch Cancer Foundation (KWF Kankerbestrijding).
 
Introduction
Oesophageal cancer is an aggressive disease, characterized by sub-
stantial percentages of locoregional and distant recurrence after pri-
mary surgical resection and a poor five-year overall survival rate that 
rarely exceeds 40%.1-3 Much effort has been put into improving tu-
mour resectability, long-term locoregional control and overall survival, 
through addition of chemo- and/or radiotherapy to surgery, in a neoad-
juvant and/or adjuvant setting.2-5 However, many studies have failed to 
show significant long-term survival benefit.6,7
The randomised CROSS (ChemoRadiotherapy for Oesophageal cancer 
followed by Surgery Study) trial8 compared neoadjuvant chemoradi-
otherapy (nCRT) plus surgery to surgery alone. The trial enrolled 368 
patients between March 2004 and December 2008 from eight Dutch 
participating centres, randomly assigning patients to the nCRT plus 
surgery group or to the surgery alone group. Initial results were pub-
lished in 2012 after a minimal follow-up of 24 months (median fol-
low-up 45 months). We observed an absolute 13% benefit in five year 
overall survival in favour of the multimodality group. The nCRT regi-
men was completed by 94% of patients who recveived any nCRT, with 
a relatively low frequency of high-grade toxic effects. Furthermore, a 
microscopically radical resection (i.e. no vital tumour present at 1 mm 
or less from the proximal, distal, or circumferential resection margins) 
was achieved in 92% of patients in the multimodality group, compared 
to 69% in the surgery alone group (p<0.001).
Here, we aim to investigate the consistency of longer-term results with 
our earlier findings and to analyse secondary end-points, such as pro-
gression-free survival and recurrence patterns. 
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Methods
Study design and participants
Full details of patients’ eligibility criteria and procedures of this trial 
have been reported previously.8,9 Briefly, patients were eligible if aged 
75 years or younger, had adequate haematological, renal, hepatic and 
pulmonary function and a WHO-performance score of 2 or better, 
without a past or current history of other malignancy. Only patients 
with locally advanced (cT1N1M0 or cT2-3N0-1M0, according to the 
Union for International Cancer Control (UICC) TNM Cancer Staging, 6th 
edition10), histologically proven and potentially curable squamous cell 
carcinoma or adenocarcinoma of the oesophagus or oesophago-gas-
tric junction (i.e. tumours involving both the cardia and the oesophagus 
on endoscopy) were eligible for inclusion. All patients provided written 
informed consent. The institutional review board at each participating 
centre approved the study protocol.
Randomisation 
Patients were stratified according to histological tumour type, treat-
ment centre, clinical N-status and WHO-performance score. Randomi-
sation was performed centrally, using computer generated randomisa-
tion lists for each stratum, with random block sizes of 4 or 6.
Procedures
All patients underwent pretreatment staging, including upper gastroin-
testinal endoscopy with histological biopsy and endoscopic ultrasonog-
raphy (EUS), CT scanning of the neck, chest and upper abdomen, and 
external ultrasonography of the neck, with fine needle aspiration of 
suspected lymph nodes on indication. 
Carboplatin (AUC=2 mg/ml per min) and paclitaxel (50 mg/m2 of 
body-surface area) were administered intravenously in five cycles, 
starting on days 1, 8, 15, 22 and 29. A total concurrent radiation dose 
of 41.4 Gy was given in 23 fractions of 1.8 Gy, five fractions per week, 
starting on the first day of the first chemotherapy cycle. Total duration 
of neoadjuvant treatment was 23 days. If on days 8, 15, 22, or 29 the 
white blood cell count was below 1.0x109/L or the platelet count was 
below 50x109/L administration of nCRT was delayed by one week until 
recovery above these thresholds. Also, in case of mucositis with oral 
ulcers or protracted vomiting despite antiemetic premedication, nCRT 
was delayed by one week. Further chemotherapy was withheld in case 
febrile neutropenia (defined as a neutrophil count below 0.5x109/L and 
a temperature above 38.5°C), persistent creatinine clearance of less 
than 50% of the pretreatment level, symptomatic cardiac arrhythmia 
or atrioventricular block (with the exception of first-degree atrioven-
tricular block), or other major organ toxicity, grade 3 or higher (with 
the exception of oesophagitis). During nCRT, laboratory tests (includ-
ing complete blood cell counts and creatinine) were performed on a 
weekly basis, while radiological evaluations were performed only on 
indication. All patients in the nCRT plus surgery group were included 
into the  ‘intention-to-treat’ analysis, irrespective of total dose of nCRT 
received.
Patients in the surgery alone group were operated on as soon as possi-
ble, while patients in the nCRT plus surgery group were preferably op-
erated on within 4-6 weeks after completion of nCRT. For carcinomas 
at or above the level of the carina a transthoracic oesophageal resec-
tion with two-field lymph node dissection was performed. For carci-
nomas located well below the level of the carina, either a transtho-
racic approach with two-field lymph node dissection or a transhiatal 
approach was performed, depending on both patient characteristics 
and local preferences. For carcinomas involving the OGJ, a transhiatal 
oesophageal resection was favoured. In both approaches, an upper 
abdominal lymphadenectomy, including resection of nodes along the 
hepatic artery, splenic artery and left gastric artery, was performed.
For TNM-classification, tumour grading and stage grouping, the sixth 
edition of the UICC TNM Cancer Staging was used.10 Proximal, distal and 
circumferential resection margins were evaluated. Microscopically radical 
resection (R
0
) was defined as a tumour-free resection margin ≥1 mm. 
During the first year after treatment completion, patients were seen 
every three months. In the second year, follow-up took place every 
six months, and subsequently yearly until five years after treatment. 
Additional interim visits were scheduled if complaints arose before the 
next scheduled visit. Diagnostic investigations were only performed on 
indication during follow up.
Outcomes
The primary endpoint was overall survival. Overall survival was calcu-
lated from the date of randomisation to the date of all-cause death or 
to the last day of follow-up. Last day of follow-up was 31st December 
2013, guaranteeing a minimal potential follow-up of 60 months for 
all included patients. Secondary endpoints included progression-free 
survival and progression-free interval. Progression-free survival was 
defined as the interval between randomisation and the earliest oc-
currence of disease progression resulting in primary (or peroperative) 
irresectability of disease, locoregional recurrence (after completion of 
therapy), distant dissemination (during therapy or after completion of 
therapy) or death from any cause. This definition for progression-free 
survival was taken from the modified STEEP criteria for neoadjuvant 
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treatment trials.12,13 Last day of follow-up for progression-free survival 
varied, depending on the last (scheduled) contact with the patient. Pro-
gression-free interval was similar to progression-free survival, with the 
difference that treatment related deaths and non-oesophageal-can-
cer-related deaths were not counted as events. Locoregional progres-
sion was defined as either progression of locoregional disease during 
therapy (resulting in irresectability) or as locoregional recurrence after 
completion of therapy. Locoregional sites included the mediastinum, 
the supraclavicular region and the celiac trunk region. Distant progres-
sion was defined as occurrence of disseminated disease, either during 
therapy or after completion of therapy. Distant disease included cervi-
cal and (para-aortic) lymph node dissemination below the level of the 
pancreas, malignant pleural effusions, peritoneal carcinomatosis and 
further haematogenous (organ) dissemination. Furthermore, no addi-
tional adverse event data were gathered for this current update.
Statistical analysis
Data were analysed according to the ‘intention-to-treat’ principle. In 
order to detect a difference of six months in median overall survival 
(22 months in the nCRT plus surgery group versus 16 months in the 
surgery alone group; two-sided test; alpha level, 0.05; beta level, 0.80), 
it was calculated that 175 patients were needed per group. Statistical 
significance was set to 0.05. 
The Kaplan-Meier method was used for estimating overall and pro-
gression-free survival with the log-rank test for determining signifi-
cance. Univariable and multivariable Cox proportional-hazards models 
were used to determine the effect of neoadjuvant chemoradiotherapy 
in subgroups, adjusting for baseline covariates.8 Univariable Cox re-
gression modelling was used to analyse differences in progression-free 
interval between treatment groups, expressed as hazard ratios (HRs). 
Follow-up time was divided to study the temporal distribution of dis-
ease progression. Three separate analyses were performed, including 
follow-up until 6 months, 12 months and 24 months after randomisa-
tion. Progression was defined as locoregional or distant. Patients in 
whom both types of disease progression occurred had events scored in 
both categories. In the scoring of disease progression in one category, 
disease progression in the other category and death without progres-
sion were censored. For each time-point the number of events was 
compared between treatment groups, before the cut-off time-point 
and after. Statistical analysis was performed by JS and EWS using 
Statistical Package for Social Sciences version 21.0 (SPSS Inc., Chica-
go, IL, USA). This trial is registered with the Netherlands Trial Register, 
number NTR487.
Role of funding source
This trial was financially supported by the Dutch Cancer Foundation 
(KWF Kankerbestrijding). The funder had no role in the study design, 
data collection, data analysis, data interpretation or writing of the 
manuscript. The corresponding author had full access to all the data 
in the study and had final responsibility for the decision to submit for 
publication.
Results
Between March 30, 2004 and December 2, 2008, 368 patients were 
enrolled in the study; 180 patients were randomised to the nCRT plus 
surgery group (of whom 2 patients later withdrew consent) and 188 
patients to the surgery alone group (figure 1). Baseline characteris-
tics were well balanced between the two treatment groups (table 1). 
A single patient in the surgery alone group was originally misclassified 
as not having received a resection. However, in the current update it 
was found that this patient had undergone a resection abroad. This 
misclassification bears no influence on current or previous analyses, 
due to the ‘intention-to-treat’ principle. Also, a patient in the nCRT 
plus surgery group moved abroad and was therefore lost to follow-up 
73 months after randomisation. The nCRT regimen was completed by 
95% (162/171) of patients who received any nCRT in the multimodality 
group. Some 8% (13/171) and 11% (18/171) of patients experienced 
grade 3 or higher haematological- and non-haematological toxicity, 
respectively. The most common grade 3 or higher toxicities were leuko-
penia in 6% (11/171), anorexia in 5% (9/171) and fatigue in 3% (5/171) 
of patients. In the nCRT plus surgery group, 90% (161/178) of patients 
underwent resection, as compared to 86% (162/188) of patients in 
the surgery alone group. The percentage of transhiatal resections was 
comparable between both treatment groups, 45% (72/161) in the 
nCRT plus surgery group as compared to 44% (72/162) in the surgery 
alone group (χ2 0.01, p=0.96). 
Overall survival
At the time of this analysis, median follow-up for surviving patients 
was 84.1 months (range, 61.1–116.8). Of the 366 analysed patients, 
126 patients were still alive at final analysis, 73 of 178 patients in the 
nCRT plus surgery group and 53 of 188 patients in the surgery alone 
group. This corresponds with 19 (22%) and 21 (18%) additional events 
since the last follow-up of the original publication.8 Median overall 
survival was 48.6 months (95%CI 32.1–65.1) in the nCRT plus surgery 
group and 24.0 months (95%CI 14.2–33.7) in the surgery alone group. 
Median overall survival for squamous cell carcinomas was 81.6 months 
(95%CI 47.2–116.0) in the nCRT plus surgery group and 21.1 months 
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(95%CI 15.4–26.7) in the surgery alone group. Median overall survival 
for adenocarcinomas was 43.2 months (95%CI 24.9–61.4) in the nCRT 
plus surgery group and 27.1 months (95%CI 13.0–41.2) in the sur-
gery alone group. The overall survival rates at one, two, three and five 
years were 81% (145/178), 67% (119/178), 58% (103/178) and 47% 
(83/178), respectively, in the nCRT plus surgery group, as compared to 
70% (131/188), 50% (94/188), 44% (83/188) and 33% (62/188) in the 
surgery alone group. During follow-up, 16 patients died from treatment 
related causes, i.e. during nCRT or during postoperative hospital stay (9 
patients in the nCRT plus surgery group and 7 patients in the surgery 
alone group) and 23 patients died from non-disease-related causes 
beyond the first 90 postoperative days (13 patients in the nCRT plus 
surgery group and 10 patients in the surgery alone group).
Overall survival was significantly improved in the nCRT plus surgery 
group as compared to the surgery alone group (log-rank p=0.002; fig-
ure 2a). This significant difference was observed both in patients with 
squamous cell carcinoma as well as in patients with adenocarcinoma 
(log-rank p=0.008 and p=0.038, respectively; figure 2b). The estimated 
number of patients who need to be treated to prevent one additional 
death at five year was 7.1 (95%CI 4.6–13.2).14 The overall survival ben-
efit of nCRT plus surgery was generally confirmed across subgroups 
(table 2). The concordance of the multivariable model for overall surviv-
al in all patients was 0.584.15 The proportionality of hazards assump-
tion for the main analysis was not violated (χ2 0.77, p=0.38).16 
Progression-free survival
Of the 366 analysed patients, 116 patients were alive and disease free 
(eventually without evidence of recurrent disease) at final analysis, 69 
of 178 patients in the nCRT plus surgery group and 47 of 188 patients 
in the surgery alone group. Median progression-free survival was 37.7 
months (95%CI 23.7–51.8) in the nCRT plus surgery group and 16.2 
months (95%CI 10.7–21.7) in the surgery alone group. Median pro-
gression-free survival for squamous cell carcinomas was 74.7 months 
(95%CI 55.1–94.4) in the nCRT plus surgery group and 11.6 months 
(95%CI 4.4–18.8) in the surgery alone group. Median progression-free 
survival for adenocarcinomas was 29.9 months (95%CI 15.9–43.9) in 
the nCRT plus surgery group and 17.7 months (95%CI 11.9–23.5) in the 
surgery alone group. The progression-free survival rates at one, two, 
three and five years were 71% (127/178), 60% (106/178), 51% (90/178) 
and 44% (74/178), respectively, in the nCRT plus surgery group, as 
compared to 54% (102/188), 41% (77/188), 35% (66/188) and 27% 
(50/188) in the surgery alone group.
Progression-free survival was significantly improved in the nCRT plus 
surgery group as compared to the surgery alone group (log-rank 
p<0.001; figure 3a). This significant difference was observed both in 
patients with squamous cell carcinoma as well as in patients with ad-
enocarcinoma (log-rank p=0.006 and p=0.010, respectively; figure 3b). 
The estimated number of patients who need to be treated to prevent 
one additional disease progression at five year was 6.1 (95%CI 4.2–
10.0).14 The progression-free survival benefit of nCRT plus surgery was 
generally confirmed across subgroups (supplementary table 1). 
Locoregional and distant progression-free interval
We studied the progression-free intervals, as opposed to progres-
sion-free survival, to focus in more detail on recurrence patterns in both 
treatment groups. From randomisation, 211 patients showed disease 
progression (table 3). In the nCRT plus surgery group, 87 patients had 
disease progression, of whom 39 had locoregional progression and 70 
had distant progression (22 patients had both locoregional and distant 
progression). In the surgery alone group, 124 patients had disease pro-
gression, of whom 72 had locoregional progression and 90 had distant 
progression (38 patients had both locoregional and distant progression). 
Disease progression during therapy (causing adjustment from curative 
to palliative treatment intent) occurred in 17 patients in the nCRT plus 
surgery group and in 26 patients in the surgery alone group. 
Patients in the nCRT plus surgery group developed significantly less 
locoregional progression and significantly less distant progression, as 
compared to patients in the surgery alone group (HR 0.45 95%CI 0.30–
0.66, p<0.001 and HR 0.63 95%CI 0.46–0.87, p=0.004, respectively; 
table 3). The reduction in locoregional progression was already appar-
ent during the first six months of follow-up and remained significant 
in the period after the first 24 months of follow-up (HR 0.50 95%CI 
0.31–0.79, p=0.003 and HR 0.39 95%CI 0.17–0.89, p=0.025, respec-
tively; supplementary table 2). This indicates that the effect of reduc-
tion in locoregional progression continued throughout an extended pe-
riod after randomisation. The reduction in distant progression was also 
already found during the first six months of follow-up (HR 0.38 95%CI 
0.18–0.78, p=0.009). The effect remained significant during the first 
24 months of follow-up, but not thereafter (HR 0.57 95%CI 0.40–0.81, 
p=0.002 and HR 0.94 95%CI 0.48–1.83, p=0.845, respectively). Thereby, 
indicating that the reduction in distant progression occurred primarily 
within the first 24 months after randomisation. 
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Discussion
 
These long-term results, after a median follow-up for surviving patients 
of 84 months, confirm the initially observed survival benefit for nCRT 
plus surgery as compared to surgery alone (median overall survival 49 
months vs. 24 months and five-year overall survival rate 47% vs. 33%, 
respectively). The improvement in distant disease control occurred 
within the first two years after start of treatment, while the improve-
ment in locoregional control continued for more years. These results 
further support the clinical value of this multimodality treatment 
strategy.
The overall survival benefit and the progression-free survival benefit 
were confirmed for both histological subtypes and for other clinically 
relevant subgroups. While unvariable and multivariable hazard ratios 
for individual subgroups were reported for informative purposes, no 
significant interactions in treatment effect were identified for any of 
the subgroups. This means that differences in treatment effect be-
tween subgroups could well have arisen by chance, and the overall 
treatment effect should be considered valid for all considered sub-
groups. In other words, there is no clear evidence to assume that the 
adjusted overall treatment effect of nCRT does not also apply to ad-
enocarcinoma patients. We, therefore, conclude that both squamous 
cell carcinoma patients and adenocarcinoma patients benefit signifi-
cantly from the CROSS regimen.
By adding nCRT to primary surgery, locoregional disease control was 
significantly improved (table 3). Interestingly, the largest reported trials 
with neoadjuvant chemotherapy (nCT) only showed limited improve-
ment in R
0
 resection rates, in pathologically complete response (pCR) 
rates and in locoregional recurrence rates. Furthermore, two small 
randomised trials17,18 comparing nCT plus surgery to nCRT plus surgery 
both found similar R
0
 resection rates between treatment groups, but 
significantly higher pCR rates and lower locoregional recurrence rates 
in the nCRT plus surgery groups. Therefore, results from these nCT tri-
als point towards neoadjuvant radiotherapy combined with sensitizing 
chemotherapy rather than nCT alone as the likely cause of improved 
locoregional control, as achieved in the CROSS trial.
In the CROSS trial, not only locoregional control, but also distant dis-
ease control improved significantly in the nCRT plus surgery group 
(table 3). Theoretically, this improved distant disease control may be 
explained in several ways. First, if fewer locoregional recurrences occur, 
then possibly less distant dissemination develops from these locore-
gional recurrences. Secondly, it has been described in some cancer 
types that effective treatment of the primary tumour in the presence 
of disseminated disease can prolong survival. Therefore, a mechanism 
by which improved locoregional control might improve distant disease 
control could simply be control of the primary tumour itself, there-
by removing a currently unknown stimulus for disseminated tumour 
outgrowth. A third explanation is that improved distant disease con-
trol could be caused by a direct systemic effect of chemotherapy. In 
the current study, we found a significant reduction in distant disease 
progression already within the first six months after randomisation 
(supplementary table 2). Such an early reduction in distant disease 
progression, without evidence of reduction beyond the first 24 months, 
supports a direct systemic effect of this neoadjuvant chemotherapy 
regimen. The reduction in distant disease progression achieved by this 
neoadjuvant chemoradiotherapy regimen is comparable to reductions 
achieved with more protracted (and more toxic) perioperative chemo-
therapy regimens.4,5 
Results from this trial may not be readily extrapolated to patients with 
poorer performance status, patients with more advanced age or pa-
tients with tumour located in the proximal or middle oesophagus, due 
to the relative scarcity of occurrences in these categories. The value of 
this treatment regimen will need to be confirmed for these patients in 
future follow-up studies. 
Despite recent advances in curative treatment of oesophageal or junc-
tional cancers, benefit of (neo)adjuvant treatment is generally quite 
limited and a definitive statement on the optimal perioperative treat-
ment in terms of survival is still lacking. A recent meta-analysis sug-
gested a (non-significant) advantage of neoadjuvant chemoradiother-
apy over neoadjuvant chemotherapy alone in both the direct and the 
indirect comparisons (HR 0.77 95%CI 0.53–1.12 and HR 0.88 95%CI 
0.76–1.01, respectively).7 Probably the ongoing Japanese randomised 
NExT trial (JCOG1109)19 and the Irish randomised Neo-AEGIS trial 
(ICORG 10-14)20 will provide more definitive evidence on the optimal 
perioperative treatment for squamous cell carcinoma and adenocarci-
noma, respectively. Unless convincing, contrary results become availa-
ble, strong evidence from the CROSS trial continues to support neo-
adjuvant chemoradiotherapy as a standard of care for both squamous 
cell carcinoma and adenocarcinoma of the oesophagus or oesopha-
go-gastric junction.
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Conclusions
Neoadjuvant chemoradiotherapy according to the CROSS regimen 
improves long term overall and progression-free survival in oesopha-
geal and junctional cancer patients. This improvement is statistically 
significant and clinically relevant for both squamous cell carcinoma 
and adenocarcinoma subtypes and for both locoregional and distant 
control. The improvement in distant control occurs early after start of 
treatment, suggesting a direct systemic effect of chemotherapy, while 
the improvement in locoregional control continues longer. Neoadjuvant 
chemoradiotherapy according to CROSS followed by surgical resection 
should be considered a standard of care for resectable locally ad-
vanced oesophageal or junctional cancer patients.
Research in context 
Evidence before this study
Based on the extensive meta-analysis by Sjoquist et al.7, at the initia-
tion of the CROSS trial in 2004, results from four previous randomised 
trials21-24 comparing neoadjuvant concurrent chemoradiotherapy plus 
surgery to surgery alone had been reported. Chemotherapy in these 
trials consisted of cisplatin and 5-fluorouracil (and also vinblastine in a 
single trial), with a total concurrent radiation dose ranging from 40 to 
45 Gy. However, these trials included only small numbers of patients 
and showed opposing results. Our previous non-randomised phase II 
feasibility trial11, tested a regimen of weekly administrations of carbo-
platin and paclitaxel with 41.4 Gy concurrent radiotherapy and showed 
a radical resection percentage of 100%, with low treatment related 
toxicity. These promising short-term results provided the rationale for 
testing this CROSS neoadjuvant chemoradiotherapy regimen in a sub-
sequent randomised phase III trial. 
Added value of this study 
At long-term follow-up, the CROSS trial has now shown that treatment 
of locally advanced oesophageal or junctional cancer with carboplatin, 
paclitaxel and concurrent radiotherapy followed by surgery significant-
ly improves 5-year overall and progression-free survival, as compared 
to treatment with surgery alone.
Implications of all the available evidence
Despite the favourable results of the initial CROSS trial8, pre- or 
peri-operative chemotherapy is still considered standard of care in 
some countries for oesophageal and junctional cancer patients. Mainly 
because of the important results of the MAGIC trial4, which compared 
perioperative chemotherapy, consisting of epirubicin, cisplatin, and 
infused fluorouracil plus surgery to surgery alone. However, only a mi-
nority of included patients had distal oesophageal cancers (14%) or 
junctional cancers (12%). Thus questioning the applicability of these 
results for oesophageal and junctional cancers. Furthermore, the MAG-
IC trial, which was published in 2006 after a minimum follow-up of less 
than two years, has not yet reported its long-term results. This makes 
it unclear whether the initially reported survival benefit of periopera-
tive chemotherapy is sustained at long-term follow-up. Probably, the 
ongoing Japanese randomised NExT trial (JCOG1109)19 and the Irish 
randomised Neo-AEGIS trial (ICORG 10-14)20 will provide more defini-
tive evidence on the current optimal pre- or peri-operative treatment 
for oesophageal squamous cell carcinoma and adenocarcinoma, re-
spectively. Future research should focus on more individualised treat-
ment strategies, such as ‘watchful waiting’ protocols after neoadju-
vant therapy, where surgery is offered only to those patients in whom 
locoregional disease is detected (in the absence of signs of distant 
dissemination). Also, newer, more effective combinations of systemic 
agents need more study, such as adding targeted therapy to existing 
chemoradiotherapeutic treatment regimens. 
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Table 1 — Baseline characteristics of 366 analysed patients, 
according to treatment group.
Characteristics
Age [years]
Gender
Women
Men
Tumour histology
Squamous cell carcinoma
Adenocarcinoma
Could not be determined
Tumour length [cm]
Tumour location
Proximal third oesophagus
Middle third oesophagus
Distal third oesophagus
Oesophagogastric-junction
Missing data
Clinical T-stage
cT1
cT2
cT3
cT4
Could not be determined
Clinical N-stage
cN0
cN1
Could not be determined
WHO-performance score
0
1
Legend table 1
Baseline characteristics of 366 analysed patients, according to treatment group
Data presented as median (25th-75th percentile) or number (%).
nCRT plus surgery
(n=178)
60 (55 – 67)
44 (25)
134 (75)
41 (23)
134 (75)
3 (2)
4 (3 – 6)
4 (2)
25 (14)
104 (58)
39 (22)
6 (3)
1 (1)
26 (15)
150 (84)
-
1 (1)
59 (33)
116 (65)
3 (2)
144 (81)
34 (19)
Surgery alone
(n=188)
60 (53 – 66)
36 (19)
152 (81)
43 (23)
141 (75)
4 (2)
4 (3 – 6)
4 (2)
24 (13)
107 (57)
49 (26)
4 (2)
1 (1)
35 (19)
147 (78)
1 (1)
4 (2)
58 (31)
120 (64)
10 (5)
163 (87)
25 (13)
Table 2 — Univariable and multivariable hazard ratios for all-cause 
mortality in 366 patients according to subgroup characteristics. 
HR
0.68
0.83
0.65
0.48
0.73
0.50
0.81
0.66
0.75
95% CI
(0.53 – 0.89)
(0.48 – 1.50)
(0.49 – 0.88)
(0.26 – 0.79)
(0.56 – 1.01)
(0.30 – 0.80)
(0.61 – 1.13)
(0.51 – 0.90)
(0.41 – 1.51)
Subgroup
All patients
Gender
Women
Men
Tumour histology
Squamous cell 
carcinoma
Adenocarcinoma
Clinical N-stage
cN0
cN1
WHO-performance 
score
0
1
95% CI
(0.53 – 0.88)
(0.47 – 1.45)
(0.49 – 0.86)
(0.28 – 0.83)
(0.55 – 0.98)
(0.31 – 0.80)
(0.59 – 1.10)
(0.50 – 0.88)
(0.40 – 1.41)
p
0.004
0.570
0.004
0.005
0.059
0.004
0.237
0.006
0.473
nCRT plus 
surgery
(n=178)
number of 
events (%)
105 (59)
25 (14)
80 (45)
21 (12)
81 (46)
27 (15)
77 (43)
84 (47)
21 (12)
Surgery 
alone
(n=188)
number of 
events (%)
135 (72)
24 (13)
111 (59)
32 (17)
101 (54)
42 (22)
85 (45)
117 (62)
18 (10)
p
0.003
0.502
0.003
0.009
0.037
0.004
0.176
0.004
0.367
Inter - 
action
p
0.078
0.451
0.207
0.170
0.729
aHR
0.69
0.85
0.66
0.46
0.75
0.49
0.83
0.67
0.79
Univariable Multivariable
Legend table 2
Univariable and multivariable hazard ratios for all-cause mortality in 366 patients ac-
cording to subgroup characteristics.
HR: hazard ratio (nCRT plus surgery vs. surgery alone); aHR: adjusted hazard ratio; CI: 
confidence interval.
Multivariable analysis included the following baseline characteristics: gender, tumour 
histology, clinical N-stage and WHO-performance score. 
Clinical lymph-node (N) stage was based on endoscopic ultrasonography, computed 
tomography, or 18F-fluorodeoxyglucose positron-emission tomography; cN0: no nodes 
suspected or positive, cN1: at least one node suspected or positive.
World Health Organisation (WHO) performance status25; grade 0: able to carry out all 
normal activity without restrictions, grade 1: restricted in physically strenuous activity 
but ambulatory and able to carry out light work.
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nCRT plus surgery
(n=178)
number of events (%)
39 (22)
70 (39)
87 (49)
Surgery alone
(n=188)
number of events (%)
72 (38)
90 (48)
124 (66)
P
< 0.001
 0.004
< 0.001
HR
0.45
0.63
0.58
95% CI
(0.30 – 0.66)
(0.46 – 0.87)
(0.44 – 0.76)
Locoregional progression
Distant progression
Overall progression
Table 3 — Number of patients with locoregional or distant 
progression and comparison of locoregional and distant progression 
between treatment groups.
Legend table 3
Number of patients with locoregional or distant progression and comparison of locore-
gional and distant progression between treatment groups.
HR: hazard ratio (nCRT plus surgery vs. surgery alone); CI: confidence interval.
Comparison between treatment groups was based on univariable cause-specific Cox 
regression modelling of progression-free intervals. Deaths from non-disease-related 
causes were censored.
Overall progression was defined as either locoregional progression or distant progres-
sion. Patients with both locoregional disease progression and distant disease progres-
sion (n=22 in the nCRT plus surgery group and n=38 in the surgery alone group) were 
counted in both locoregional progression and distant progression categories.
Supplementary table 1 — Univariable and multivariable hazard 
ratios for overall disease progression in 366 patients according to 
subgroup characteristics.
Legend supplementary table 1
Univariable and multivariable hazard ratios for overall disease progression in 366  
patients according to subgroup characteristics.
HR: hazard ratio (nCRT plus surgery vs. surgery alone); aHR: adjusted hazard ratio; CI: 
confidence interval.
Multivariable analyses included the following baseline characteristics: gender, tumour 
histology, clinical N-stage and WHO-performance score. 
Clinical lymph-node (N) stage was based on endoscopic ultrasonography, computed 
tomography, or 18F-fluorodeoxyglucose positron-emission tomography; cN0: no nodes 
suspected or positive, cN1: at least one node suspected or positive.
World Health Organisation (WHO) performance score25; grade 0: able to carry out all 
normal activity without restrictions, grade 1: restricted in physically strenuous activity 
but ambulatory and able to carry out light work.
HR
0.64
0.71
0.62
0.48
0.69
0.49
0.76
0.63
0.62
95% CI
(0.50 – 0.83)
(0.42 – 1.25)
(0.47 – 0.84)
(0.27 – 0.80)
(0.53 – 0.94)
(0.29 – 0.76)
(0.58 – 1.06)
(0.49 – 0.85)
(0.36 – 1.25)
Subgroup
All patients
Gender
Women
Men
Tumour histology
Squamous cell 
carcinoma
Adenocarcinoma
Clinical N-stage
cN0
cN1
WHO-performance 
score
0
1
95% CI
(0.49 – 0.82)
(0.41 – 1.21)
(0.47 – 0.82)
(0.28 – 0.82)
(0.52 – 0.92)
(0.30 – 0.78)
(0.56 – 1.03)
(0.48 – 0.83)
(0.33 – 1.14)
p
0.001
0.248
0.001
0.005
0.017
0.002
0.108
0.002
0.207
nCRT plus 
surgery
(n=178)
number of 
events (%)
109 (61)
27 (15)
82 (46)
22 (12)
84 (47)
28 (16)
80 (45)
88 (49)
21 (12)
Surgery 
alone
(n=188)
number of 
events (%)
141 (75)
26 (14)
115 (61)
33 (18)
105 (56)
43 (23)
89 (47)
121 (64)
20 (11)
p
0.001
0.205
0.001
0.007
0.010
0.003
0.072
0.001
0.129
Inter - 
action
p
0.168
0.673
0.459
0.138
0.933
aHR
0.64
0.73
0.63
0.46
0.70
0.47
0.78
0.65
0.67
Univariable Multivariable
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Supplementary table 2 — Number of patients with locoregional 
or distant progression and comparison of locoregional and distant 
progression between treatment groups, during and after the first 6, 
12 and 24 months of follow-up.
nCRT plus surgery
(n=178)
number of events (%)
11 (6)
28 (16)
21 (12)
18 (10)
30 (17)
9 (5)
10 (6)
60 (34)
30 (17)
40 (22)
50 (28)
20 (11)
19 (11)
68 (38)
42 (24)
45 (25)
63 (35)
24 (13)
Surgery alone
(n=188)
22 (12)
50 (27)
43 (23)
29 (15)
56 (30)
16 (9)
26 (14)
64 (34)
55 (29)
35 (19)
75 (40)
15 (8)
43 (23)
81 (43)
78 (41)
46 (24)
100 (53)
24 (13)
p
0.003
<0.001
0.001
0.008
<0.001
0.025
0.009
0.073
0.002
0.450
0.002
0.845
0.003
0.008
<0.001
0.106
<0.001
0.212
HR
0.50
0.43
0.45
0.45
0.44
0.39
0.38
0.72
0.49
0.84
0.57
0.94
0.44
0.64
0.49
0.71
0.55
0.70
95% CI
(0.31 – 0.79)
(0.27 – 0.68)
(0.29 – 0.72)
(0.25 – 0.81)
(0.27 – 0.69)
(0.17 – 0.89)
(0.18 – 0.78)
(0.51 – 1.03)
(0.31 – 0.76)
(0.53 – 1.32)
(0.40 – 0.81)
(0.48 – 1.83)
(0.26 – 0.75)
(0.47 – 0.89)
(0.34 – 0.71)
(0.47 – 1.07)
(0.40 – 0.75)
(0.40 – 1.23)
Locoregional progression
During first 6 months
After first 6 months
During first 12 months
After first 12 months
During first 24 months
After first 24 months
Distant progression
During first 6 months
After first 6 months
During first 12 months
After first 12 months
During first 24 months
After first 24 months
Overall progression
During first 6 months
After first 6 months
During first 12 months
After first 12 months
During first 24 months
After first 24 months
Legend supplementary table 2
Number of patients with locoregional or distant progression and comparison of locore-
gional and distant progression between treatment groups, during and after the first 6, 
12 and 24 months of follow-up.
HR: hazard ratio (nCRT plus surgery vs. surgery alone); CI: confidence interval.
Comparison between treatment groups was based on univariable Cox regression mod-
elling of progression-free intervals.
Overall progression was defined as either locoregional progression or distant progres-
sion. Patients with both locoregional disease progression and distant disease progres-
sion (n=22 in the nCRT plus surgery group and n=38 in the surgery alone group) were 
counted in both locoregional progression and distant progression categories.
Figure 1 — CONSORT diagram for patient enrolment in the 
randomised CROSS trial.
Patients assessed for 
esophagal or EGJ cancer 
(n=837)
Underwent randomization (n=368)
Assigned to surgery alone (n=188)
Underwent surgery (n= 187) 
Underwent: resection (n=162)
Were included in the analysis (n=188)Were included in the analysis (n=178)
Received nCRT and surgery (n= 166) 
Received CRT only: resection (n=5) 
Underwent surgery only (n=2) 
Received neither CRT nor surgery (n=5) 
Underwent resection (n=161)
Assigned to nCRT and surgery (n=180)
Withdrew consent (n=2)
Excluded (n=469)
129128 Part II - Chapter 6
Figure 2b — Overall survival, according to treatment group and 
histological tumour type.
Figure 2a — Overall survival, according to treatment group.
Overall survival, according to treatment group and histological tumour type
SCC: squamous cell carcinoma, AC: adenocarcinoma.
Comparison based on log-rank test, SCC nCRT plus surgery vs. surgery alone, χ2 7.0, df 
1, p=0.008; AC nCRT plus surgery vs. surgery alone, χ2 4.3, df 1, p=0.008.
Seven patients were excluded from this analysis because histological tumour type could 
not be determined.
Comparison based on log-rank test, nCRT plus surgery vs. surgery alone, χ2 9.8, degree 
of freedom (df) 1, p=0.002.
log-rank p=0.002
SCC, log-rank p=0.008
AC, log-rank p=0.038
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Patients at risk Patients at risk
nCRT plus surgery 
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Total
178
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145
131
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94
213
35 
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107 
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359
103
83
186
30 
19 
87 
73
209
91
70
161
28 
17 
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182
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145
26 
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158
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42
101
25 
13 
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143
40
28
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17 
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32
100
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14
36
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29 
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4 
16 
10
36
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AC, surgery alone
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Figure 3b — Progression-free survival, according to treatment group 
and histological tumour type.
Figure 3a — Progression-free survival, according to treatment group.
Progression-free survival, according to treatment group and histological tumour type
SCC: squamous cell carcinoma, AC: adenocarcinoma.
Comparison based on log-rank test, SCC nCRT plus surgery vs. surgery alone, χ2 7.4, df 
1, p=0.006; AC nCRT plus surgery vs. surgery alone, χ2 6.7, df 1, p=0.010.
Seven patients were excluded from this analysis because histological tumour type could 
not be determined.
Progression-free survival, according to treatment group.
Comparison based on log-rank test, nCRT plus surgery vs. surgery alone, χ2 13.7, degree 
of freedom (df) 1, p<0.001.
log-rank p=0.001
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Abstract
Objective 
To gain insight into the exact location of residual esophageal cancer 
in the esophageal wall and regional lymph nodes after neoadjuvant 
chemoradiotherapy (nCRT) and to determine the pattern of regression.
Background data 
Data from the recently published CROSS trial showed that 49% of 
squamous cell carcinomas and 23% of adenocarcinomas had a patho-
logically complete response (pCR) in the resection specimen after 
nCRT. These results impose the ethical imperative to reconsider the 
necessity of esophagectomy with its substantial morbidity and mortal-
ity in patients with pCR. However, it remains challenging to accurately 
identify these patients before resection. 
Methods 
Between January 2003 and July 2011, all patients with esophageal 
cancer in a tertiary referral center, who underwent nCRT (5 weekly 
courses of carboplatin and paclitaxel plus 41.4 Gy concurrent radio-
therapy) and surgical resection, were analyzed. The resection speci-
mens were carefully re-evaluated by an experienced gastrointestinal 
pathologist. Tumor regression grade (TRG) was meticulously scored for 
each specific layer of the esophageal wall and for all removed lymph 
nodes. 
Results 
One-hundred and two consecutive patients were included. Seven-
ty-one (70%) of 102 patients were non-complete responders (≥TRG2) 
and in 63 of these patients (89%) residual tumor cells were seen in the 
mucosa and/or submucosa. Five of eight patients without involvement 
of the mucosa and submucosa had isolated remnants in the muscle 
layer (5/102=5%); the other three patients had tumor cells only in a 
single lymph node (3/102=3%). The surrounding stroma showed the 
highest percentage of TRG1 (=pCR: 47%). In patients with pretreat-
ment lymph node positivity, the percentage of TRG1 in all lymph nodes 
was also favorable (52%). Overall regression showed a non-random 
mixed pattern of both concentric regression and regression towards 
the lumen. 
Conclusions 
After neoadjuvant chemoradiotherapy for esophageal cancer both the 
mucosa and submucosa show frequent residual malignant involve-
ment. The surrounding stroma and the regional lymph nodes show 
the highest percentage of pathologically complete response and the 
overall regression pattern is most frequently a mixed pattern of both 
concentric regression and regression towards the lumen. This overall 
regression pattern lends support to careful testing of a wait-and-see 
approach in a subgroup of esophageal cancer patients after nCRT. 
 
Introduction
Over the last decades, the value of preoperative chemo- and/or radio-
therapy for esophageal cancer has been studied. Neoadjuvant therapy 
has the potential for downstaging the tumor, which in turn increas-
es the radical resectability rate, reduces the locoregional recurrence 
rate and possibly improves long-term survival. The recently published 
multicenter Dutch CROSS trial investigated the value of neoadjuvant 
chemoradiotherapy (nCRT) combining carboplatin and paclitaxel with 
41.4 Gy concurrent radiotherapy1. Results showed a significant 13% 
increase in long-term survival for nCRT plus surgery as compared to 
surgery alone. Further analysis showed that 49% of the squamous cell 
carcinomas and 23% of the adenocarcinomas had a pathologically 
complete response (pCR) in the resection specimen (i.e. no viable tumor 
cells found, neither at the site of the primary tumor, nor in the resect-
ed regional lymph nodes, as determined by conventional histological 
examination). 
Although surgical resection of the esophagus is still considered the 
cornerstone of intentionally curative treatment for esophageal cancer, 
it is associated with severe postoperative morbidity and a substantial 
impact on the quality of life2-6. Patients with pCR after nCRT plus sur-
gery, achieve a favorable disease-specific 5-year survival rate of 68%7. 
However, it is questionable, whether patients with pCR after nCRT do 
have sufficient additional benefit to justify subsequent esophagec-
tomy. Therefore, these high complete response rates impose a strong 
ethical imperative to clinically identify patients with pCR after nCRT. 
Under analogous conditions, a non-operative management in rectal 
cancer patients with a clinically complete response after nCRT has 
been shown feasible and safe, leading to organ-sparing treatment with 
low morbidity- and mortality rates and favorable long-term survival in 
a subset of these rectal cancer patients8-10. 
Several published studies have tried to identify esophageal cancer pa-
tients with pCR after nCRT using conventional endoscopy with histo-
logical biopsies, endoscopic ultrasonography (EUS), computed tomog-
raphy (CT) and positron emission tomography (PET)11-17. So far, results 
from these studies have been mostly disappointing. It has been proven 
difficult to locate and to take targeted biopsies of limited amounts of 
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residual tumor in the esophagus, when restaging is performed only at an 
early single time point after completion of nCRT. Before a wait-and-see 
policy can be safely considered in a subgroup of patients with esophage-
al cancer after nCRT, a better insight into the exact location of residual 
tumor in the esophageal wall and regional lymph nodes is needed. 
Therefore, the aim of the present study was (I) to describe the exact 
location of residual tumor in the esophageal wall and resected lymph 
nodes after nCRT, and (II) to describe the tumor regression pattern of 
esophageal cancer as induced by nCRT. In this way it will be possible 
to identify which layer(s) would yield the highest chance of detecting 
residual disease.
Patients and methods
Patients
All newly diagnosed patients with esophageal cancer at the Erasmus 
MC – University Medical Center, a tertiary referral hospital in Rotter-
dam, The Netherlands, who underwent nCRT according to the CROSS 
regimen followed by esophagectomy between January 2003 and July 
201118, 19, were included (T2-3, N0-1, M0, max. tumor length 8 cm). This 
inclusion period contained three consecutive patient cohorts. The first 
cohort consisted of a consecutive subset of patients from a phase-II 
feasibility trial (February 2001 through January 2004)18, the second 
cohort took part in the multimodality arm of a phase-III randomized 
controlled trial (March 2004 through December 2008)1 and the third 
cohort received the CROSS regimen as standard treatment for re-
sectable esophageal cancer in the period after completion of the two 
trials (January 2009 through July 2011). Patients with irresectable 
tumors (T4b) and/or disseminated disease (M1) were excluded as well 
as patients with tumors clinically limited to the mucosa or submucosa 
and without signs of positive lymph nodes during pretreatment work-
up (cT1N0). Pretreatment staging procedures included endoscopy with 
histological biopsy, EUS (with fine needle aspiration (FNA) of suspected 
lymph nodes, when indicated), CT scan of the neck, chest and abdo-
men and external ultrasonography of the neck (with FNA when indicat-
ed) in all patients. PET(-CT) scans were not routinely performed during 
this study period. 
Neoadjuvant chemoradiotherapy and surgery
Patients received neoadjuvant chemoradiotherapy according to the 
CROSS regimen: carboplatin (area-under-curve=2) and paclitaxel (50 
mg/m2) administered by intravenous infusion on days 1, 8, 15, 22, and 
29 plus concurrent external beam radiation with a total dose of 41.4 
Gy, given in 23 fractions of 1.8 Gy, 5 fractions a week. Esophagectomy 
was planned 4 to 6 weeks after completion of neoadjuvant chemora-
diotherapy. For carcinomas proximal to or at the level of the carina a 
transthoracic esophageal resection with a two field lymph node dissec-
tion was performed. For carcinomas located well below the level of the 
carina, either a transthoracic approach with an extended lymph node 
dissection or a transhiatal approach was performed. For carcinomas 
involving the gastro-esophageal junction, a transhiatal esophageal re-
section was the preferred technique. In both approaches, an upper ab-
dominal lymphadenectomy, including nodes along the hepatic artery, 
splenic artery and left gastric artery, was performed.
Histomorphological analysis
All resection specimens were initially processed using a standardized 
protocol20. During the original pathological examination, information 
was recorded concerning the macroscopic appearance and location 
and the proximal-, distal- and lateral extension of the tumor. If macro-
scopically no tumor could be identified, subtle lesions such as an ulcer 
or an irregular area covered by mucosa were embedded in toto togeth-
er with surrounding areas in order to be adequately evaluated for the 
presence of residual tumor and/or secondary therapy effects.
For the present study, all 102 patients were systematically re-evaluat-
ed histomorphologically by an experienced gastrointestinal pathologist 
(FJWtK), irrespective whether a macroscopic lesion was identifiable. 
This re-evaluation also included re-assessment of all resected lymph 
nodes. Presence of vital tumor cells near the proximal- , distal- and 
circumferential resection margins, tumor type, tumor differentiation 
grade, depth of tumor invasion into the esophageal wall and the num-
ber of involved lymph nodes were rescored by the pathologist. Tumor 
cells were considered vital if the cytomorphological integrity of the 
tumor cells was intact. A radical resection (R
0
) was defined as a mini-
mal distance of 1 mm between vital tumor and the resection margins. 
The 7th edition of the Union Internationale Contre le Cancer (UICC) 
TNM-classification manual was used for tumor staging21. 
The original tumor area – before nCRT – was estimated based both on 
the extent of regressional changes (e.g. fibrosis, mucous lakes, keratin 
pearls and/or foreign body giant cell reactions) and on the presence of 
residual tumor cells in the resection specimen (figure 1), as has been 
described previously in rectal cancer patients22-25 . These measure-
ments were expressed as preypT and preypN, reflecting the assumed 
original depth of the primary tumor and the assumed number of orig-
inally involved lymph nodes, respectively. Some of the fibrotic changes 
seen in the post-nCRT resection specimen are caused by a preexist-
ent desmoplastic reaction. This reaction is caused by the interaction 
between tumor cells and the surrounding stroma and cannot be easily 
141140 Part II - Chapter 7
distinguished from therapy induced fibrosis. In order to determine the 
presence of regressional changes (e.g. mucous lakes, keratin pearls 
and/or foreign body giant cell reactions) as well as the amount of the 
preexisting desmoplastic reaction in the absence of nCRT, we investi-
gated a set of 20 consecutive patients from the surgery-only arm of 
the CROSS trial. Tumors with invasion into the pleura and/or the dia-
phragm were not considered irresectable; therefore (pre)ypT4a tumors 
were categorized as (pre)ypT3.
The overall tumor regression grade (TRG) was evaluated using the 
modified Mandard scoring system as reported by Chirieac et al.26. The 
extent of tumor regression was divided into one of four categories, 
TRG1: no residual tumor cells found (pathologically complete respon-
se=pCR); TRG2: between 1-10% residual tumor cells; TRG3: between 
11-50% residual tumor cells; TRG4: more than 50% residual tumor cells. 
The TRG was also scored per individual esophageal wall layer and for 
all resected lymph nodes. For this purpose the esophageal wall was 
subdivided into four layers from superficial to deep: mucosa, submuco-
sa, proper muscle layer and surrounding stroma (figure 2). The scoring 
was performed by first estimating the area with regressional changes 
for each individual layer and for all lymph nodes (using a 20x-40x mag-
nification). In slides containing residual tumor cells, the area containing 
residual tumor cells was estimated relative to the area showing regres-
sional changes. This was done for each layer and lymph node indi-
vidually for all slides of the resection specimen. An average TRG was 
calculated for each individual layer of the esophageal wall and for all 
resected lymph nodes combined by averaging the TRG score of each 
individual layer in all slides. 
To address the directionality in the pattern of regression within the 
esophageal wall, different potential patterns of regression after nCRT 
were investigated. This evaluation was performed by comparing the 
average TRG in two esophageal wall layers with the average TRG in the 
other two wall layers. A lower average TRG indicated a better response 
(i.e. more regression). The tested directions of regression were cate-
gorized as regression towards the lumen (i.e. more regression in the 
proper muscle layer and surrounding stroma as compared to the mu-
cosa and submucosa); regression towards the invasive front (i.e. more 
regression in the mucosa and submucosa as compared to the proper 
muscle layer and surrounding stroma); concentric regression (i.e. more 
regression in the mucosa and surrounding stroma as compared to the 
submucosa and proper muscle layer) and random regression (i.e. com-
parable extent of regression in all layers) (figure 2). 
The estimated distribution of residual tumor cells within the esopha-
geal wall and lymph nodes was assessed by the relative distribution 
of regression between layers within each individual patient. TRG2 was 
set to 0.05 (=average 0-10% residual tumor cells), TRG3 was set to 
0.30 (=average 10-50% residual tumor cells) and TRG4 was set to 0.75 
(=average 50-100% residual tumor cells). Subsequently, the relative 
contribution of each layer was determined by dividing the score in that 
layer by the total score for all layers in that individual patient. For ex-
ample, in a patient with TRG2, TRG3, TRG3, TRG1 and TRG1 in the mu-
cosa, submucosa, proper muscle layer, surrounding stroma and lymph 
nodes, respectively, the relative percentage of residual tumor cells in 
the mucosa was determined to be 0.05/(0.05+0.30+0.30+0+0)=7.7%. 
 
To estimate the potential clinical detectability of residual cancer cells 
after nCRT, patients with an overall TRG2 response were classified as 
major responders (i.e. less than 10% of original tumor cells remaining), 
while patients with an overall TRG3 or TRG4 response were classified 
as minor responders (i.e. more than 10% of original tumor cells remain-
ing). It was assumed that major responders can probably not be de-
tected reliably during clinical restaging, using either (cyto)histological 
sampling or PET-CT, due to the (very) low amount of residual tumor in 
the esophageal wall. 
This study was performed on microscopy slides as used during regular 
patient diagnostics. None of the material used is traceable to individ-
ual patient data. The Ethics Council of the Erasmus MC – University 
Medical Center approves research conducted on diagnostic tissues, 
without special permission. Therefore, no additional ethical approval 
was sought for. 
Statistical analysis
Grouped data were compared using the non-parametric Kruskall-Wal-
lis H test or one-way ANOVA F test when appropriate with Bonferroni 
correction. Distributions of tumor regression grades per esophageal 
wall layer for all patients were compared using the non-parametric 
Friedman’s test for related ordinal grades among all layers, with post-
hoc testing using the one-on-one Wilcoxon’s signed rank test with 
Bonferroni correction. For comparing distributions of pathologically 
complete response percentages, the non-parametric Cochran’s Q test 
for related binary results was used, with post-hoc testing using the 
one-on-one McNemar’s test with Bonferroni correction. For determin-
ing correlations between two ordinal variables Kendall’s tau-b coef-
ficient was used. The level of significance was set to p<0.05. All sta-
tistical tests were performed using IBM SPSS Statistics for Windows, 
Version 20.0 (IBM; Armonk, NY, USA). 
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Results
One-hundred and two consecutive patients who underwent neoad-
juvant chemoradiotherapy (nCRT) followed by esophagectomy be-
tween January 2003 and July 2011 were included in this study. Their 
clinicopathological characteristics are summarized in Table 1. Median 
age was 62 years (range: 18 – 79 years), the majority of patients were 
male (72%) and had an adenocarcinoma (73%); clinical staging most 
frequently was cT3 (73%) and cN1 (62%). The tumor was located at the 
esophagogastric junction in 26/102 (25%) patients. The median delay 
between the end of nCRT and subsequent surgical resection was 49 
days (range: 20 – 82 days). A microscopically radical (R
0
) resection – 
with no tumor within 1 mm of the resection margins – was achieved in 
95/102 (93%) patients. The median number of resected and identified 
lymph nodes was 19 (range: 2 – 58). The overall distribution of regres-
sion for all esophageal wall layers and lymph nodes combined accord-
ing to Chirieac et al.26 was TRG1=31 (30%), TRG2=35 (34%), TRG3=16 
(16%) and TRG4=20 (20%). The pathologically complete response rate 
(pCR=TRG1) was 46% for squamous cell carcinomas and 24% for ad-
enocarcinomas (Table 2a). Comparisons of clinicopathological char-
acteristics between the three included time-based cohorts are also 
depicted in Table 1. Results show a significantly longer delay between 
nCRT and surgery in the post CROSS cohort (median 44, 44 and 55 
days, respectively, p=0.007) and a significantly higher median number 
of lymph nodes identified in the resection specimen (median 12, 19 and 
23 nodes, respectively, p<0.001).
Location of residual tumor in the esophageal wall and resected 
lymph nodes after nCRT 
Thirty-one (30%) of the 102 included patients showed a pathologically 
complete response (=pCR) in the resection specimen, while 71 (70%) 
patients had residual tumor cells remaining after nCRT (figure 3a). The 
31 patients with a pCR were ‘excluded’ from further analysis because 
they had no viable residual tumor cells left in the resection specimen 
and could therefore not contribute in localizing residual disease or de-
termining direction of regression.
In the remaining 71 patients, the exact location of residual tumor was 
identified: the mucosa, submucosa, proper muscle layer, surrounding 
stroma and lymph nodes contained residual disease in 51 (72%), 53 
(75%), 46 (65%), 30 (42%) and 26 (37%) patients, respectively (figure 
3b). These results indicate that the mucosa, submucosa and prop-
er muscle layer all contained residual tumor cells significantly more 
frequently than the surrounding stroma and regional lymph nodes 
(p≤0.002, figure 3b). Further analysis of histological subtypes in these 
71 patients showed that the pathologically complete response rate per 
individual wall layer did not differ significantly between squamous cell- 
and adenocarcinomas (Table 2b).
The relative distribution of residual tumor within the esophageal 
wall and lymph nodes in individual patients is summarized for all 71 
non-complete responders in figure 3c. These data show that 63 (89%) 
of 71 patients had residual tumor present in the mucosa, the submuco-
sa or both. Eight (11%) patients had no residual tumor present in either 
mucosa or submucosa; five (5%) of whom had residual tumor involving 
the proper muscle layer and surrounding stroma and / or lymph nodes 
selectively and three (3%) patients had residual tumor only in a single 
lymph node. None of the analyzed patients had residual tumor in the 
surrounding stroma only or in multiple lymph nodes only. 
However, it should be noted that these results do not distinguish be-
tween the absence of tumor due to actual tumor regression versus the 
absence of tumor because not all layers contained tumor initially (i.e. 
pretreatment). In order to analyze the biology of nCRT induced tumor 
regression (i.e. tumor regression pattern) one should focus only on the 
regression pattern in patients with pretreatment T3 tumors (preypT3): 
see below.
Tumor regression pattern within the esophageal wall and resected 
lymph nodes as induced by nCRT
To further characterize the tumor regression pattern, we specifically 
looked into those 57 patients from the 71 non-complete responders 
(figure 4), who showed regressional changes and/or residual tumor 
reaching into the surrounding stroma (preypT3), thereby selecting pa-
tients who had initial involvement of all layers of the esophageal wall 
ánd had residual tumor remaining after nCRT (figure 4a). 
Results indicate that the surrounding stroma, as an individual layer, did 
show a significantly higher percentage of TRG1 (=pCR: 47%) in these 
patients as compared to the submucosa (21%; p=0.002) and proper 
muscle layer (26%; p=0.003) (figure 4b). The mucosa (TRG1=pCR=32%) 
did not differ significantly from the submucosa (p=0.180), proper 
muscle layer (p=0.664) or surrounding stroma (p=0.108). In these 57 
patients there was no statistically significant difference in the patho-
logically complete response rate per individual wall layer between the 
two histological subtypes (Table 2c). 
Subsequently, the overall regression pattern was analyzed as depicted 
in figure 2. Results show that regression towards the lumen was signif-
icantly more common as compared to regression towards the invasive 
front, 49% and 21%, respectively (p=0.012). However, only a non-sig-
nificant trend was found in the percentage of patients with a TRG1 in 
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both deeper layers (i.e. proper muscle layer and surrounding stroma) as 
compared to both superficial layers (i.e. mucosa and submucosa), 25% 
and 14%, respectively (p=0.210). A concentric regression pattern was 
found in 46% of patients, while a random regression pattern (i.e. com-
parable regression in all layers) was much less common as compared 
to a non-random regression pattern (i.e. not all layers having a compa-
rable TRG), 21% and 79%, respectively (p<0.001). These results indicate 
a mixed non-random pattern of both concentric regression and regres-
sion towards the lumen. 
Fifty-four (53%) of the 102 included patients showed regressional 
changes and/or residual tumor in one- or more resected lymph nodes 
(Table 3), indicating pretreatment lymph node positivity. Of these 54 
patients, 28 (52%) patients had a pathologically complete response 
(TRG1) in all resected lymph nodes, while 26 (48%) patients had resid-
ual tumor cells in one- or more of the resected lymph nodes, indicating 
the relatively high percentage of pathologically complete responders in 
regional lymph nodes as compared to the percentage of overall patho-
logically complete responders (30%). Thirteen of 54 patients had an 
overall pathologically complete response (including the lymph nodes), 
while positive nodes were found in 9/20 patients (45%) with an over-
all TRG2, 5/7 patients (71%) with an overall TRG3 and 12/14 patients 
(86%) with an overall TRG4. The correlation between the overall re-
gression of the tumor and the percentage of patients with nodes that 
remain positive after nCRT was significant (τ
b
=0.406, p=0.009). 
In order to determine the presence of regressional changes (e.g. mu-
cous lakes, keratin pearls and/or foreign body giant cell reactions) as 
well as the amount of the preexisting desmoplastic reaction in the 
absence of nCRT, we investigated a set of 20 consecutive patients 
from the surgery-only arm of the CROSS trial. Results show that none 
of the specific regressional changes were observed in these patients 
and that a desmoplastic reaction was seen to varying degrees, more 
pronounced in squamous cell carcinomas than in adenocarcinomas. 
The extent of the desmoplastic reaction was equally distributed across 
all layers of the esophageal wall and closely followed the contours of 
the tumor area, with little extension beyond the invasive front. The total 
area of the desmoplastic reaction in these patients was clearly smaller 
than the areas of fibrosis typically seen after nCRT. 
Potential improvements for the identification of patients with a 
minor response after nCRT
We subsequently aimed to explain why previous studies had shown a 
relatively low success-rate for discrimination between complete ver-
sus non-complete responders after nCRT and to define potential ways 
for diagnostic improvements. Of the 102 included patients, 16 (16%) 
patients had an overall TRG3 response and 20 (20%) patients had an 
overall TRG4 response, respectively. Combined, these 36 patients were 
defined as minor responders. Of these 36 overall minor responders, 30 
(83%), 30 (83%), 26 (72%), 16 (44%) and 10 (28%) patients also showed 
a minor response in the mucosa, submucosa, proper muscle layer, 
surrounding stroma and lymph nodes, respectively. This indicates that 
in patients with an overall minor response, the mucosa and submuco-
sa most frequently showed a minor response as well, thus offering the 
highest chance of detecting residual tumor cells in these two specific 
layers. However, these percentages only apply to the 36 overall minor re-
sponders. The remaining 35 of the 71 non-complete responders had an 
overall major response (i.e. TRG2). Of these 35 overall major responders, 
5(14%), 4 (11%), 2 (6%), 0 (0%) and 1 (1%) patients had a TRG3 or TRG4 
(i.e. substantial residual disease) in the mucosa, submucosa, proper 
muscle layer, surrounding stroma and lymph nodes, respectively. Taken 
together, these results indicate that 30/36 overall minor responders plus 
5/35 overall major responders =35/71 (49%) had substantial residual 
disease (more than 10% of residual tumor cells) in the mucosa which 
might potentially be detected by targeted mucosal biopsies alone. 
During restaging, however, submucosal sampling, either by histological 
bite-on-bite biopsies or by cytological fine-needle aspirations, could 
be added to future restaging protocols. This would lead to a potential 
additional yield of 8 patients (=23% increase), who have a (probably 
undetectable) major response in the mucosa, but a (potentially detect-
able) minor response in the submucosa. 
Discussion
Results show that after nCRT, 70% of patients had residual tumor cells 
in their resection specimen. In 89% of these patients with a non-com-
plete response, the mucosa and/or submucosa contained residual tu-
mor cells, while 5 patients had residual tumor cells limited to the proper 
muscle layer plus surrounding stroma / lymph nodes and 3 patients 
had residual tumor cells in a single lymph node only. Of all initially in-
volved layers of the esophageal wall, the surrounding stroma showed 
the highest percentage of TRG1 (=pCR: 47%). In patients with pretreat-
ment lymph node positivity, the percentage of TRG1 in all lymph nodes 
was also favorable (52%). 
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The overall regression pattern within the esophageal wall showed a 
non-random distribution between different layers. Overall regression 
showed a mixed pattern of both concentric regression and regression 
towards the lumen, indicating the preferential persistence of malignant 
cells in the (sub)mucosa and underlining the relatively high responsive-
ness of the surrounding stroma. This difference in response to neoad-
juvant chemoradiotherapy between the different layers of the eso-
phageal wall could possibly be explained by both cancer cell specific 
(intrinsic) factors and location specific (extrinsic) factors. An important 
intrinsic factor that could possibly explain the difference in responsive-
ness is selective advantage due to intratumoral genetic heterogeneity, 
as was recently shown for renal-cell carcinoma as a proof of princi-
ple27. This heterogeneity could be caused by microsatellite instability28, 
loss of heterozygosity29, 30 and copy number variations31, 32. Extrinsic 
factors include differences in oxygenation levels and cancer cell-stro-
ma interactions. It has long been recognized that low tissue oxygen-
ation levels are negatively correlated with cancer cell sensitivity to 
radiotherapy33, 34 and chemotherapy35. The relative blood flow through 
the intestinal wall has been found lowest in the submucosa36, offering 
further support to a hypoxia-related relative resistance of tumor cells 
in the submucosa. Another location specific mechanism by which dif-
ferences in regression might arise is cancer cell-stroma interaction. The 
tumor microenvironment has been found an important player in deter-
mining cancer cell sensitivity to radiotherapy37, 38 and chemotherapy39. 
Although the mechanisms of heterogeneous regression between the 
different layers of the esophageal wall are not exactly known, several 
of these intrinsic- and extrinsic factors might jointly contribute to dif-
ferences in tumor cell sensitivity to nCRT between the different layers 
of the esophageal wall, as described here. 
It might seem logical and self-evident that in the mucosa (and submu-
cosa), being the presumed point of origin of both squamous cell- and 
adenocarcinomas of the esophagus, the largest amount of residual 
tumor was found. Interestingly however, a recent study which looked 
at the distribution of residual rectal cancer cells within the bowel wall 
after neoadjuvant chemoradiotherapy40 found a pattern which was 
the exact opposite from ours. They describe the preferential clearing 
of residual cancer cells from both the mucosa and submucosa and 
report the highest percentage of residual cancer cells near the invasive 
front. We currently have no explanation for the apparent discrepancy 
between the two studies.
Our main motivation to undertake this study was the (surprisingly) but 
consistently high pathologically complete response (pCR) rate found in 
the CROSS trial1. In this trial it was found that 49% of squamous cell 
carcinomas and 23% of adenocarcinomas had a pCR in the resection 
specimen. If one is willing to consider a wait-and-see approach in these 
patients it is of importance to know where residual tumor cells are 
most likely located. This might help to increase the chance of detect-
ing residual and recurrent disease during initial clinical restaging after 
nCRT and subsequent surveillance by focusing tissue sampling not 
only at the mucosa but also at the submucosa. Also, these results in 
combination with the findings that the surrounding stroma and lymph 
nodes most frequently show a pCR suggest that a local recurrence 
might become clinically detectable before it becomes locoregionally 
irresectable. 
However, it is unlikely that early after nCRT, pathologically complete 
responders (TRG1) could ever become clinically distinguishable from 
pathologically near-complete responders (TRG2), because differences 
between these two categories frequently constitute of no more than 
one- or two percent of residual tumor cells. Moreover, even a patho-
logically complete response does not guarantee long-term survival 
without locoregional recurrence. We showed earlier, that even after 
extended surgical resection pathologically complete responders carry a 
13% risk for developing a locoregional recurrence41. Therefore, the main 
goal in the early period immediately following nCRT should perhaps 
rather be to identify minor responders (TRG3 and TRG4) first. If minor 
responders can readily be detected early after completion of nCRT, 
delay towards surgery would be minimal for these patients and their 
course of treatment would be unaltered. Over time, some patients with 
a near-complete response will recur locally or expose their (already) 
disseminated disease, while truly complete responders may only recur 
at distant sites. Therefore, time will be the discriminator between those 
who would benefit from delayed surgical resection and those who 
would not.
Several earlier studies have already investigated the sensitivity of dis-
criminating between complete- and non-complete responders after 
nCRT11,12,15,16, but only few focused on (cyto)histological confirmation. 
The first prospective study to evaluate the role of endoscopy with mu-
cosal biopsies in detecting residual disease was performed by Bates et 
al.42. In this study 35 patients were included. Most were male (69%) and 
had a squamous cell carcinoma (80%). Neoadjuvant chemoradiothera-
py consisted of cisplatin and 5-FU with 45 Gy concurrent radiotherapy. 
The pathologically complete response rate was 51%. Twenty-two pa-
tients underwent restaging by endoscopy with brushings and biopsies 
after nCRT. In these 22 patients, 17 (77%) patients had negative (cyto)
histology. In these 17 negative patients, 7 (32%) patients had residual 
tumor cells in their resection specimen, while 10 (45%) patients had a 
pathologically complete response. These results indicate that the sen-
sitivity of restaging with endoscopy and brushings and/or biopsies was 
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42% (5/12) and the accuracy of detection was 68%. The percentage of 
detected patients in this study (42%) approaches our own percentage 
of patients (49%) with a minor response (TRG3 or TRG4) in the muco-
sa, whom we might assume to have potentially detectable amounts of 
residual disease in the mucosa. 
A second prospective study by Schneider et al.14, investigated the ac-
curacy of endoscopy, mucosal biopsies and EUS during restaging after 
nCRT. This study included 80 patients. Most patients were men (81%) 
and had locally advanced disease (uT3; 74%) of the squamous cell car-
cinoma subtype (61%). Neoadjuvant chemoradiotherapy consisted of 
cisplatin and 5-FU with 36 Gy concurrent radiotherapy. Of the 80 pa-
tients, 12 (15%), 21 (26%), 17 (21%) and 30 (38%) had an overall TRG1, 
TRG2, TRG3 and TRG4, respectively. The relatively low number of TRG1 
responses and relatively high number of TRG4 responses in these 
patients (of whom a majority had squamous cell carcinoma) is not in 
line with more recent literature. However, this could possibly be relat-
ed to the relatively low dose of radiation delivered in these patients. 
The overall sensitivity for histological identification of non-complete 
responders was 36% (20/55) which is lower than expected. It remains 
speculation what factors might have contributed to this low yield. The 
relatively short interval (2-3 weeks) between completion of nCRT and 
restaging might have increased the difficulty in finding positive his-
tology within this study. In the period immediately following nCRT, the 
esophageal epithelium is frequently swollen and exhibits signs of acute 
inflammation, which might lead to more false-negative biopsy results. 
 
Together, these two earlier studies show a relatively low sensitivity for 
detecting residual tumor cells by mucosal biopsies after nCRT, albeit 
higher in patients with a minor response. How can we potentially im-
prove these unfavorable results before carefully attempting a wait-
and-see approach after nCRT?
In several aspects the present data support the relative safety of de-
laying surgery temporarily. First, additional (cyto)histological sampling 
of the submucosa could increase the yield of detecting residual dis-
ease. The mucosa and submucosa together show residual tumor cell 
involvement in 89% of non-complete responders. In the present study 
11% of non-complete responders have TRG1 or TRG2 in the mucosa 
while TRG3 or TRG4 is present in the submucosa. These patients are 
easily missed with regular endoscopic biopsies, but might be detected 
with bite-on-bite biopsies or fine-needle aspirations of the submucosa. 
Second, of all esophageal wall layers, the surrounding stroma has the 
highest percentage of TRG1, reflecting effective tumor downstaging 
with increased distance between the residual tumor and the circum-
ferential resection margin and possibly allowing for a lag period before 
the radicality of the circumferential resection margin is surgically 
threatened. Third, only three (3%) of 102 included patients in this study 
had isolated residual lymphatic disease and this was always limited to 
a single lymph node. No patient had isolated residual disease in mul-
tiple lymph nodes, indicating that the risk of missing isolated regional 
lymph node metastases is likely to be small. 
Finally, a recent study by Furlong et al.43 reported on their favorable 
results with a wait-and-see approach for high-risk esophageal cancer 
patients with a complete clinical response after neoadjuvant chemora-
diotherapy. Taken together, these results strengthen our willingness to 
formally test a wait-and-see approach in esophageal cancer patients 
otherwise fit to undergo resection.
Limitations of the study
The first limitation of this study is that the reproducibility of the pre-
sented data was not tested. Having the slides reviewed by a single pa-
thologist does limit the conclusions that can be drawn from this study. 
However, the measurements performed in this study are essentially the 
same as a standard pathological response evaluation (e.g. Mandard 
score44), which includes tumor regression grading (TRG) for the entire 
resection specimen. These measurements are currently being per-
formed routinely in day-to-day clinical practice for many tumor types 
after neoadjuvant therapy. Our report of the TRG per individual wall 
layer thus uses this same scoring technique within different defined 
areas of the esophageal wall. 
The second limitation is the assumption that the area of regressional 
changes plus residual disease truly represents the original (pretreat-
ment) tumor location. Regressional changes such as mucous lakes 
and foreign body giant cell reactions were not observed in primarily 
resected patients and therefore seem to be exclusively correlated with 
neoadjuvant therapy. There might be a systematic overestimation of 
the original tumor area due to the presence of a desmoplastic reac-
tion. However, this overestimation is probably small and most likely 
will not cause any skewing of the TRG data between different layers 
of the esophageal wall within the same patient. Also, the alternative 
gold-standard would be clinical staging based on EUS, which, although 
accepted as the most accurate clinical T-staging modality, is still con-
sidered relatively inaccurate, especially for less advanced tumors45. 
Therefore, we consider the staging method based on preypT (because 
of its high resolution) preferable for this study as opposed to clinical 
staging by EUS.
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The third limitation is that all residual disease was scored based on 
the ratio between residual tumor area and residual fibrotic area. This 
ratio does not include information on the absolute size of either areas, 
because of technical limitations this was not feasible. A final limitation 
is that it is unknown what the described regression patterns would 
look like in patients treated with other neoadjuvant therapies, such as 
chemotherapy alone or cisplatin and 5-FU based chemoradiotherapy.
Conclusions
After neoadjuvant chemoradiotherapy for esophageal cancer both the 
mucosa and submucosa show relatively frequent residual malignant 
involvement, offering the opportunity for successful targeted sampling 
of both layers. Chemoradiotherapy induced regression of esophageal 
cancer within the esophageal wall and regional lymph nodes is heteroge-
neous. The surrounding stroma and the regional lymph nodes show the 
highest percentage of pathologically complete response and the overall 
regression pattern is most frequently a mixed pattern of both concentric 
regression and regression towards the lumen. This suggests that a local 
recurrence might become clinically detectable before it becomes locore-
gionally irresectable. Taken together these results point towards possi-
ble new improvements in identifying non-complete responders during 
clinical restaging and lend support to careful testing of a wait-and-see 
approach after nCRT in a subgroup of esophageal cancer patients, as 
has recently been proposed for rectal cancer patients. 
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Legend table 1
*  Preoperative T and N stages as determined by endoscopic ultrasonography, with or 
without cytohistological confirmation of suspected lymph nodes. 
∂  Resection status: R
0
 was defined as a minimal distance of 1 mm between vital tumor 
and the resection margins; R
1
 was defined as vital tumor within 1 mm of the resec-
tion margins; R
2
 was defined as a macroscopically irradical resection.
°  ypT and ypN are the T- and N-stages as determined in the resection specimen after 
neoadjuvant chemoradiotherapy.
#  TRG: tumor regression grade as defined by Chirieac et al.26; TRG1: pathologically 
complete response, no viable tumor cells remaining; TRG2: ≤ 10% viable tumor cells 
remaining; TRG3: between 11 and 50% viable tumor cells remaining; TRG4: ≥ 50% 
viable tumor cells remaining. 
Comparisons between groups were performed using the non-parametric Kruskall-Wal-
lis H test or one-way ANOVA F test with Bonferroni correction. The significance level af-
ter correction was set at p<0.017 (=0.05/3). Significant P-values are highlighted in bold. 
Table 2a — Overall distribution of tumor regression grade (TRG) per 
tumor type in 102 patients who underwent esophagectomy after 
neoadjuvant chemoradiotherapy according to CROSS1.
Parameter
TRG 
TRG1
TRG2
TRG3
TRG4
Total
30% (31)
34% (35)
16% (16)
20% (20)
Squamous cell 
carcinoma 
n=28
46% (13)
29% (8)
11% (3)
14% (4)
Adenocarcinoma 
n=74
24% (18)
36% (27)
18% (13)
22% (16)
Table 2b — Percentage of pathologically complete responders 
(TRG1) per individual wall layer for both tumor types in 71 patients 
with a pathologically non-complete response after neoadjuvant 
chemoradiotherapy according to CROSS1.
Mucosa
Submucosa
Proper muscle layer
Surrounding stroma
Squamous cell 
carcinoma 
n=15
33% (5)
27% (4)
33% (5)
67% (10)
Adenocarcinoma
n=56
27% (15)
25% (14)
36% (20)
55% (31)
p
0.617
0.895
0.864
0.431
Table 1 — Comparison of clinicopathological characteristics of 
102 patients who underwent esophagectomy after neoadjuvant 
chemoradiotherapy according to CROSS1 in the three time-based 
cohorts: CROSS I , CROSS II and post CROSS.
Total
n=102
62 (18-79)
73 (72%)
29 (28%)
28 (27%)
74 (73%)
2 (2%)
26 (25%)
74 (73%)
32 (31%)
63 (62%)
6 (6%)
1 (1%)
49 (20- 82)
95 (93%)
6 (6%)
1 (1%)
19 (2-58)
34 (33%)
21 (21%)
18 (18%)
29 (28%)
76 (73%)
17 (18%)
6 (6%)
3 (3%)
31 (30%)
35 (34%)
16 (16%)
20 (20%)
CROSS I
n=19
62 (41 - 74)
17 (89%)
2 (11%)
6 (32%)
13 (68%)
-
1 (5%)
18 (95%)
8 (42%)
11 (52%)
 - 
 - 
44 (25 - 74)
18 (95%)
- 
1 (5%)
12 (2 - 28)
6 (32%)
4 (21%)
3 (15%)
6 (32%)
15 (79%)
2 (11%)
1 (5%)
1 (5%)
6 (32%)
7 (37%)
2 (10%)
4 (21%)
CROSS II
n=31
60 (44 - 74)
21 (68%)
10 (32%)
13 (42%)
18 (58%)
1 (3%)
9 (29%)
21 (68%)
9 (29%)
22 (71%)
- 
- 
44 (20 - 82)
28 (90%)
3 (10%)
-
19 (5 - 34)
11 (35%)
6 (19%)
5 (17%)
9 (29%)
23 (74%)
5 (16%)
3 (10%)
-
9 (29%)
13 (42%)
5 (16%)
4 (13%)
post 
n=52
62 (18 – 79)
35 (67%)
17 (33%)
9 (17%)
43 (83%)
1 (2%)
16 (31%)
35 (67%)
15 (29%)
30 (58%)
6 (12%)
1 (1%)
56 (21 - 81)
49 (94%)
3 (6%)
-
23 (7 - 58)
17 (33%)
11 (21%)
10 (19%)
14 (27%)
38 (73%)
10 (19%)
2 (4%)
2 (4%)
16 (31%)
15 (29%)
9 (17%)
12 (23%)
p
0.463
0.162
0.047
0.067
0.216
0.007
0.819
<0.001
0.969
0.870
0.868
Parameter
Median age (range), [years]
Gender
Male
Female
Histology
Squamous cell carcinoma
Adenocarcinoma
Preoperative T-stage*
cT1
cT2
cT3
Preoperative N-stage*
cN0
cN1
cN2
cN3
Median delay between nCRT  
and surgery (range), [days]
Resection status∂
R
0
R
1
R
2
Median number of lymph 
nodes resected (range), [number]
ypT°
ypT0
ypT1
ypT2
ypT3
ypN°
ypN0
ypN1
ypN2
ypN3
TRG#
TRG1
TRG2
TRG3
TRG4
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Figure 1 — Histological examples of residual tumor and regressional 
changes in the esophageal wall and regional lymph nodes.
Legend figure 1
A. Example of substantial submucosal residual disease with a complete regression in the 
mucosa. The mucosa of this patient was scored TRG1 (=pCR) and the submucosa TRG3. 
The original mucosal surface was ulcerated, thus no epithelial lining was recognizable. 
The exact transition between mucosa and submucosa was undeterminable, due to 
extensive amounts of fibrosis; picture taken using 2.50x magnification. The red-dashed 
line indicates the edge of residual tumor.
B. Example of tumor downstaging. The surrounding stroma shows a major fibrotic area, 
indicating the initial involvement of this layer (preypT3) pretreatment. The deepest 
residual tumor cells reach well into the proper muscle layer, indicating a downstaging 
from preypT3 to ypT2. This patient was scored as an overall ypT2, TRG2; picture taken 
using 1.25x magnification. The red-dashed lines indicate the edge of residual tumor; 
the blue-dashed line indicates the edge of the major fibrotic area in the surrounding 
stroma; however, fibrotic areas are also seen in the proper muscle layer.
C. Example of two adjacent lymph nodes, with regressional changes in the left lymph 
node. Within the center of the left lymph node a large fibrotic area can be seen without 
any residual tumor cells. This node was assumed to have been tumor-positive pretreat-
ment, but achieved TRG1 (=pCR) after nCRT. The right lymph node is an example of a 
normal, unaffected lymph node; picture taken using 1.25x magnification. The blue-
dashed line indicates the edge of the major fibrotic area.
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Table 2c — Percentage of pathologically complete responders per 
individual wall layer for both tumor types in 57 patients with an 
assumed pretreatment T3 tumor and a pathologically non-complete 
response after neoadjuvant chemoradiotherapy according to 
CROSS1. 
Mucosa
Submucosa
Proper muscle layer
Surrounding stroma
Squamous cell 
carcinoma
n=12
33.3% (4)
33.3% (4)
33.3% (4)
58.3% (7)
Adenocarcinoma
n=45
31.1% (14)
17.8% (8)
24.4% (11)
44.4% (20)
p
0.883
0.240
0.534
0.394
Legend table 2a, 2b, 2c
TRG: tumor regression grade, as defined by Chirieac et al.26
TRG1: pathologically complete response, no viable tumor cells remaining; TRG2: ≤10% 
viable tumor cells remaining; TRG3: between 11 and 50% viable tumor cells remaining; 
TRG4: ≥ 50% viable tumor cells remaining. 
preypT
preypT1
preypT2
preypT3
preypN
preypN0
preypN1
preypN2
preypN3
10 (10%)
14 (14%)
78 (76%)
48 (47%)
39 (38%)
11 (11%)
4 (4%)
Table 3 — Estimate of pretreatment tumor extent in 102 
patients who underwent esophagectomy after neoadjuvant 
chemoradiotherapy according to CROSS1.
Legend table 3
The estimate of the extent of tumor before neoadjuvant chemoradiotherapy is based on 
the location of residual tumor and regressional changes in the esophageal wall and re-
sected lymph nodes. These regressional changes include fibrosis, mucous lakes, keratin 
pearls and foreign body giant cell reactions. Both preypT and preypN categories were 
staged according to the pT- and pN-stages as defined by the 7th edition of the TNM 
staging manual21.
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Figure 3 — Residual tumor location in 71 patients with a 
pathologically non-complete response in the resection specimen 
after neoadjuvant chemoradiotherapy according to CROSS1.
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complete responders
Pathologically 
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31 71
No tumor Residual tumor present
p<0.002
0% 20% 40% 60% 80% 100%
28% 72%
25%
35%
58%
63%
75%
65%
42%
37%
A
B
Mucosa 
Submucosa 
Proper muscle layer 
Surrounding stroma
Regional 
lymph nodes
Legend figure 2
The esophageal wall consists of four layers. From the lumen: mucosa, submucosa, 
proper muscle layer and surrounding stroma. The transparently colored areas repre-
sent the areas of original (i.e. pretreatment) tumor extent. The darker colored areas 
represent the areas with residual tumor cells which are present after nCRT. Regression 
towards the lumen is defined as more regression in the proper muscle layer and sur-
rounding stroma as compared to the mucosa and submucosa; residual tumor cells will 
be located mostly in mucosa and submucosa. Regression towards the invasive front is 
defined as more regression in the mucosa and submucosa, as compared to the proper 
muscle layer and surrounding stroma; residual tumor cells will be located mostly in the 
proper muscle layer and surrounding stroma. Concentric regression is defined as more 
regression in the mucosa and surrounding stroma, as compared to the submucosa and 
proper muscle layer; residual tumor cells will be located mostly in the submucosa and 
proper muscle layer. Random regression is defined as comparable extent of regression 
in all layers; residual tumor cells will be present to a comparable extent in all originally 
involved layers. 
Figure 2 — Possible regression patterns within the esophageal wall 
after neoadjuvant chemoradiotherapy.
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Figure 4 – Residual tumor location in 57 patients with a pretreatment 
T3 tumor and a pathologically non-complete response in the 
resection specimen after neoadjuvant chemoradiotherapy according 
to CROSS1.
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Legend figure 4
A. Of 102 included patients, 31 patients had a complete response and 71 patients had 
a non-complete response. Of these 71 non-complete responders, 57 patients had initial 
involvement of all four esophageal wall layers (preypT3). 
B. In these 57 patients, the tumor regression grade was scored for each individual layer 
of the esophageal wall. The surrounding stroma significantly more frequently showed a 
TRG1 as compared to the submucosa and proper muscle layer, as indicated by the bars, 
p=0.002 and p=0.003, respectively. 
Legend figure 3
A. In 102 included patients, 31 patients had a complete response and 71 patients had a 
non-complete response. 
B. In these 71 non-complete responders, residual tumor was scored for each individual 
layer of the esophageal wall and for all resected and identified lymph nodes. The mu-
cosa, submucosa and proper muscle layer contained tumor significantly less frequently 
as compared to the surrounding stroma and lymph nodes. Bars indicate a significant 
difference between individual layers, all p-values ≤0.002.
C. The estimated distribution of residual tumor cells within the esophageal wall and 
lymph nodes in all 71 non-complete responders; distribution of residual tumor cells per 
individual layer was assessed based on the relative distribution of regression between 
layers within each individual patient (see Methods for more details on the calculation 
method used); 63/71 (89%) patients had residual tumor cells in the mucosa, the sub-
mucosa or both; 8 patients had no residual tumor cells in the mucosa or submucosa, of 
whom 5/8 had residual tumor cells in deeper layers and 3/8 had residual disease in a 
single lymph node only.
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Extra discussions
If no cancer is found in endoscopic biop-
sies, the implications are either complete 
response with or without lymph node 
metastasis or regression grades 2 to 4 but 
without the presence of residual tumor in 
the mucosa or submucosa. In patientswith 
amajor response (<10% viable tumor), re-
sidual cancer is difficult to detect.However, 
it is these patients who benefit most from 
esophagectomy with a chance of cure that 
is similar to those with pCR. The risk of 
waiting for further development of can-
cer in these patients seems to be higher 
than the postoperative mortality of 3% in 
high-volume centers. Therefore, a ‘wait-
and-see’ approach based on the presented 
data is doubtful. 
Response From Joël Shapiro (The 
Netherlands): 
Thank you, Dr Hölscher, for your comments. 
We were faced with a significant number of 
patients in our cohortwho had no residual 
tumor in the resection specimen and we 
feel that it is our ethical imperative to try 
to find a solution and perhaps not operate 
on all of these patients. To try to detect 
minimal residual disease with a single 
clinical restaging shortly after completion 
of neoadjuvant chemotherapy is probably 
not the way to go as one will never be able 
to distinguish between a truly complete 
responder and those with minimal residual 
disease. We do not even know the clinical or 
biological significance of very small residual 
tumor deposits that are encased in fibrosis. 
Second, in those patients who have minimal 
residual disease, we think that it may be 
possible to perform serial clinical restag-
ing and that the location of residual dis-
ease combined with the regression pattern 
would detect residual disease before it be-
comes clinically apparent or unresectable. 
determine whether or not residual disease 
is present? Have you used modern tech-
niques or molecular imaging or any kind 
of radiological imaging, for example, PET 
scanning?
Response From Joël Shapiro (The 
Netherlands): 
Thank you for your question. To answer 
your second question first, we believe that 
a full set of diagnostic modalities should be 
employed if one is willing to try and wait. 
That includes not only biopsies of the muco-
sa and fine-needle aspiration of the sub-
mucosa. The combination of PET-CT and bi-
opsy seems to add information as opposed 
to a PET alone. So, yes, we think as much 
as possible should be done to not lose any 
patients with residual disease in the deep-
er layers, who as you pointed out, would 
benefit most from immediate resection. To 
assess the amount of tumor that is found in 
the resection specimen is technically quite 
difficult because there are many sections 
and then you have to determine the surface 
area. We determined the tumor regression 
rate on the basis of the modified tumor 
regression grade scoring system. TRG1 
means zero present, then from 1% to 10%, 
from 10% to 50%, or more than 50% of re-
sidual tumor remaining. So every layer was 
scored according to that scoring system.
Discussants 1
Arnulf Hölscher (Cologne, Germany):
The article by Shapiro and colleagues 
represents a very detailed histopatholo-
gy workup of resection specimens after 
neoadjuvant chemoradiotherapy (nCRT) 
for esophageal cancer. However, questions 
remain concerning the material and the 
suggested clinical implications. Most of the 
patients had transhiatal esophagectomy 
with lymphadenectomy only of the lower 
mediastinum. The first cohort had a me-
dian of just 12 resected lymph nodes for 
abdomen and chest. The nodal regression 
grading based on such low numbers is not 
representative. The analysis of regression 
in the 4 layers should focus on the 57 T3 
carcinomas because only in these patients 
were all layers initially involved. In this 
group, no significant difference in pCR was 
found between mucosa and surrounding 
stroma. Furthermore, no significant differ-
ence in pCR was found comparing deeper 
and superficial layers in all patients. The 
authors suggest a ‘wait-and-see’ approach 
in responders with negative endoscopic bi-
opsies because they argue that the mucosa 
is very representative for residual cancer. 
However, results of histopathology workup 
of an esophagectomy specimen are not 
comparable with histology of endoscopic 
biopsies. Clinical studies report a sensitivity 
of 50% to 60% for endoscopy plus biopsy 
for detection of residual oeso phageal can-
cer after nCRT. 
Discussants 2
Ronan O’connell (Dublin, Ireland):
Thank you for a very nice presentation 
andwhole mount preparation of the histolo-
gy.Howmany pathologistswere involved and 
how reproducible were their assessments? 
Response From Joël Shapiro (The 
Netherlands): 
Thank you for your question. All these 
analyses have been performed by a single 
pathologist. We readily acknowledge that 
that is a limitation of this study; howev-
er, the method used was the same that is 
used all over the world to determine the 
tumor regression. We simply divided this 
tumor regression rate into individual layers 
of the oesophageal wall, so we believe that 
although this is a novel way of approaching 
the resection specimen, the technique itself 
has been used for many years.
Discussants 3
Carlos Pellegrini (Seattle, WA):
I have 2 brief questions. Did you get any 
idea of the volume of residual disease in 
these patients? There are some studies 
that have clearly shown that the amount 
of residual disease, 0% to 15%, 15% to 
20%, or more than 50%, has a lot to do with 
the prognosis. Second, it seems to me, as 
pointed out by Dr Hölscher, that there is an 
unintended consequence in these findings. 
If you just did biopsies and adopted a wait 
and see approach, you would be excluding 
the patients who could be helped the most. 
So, with that in mind, is there anything 
other than a biopsy of the mucosa of the 
esophagus that you would recommend to 
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Discussants 4
Giovanni Zaninotto (Venezia, Italy):
I have 2 brief questions. When the opera-
tion was performed, after completion of 
the chemotherapy? We know from rectal 
cancer surgery the longer you wait, the 
better the response. The second question is 
whether you had any false positives in your 
group?
Response From J. Shapiro (The 
Netherlands):
The median time to operation was 49 
days. There was some variation, of course, 
mostly for logistic reasons and indeed we 
did see a trend that the longer we waited 
the greater the percentage of pathological 
complete responders. To answer the second 
question, did you mean clinical restaging or 
did you mean false positives as pathologi-
cally staged? We based our results on the 
presence of viable tumor after resection. In 
that case, we did not have false positives 
because the criterion was viable tumor cells 
identified by histology. However, we have 
seen local and regional recurrences in some 
of the patients with a pathological com-
plete response in whom we did not find a 
single tumor cell in the resection specimen.
Letter to the editor
tumors in the surrounding stroma will not 
be detected by endoscopy. 
Second, even superficial residues tend to be 
easily missed by endoscopic biopsies and 
endoscopic ultrasound. In studies investi-
gating the value of endoscopic biopsies in 
identifying residual cancer after nCRT, con-
sistently poor sensitivities of 31%,2 36%,3 
42%,4 and 59%5 were reported. In this study 
by Shapiro et al,1 the authors suggest that 
post-nCRT bite-on-bite biopsies or finenee-
dle aspirations would improve the sensitiv-
ity of identifying noncomplete responders. 
Unfortunately, however, in patients with 
residual tumor in the submucosa but not in 
the mucosa, the normal appearing lumen 
may likely mask the underlying submucosal 
residual disease, resulting in a significant 
sampling error.
Endoscopic ultrasound has shown to be of 
limited additional value in the evaluation 
of treatment response,mainly because of 
the difficulty of differentiating fibrosis and 
inflammation from residual tumor, and is 
therefore not likely to overcome the sam-
pling error problem. Therefore, a true sen-
sitivity improvement by deeper biopsies is 
doubtful and warrants investigation before 
drawing any conclusions on postponement 
of surgical treatment. Notably, safety issues 
should be addressed first, as a high risk of 
esophageal perforations with accompany-
ing morbidity and mortality is feared when 
applying deeper biopsies in a vulnerable 
irradiated esophagus. 
Third, before considering a wait-andsee 
approach, the outcomes after salvage es-
ophagectomy (in case of residual or recur-
rent disease) should be taken into account. 
Residual Esophageal Cancer After 
Neoadjuvant Chemoradiotherapy 
Frequently Involves the Mucosa and 
Submucosa. 
To the Editor:
With great interest, we read the article by 
Shapiro et al1 published in the November 
2013 edition of Annals of Surgery. The au-
thors meticulously reevaluated the resec-
tion specimens of 71 esophageal cancer 
patients showing pathological noncomplete 
response to neoadjuvant chemoradiothera-
py (nCRT). For each layer of the esophage-
al wall and for all available lymph nodes, a 
tumor regression grade was appointed by a 
pathologist. The conclusion was drawn that 
after nCRT both the mucosa and the sub-
mucosa frequently show residual malignant 
involvement as opposed to the surrounding 
stroma. However, the data analysis and in-
terpretation of results raise some questions. 
In particular, multiple concerns are raised 
regarding the conclusion of the authors 
that their findings support a wait-and-see 
approach in the subgroup of clinical com-
plete responders. 
First, in the overall population with clinical 
T3 esophageal tumors, residual disease 
may involve the surrounding stroma and 
the mucosa equally frequently. The authors 
found that in the subgroup of 57 patients 
with clinical T3 tumors (tumors where the 
initial cancer also involved the mucosa 
and surrounding stroma) the presence of 
residual tumor in the mucosa and surround-
ing stroma was not significantly different. 
Therefore, the conclusion that residual 
cancer is more often present in the muco-
sa than in the surrounding stroma should 
be interpreted with caution. The residual 
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resonance imaging may be a promising new 
tool for response evaluation as suggested by 
rectal cancer studies9 and preliminary expe-
rience in esophageal cancer.10 
In conclusion, we think that with current re-
sponse evaluation tools initiation of a wait-
and-see approach would imply deteriorated 
outcomes for patients that are erroneously 
portrayed as complete responders. In our 
opinion, these outcomes outweigh the ben-
efits of an organ preservation regimen for 
the successfully identified group.
Peter S. N. van Rossum, MD*†
Richard van Hillegersberg, MD, PhD* 
Gert J. Meijer, PhD†
Jelle P. Ruurda, MD, PhD*
Departments of *Surgery and †Radiotherapy
University Medical Center
Utrecht, The Netherlands
J.P.Ruurda@umcutrecht.nl
A recent meta-analysis by Markar et al6 
reported that salvage esophagectomy after 
definitive chemoradiotherapy is associat-
ed with a significantly increased incidence 
of postoperative mortality (10% vs 4%; 
p<0.001), anastomotic leakage (24% vs 
14%; p=0.005), and pulmonary complica-
tions (30% vs 17%; p<0.001). Also, although 
studies from neoadjuvantly treated rec-
tal cancer patients showed that a longer 
surgical delay (>8 weeks) was associated 
with a higher rate of pathological complete 
response (pCR), 2 studies in esophageal 
cancer showed that longer surgical delay 
(>8 weeks) did not result in a favorable pCR 
rate.7,8 On the contrary, longer delay was 
associated with an increased amount of 
residual cancer (eg, higher tumor regres-
sion grade scores; p=0.024), and an inferi-
or 5-year overall survival in a subgroup of 
clinical complete responders (35% vs 50%; 
p=0.038).8 
Finally, because all current modalities yield 
unsatisfactory results in the assessment 
of response to nCRT so far, and salvage 
esophagectomy is associated with poorer 
outcome, one should first aim to assess the 
value of improved response evaluation tech-
niques or even new modalities before testing 
a wait-and-see approach. More specifical-
ly, to justify a wait-and-see approach in 
individual patients, a test should first have a 
proven ‘high enough’ negative predictive val-
ue for detecting residual cancer, rather than 
a high sensitivity. In our opinion, it is doubtful 
that submucosal biopsies will improve the 
value of endoscopy, because of sampling 
error issues and the potential increased risk 
of perforations. New fields of improvement 
include 18F-fluorodeoxyglucose positron 
emission tomography studies combining 
spatial and metabolic information with com-
puter-based comprehensive spatial-tem-
poral features to evaluate tumor response 
to treatment. Also, functional magnetic 
Reply:
We thank van Rossum et al for their critical 
comments. Currently, it is unclear which 
patients benefit from surgical resection 
after neoadjuvant chemoradiotherapy 
(nCRT). One can reasonably assume that 
in a subset of patients esophagectomy is 
performed after neoadjuvant therapy with-
out benefit, either because of unrecognized 
(but already present) distant dissemination, 
or because of complete absence of disease. 
How then to preoperatively identify these 
patients in whom surgical resection would 
not be beneficial? The conceptual approach 
we suggest to be explored would be to 
postpone surgical resection until locore-
gional recurrence is detected during close 
surveillance, in the absence of disseminat-
ed disease. In such a surgery-as-needed 
approach, patients with a truly complete 
response and patients with disease man-
ifestation at distant sites (irrespective of 
synchronous locoregional residual or recur-
rent disease)would not be exposed to an 
unbeneficial and potentially harmful surgi-
cal resection. 
For such a surveillance strategy to be prom-
ising, the location and distribution of residual 
disease at the primary tumor site should be 
favorable. Presence of residual disease in 
the mucosa is helpful for early detection of 
(endoluminal) recurrence. On the contrary, 
presence of residual disease in the surround-
ing stroma would potentially be more harm-
ful because of endangerment of the circum-
ferential resection margin, if left undetected 
for extended periods of time. 
In the 57 patients, as described in our arti-
cle,1 with initial pretreatment involvement of 
all layers of the esophageal wall (= preypT3) 
and an overall noncomplete response after 
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complications (Shapiro et al, data submit-
ted for publication). Moreover, it has been 
shown in patients after definitive chemo-
radiotherapy (dCRT) that during intensive 
endoscopic surveillance protocols a prima-
ry site recurrence frequently presents as 
a newly developing erosion or submucosal 
tumor mass.2 
Conceptually, surgery-as-needed after 
nCRT differs from salvage surgery after 
dCRT in the intent (and intensity) of chemo-
radiotherapy. The goal of nCRT is to down-
stage the tumor locoregionally to facilitate 
a radical resection, whereas the goal of 
dCRT is to maximize its impact and possibly 
to achieve cure. The practical difference is 
that with dCRT higher doses of radiation 
(50–65 Gy) are applied, with questionable 
improvements in pCR rates, as compared 
with nCRT regimens (36–45 Gy). Important-
ly, the higher doses of radiation generally 
show a negative impact on surgical out-
come, although a recent publication reports 
on a favorable outcome after salvage sur-
gery.3 We disagree with van Rossum et al 
that data from salvage surgery after dCRT 
can be extrapolated to patients treated 
with nCRT.
nCRT, the mucosa contained residual dis-
ease in 39 (68%) patients, whereas the sur-
rounding stroma contained residual disease 
in 30 (53%) patients. This difference did 
not reach statistical significance. However, 
when the amount of residual disease is di-
vided between major response (≤10% resid-
ual tumor cells; TRG1 + TRG2), and minor 
response (>10% residual tumor cells; TRG3 
+ TRG4), the incidence of minor response 
in the mucosa was significantly more fre-
quent, as compared with the surrounding 
stroma: 26 (46%) versus 16 (28%) (p=0.021; 
χ2). Furthermore, of the 16 patientswith 
aminor response in the surrounding stroma, 
only 3 patients had a major response in the 
mucosa, whereas the remaining 13 patients 
had a concurrent minor response in the mu-
cosa (see also Table 1). These results indi-
cate that after nCRT only 5% (3/57) of pa-
tients with an initial pretreatment T3 tumor 
had more residual disease in the surround-
ing stroma than in the mucosa. Therefore, 
assuming equal chances of residual tumor 
outgrowth between all layers, only these 
5% of patients are exposed to a clear and 
early endangerment of the circumferential 
resection margin, without the presence of 
substantial tumor in the mucosa. 
Studies investigating the accuracy of 
endoscopic detection of residual disease 
after nCRT employed a single restaging 
strategy, relatively early after completion 
of nCRT. Results showed quite low concord-
ance with the presence of residual disease 
in the resection specimen. However, these 
results are expected to improvewith re-
peated measurements at extended time 
points after completion of nCRT. Recent 
data from the CROSS study group show 
that a prolonged time to surgery after 
completion of nCRT up to at least 12 weeks 
was associated with an increased patho-
logically complete response (pCR) rate, 
without a significant rise in postoperative 
We agree that improved restaging strat-
egies are needed, but current restaging 
techniques have not yet been adequate-
ly tested. To this day, no prospective trial 
evaluated the predictive value of a full 
combination of currently available restag-
ing techniques at an interval of at least 12 
weeks from the end of nCRT to minimize 
false-positive signals due to radiation-in-
duced inflammation. Such a prospective 
feasibility trial is currently being coordi-
nated by our center in 5 Dutch high-vol-
ume centers (including the group of van 
Hillegersberg and colleagues from the UMC 
Utrecht), aimed at including 120 patients 
with both adenocarcinoma and squamous 
cell carcinoma of the esophagus or esoph-
agogastric junction. All included patients 
will undergo 2 rounds of restaging, consist-
ing of endoscopy with biopsies, endoscop-
ic ultrasonography with tumor thickness 
measurements,4 and fine-needle aspiration 
of suspected deeper lesions, guided by 
positron emission tomography-comput-
ed tomography. Results from this trial will 
demonstrate the predictive potential of a 
set of diagnostic modalities at 2 time points 
after completion of nCRT and will hope-
fully allow for the construction of a strong 
predictive model for pathologically (near-) 
complete response.
In conclusion, nearly 30% of patients in 
the multimodality arm of the CROSS trial5 
had a pCR and another 32% of patients 
had a near-complete response (1%-10% 
residual tumor cells = TRG2) in the resec-
tion specimen. And yet, all these patients 
underwent a standard surgical resection, 
with its known morbidity and mortality. We 
feel an ethical imperative to try and iden-
tify those patients with a (near-)complete 
response because a substantial number of 
these patients probably do not have any 
benefit from standard surgical resection 
after nCRT. If results from our prospective 
feasibility trial will be promising (ie, sensitiv-
ity and specificity for predicting a patho-
logically (near-) complete response), we will 
compare a surgery-as-needed approach 
with standard surgical resection after nCRT 
in a subsequent, preferably randomized 
controlled trial.
Joël Shapiro, MD
Bas P. L.Wijnhoven, MD, PhD
J. Jan van Lanschot, MD, PhD
Department of Surgery
Erasmus MC
University Medical Center
Rotterdam, The Netherlands
j.shapiro@erasmusmc.nl
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Mucosa
Major response
Minor response
Major
Response
28
13
Surrounding Stroma
Minor
Response
3
13
Major response: ≤10% residual tumor cells;
(TRG1 + TRG2); minor response: >10% residual
tumor cells; (TRG3 + TRG4).
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Abstract
Objective 
To determine the relation between time to surgery (TTS) after neoadju-
vant chemoradiotherapy (nCRT) and pathologically complete response 
(pCR), surgical outcome and survival in patients with esophageal 
cancer. 
Background data 
Standard treatment for potentially curable esophageal cancer is nCRT 
plus surgery after 4-6 weeks. In rectal cancer patients evidence sug-
gests that prolonged TTS is associated with a higher pCR rate and 
possibly with better survival. 
Methods 
We identified patients treated with nCRT plus surgery for esophageal 
cancer between 2001-2011. TTS (last day of radiotherapy to day of 
surgery) varied mainly for logistical reasons. Minimal follow-up was 24 
months. The effect of TTS on pCR rate, postoperative complications 
and survival was determined with (ordinal) logistic, linear and Cox re-
gression, respectively. 
Results 
In total, 325 patients were included. Median TTS was 48 days 
(p25-p75=40-60). After 45 days, TTS was associated with an increased 
probability of pCR (odds ratio, OR=1.35 per additional week of TSS, 
p=0.0004) and a small increased risk of postoperative complications 
(OR=1.20, p<0.001). Prolonged TTS had no effect on disease-free and 
overall survival (HR=1.00 and HR=1.06 per additional week of TSS, 
p=0.976 and p=0.139, respectively).
 
Conclusions 
Prolonged TTS after nCRT increases the probability of pCR and is asso-
ciated with a slightly increased probability of postoperative complica-
tions, without affecting disease-free and overall survival. We conclude 
that time to surgery can be safely prolonged from the usual 4-6 weeks 
up to at least 12 weeks, which facilitates a more conservative wait-
and-see strategy after neoadjuvant chemoradiotherapy to be tested.
Introduction
Recent studies show that, in patients with potentially curable esopha-
geal or esophagogastric junction cancer, the addition of neoadjuvant 
chemoradiotherapy (nCRT) to surgery improves locoregional control 
and long-term survival1,2. Therefore, nCRT plus surgery has become the 
standard of care for patients with potentially curable esophageal or 
junctional cancer in many countries. 
Reasons for prolonged time to surgery (TTS) after nCRT include pa-
tients' malnutrition or poor physical status, comorbidities such as infec-
tions and cardiopulmonary problems, and logistical problems, such as 
hospital bed and operating room availability.
Tumor response to neoadjuvant therapy is classified in several tumor 
regression grading (TRG) systems3-6. A pathologically complete re-
sponse (pCR; i.e. no viable tumor cells found in the resection specimen) 
has been recognized as a valuable prognostic factor for long-term sur-
vival3,7-10. It remains unclear, however, whether prolonged TTS has an 
impact on pCR rate, on short-term surgical outcome and on long-term 
survival. 
Theoretically, prolonged TTS might increase pCR rate and possibly 
improve disease-free survival because of a prolonged effect of nCRT. 
Conversely, prolonged TTS might lead to residual tumor outgrowth, 
increased difficulty of surgical resection with a higher postoperative 
complication rate and possibly a worse overall survival. 
In rectal cancer patients, several studies have shown that prolonged 
TTS probably increases the percentage of pathologically complete 
responders11-18. Perioperative morbidity and -mortality, disease-free 
survival and overall survival, seem less clearly correlated with  
TTS12,13,15-22. Comparable studies in esophageal cancer patients have 
shown no effect of TTS on pCR rate and no (or little) effect on dis-
ease-free survival.23,24 
We aimed to investigate the impact of TTS after nCRT on pCR rate, 
short-term surgical outcome and disease-free and overall survival in 
a cohort of patients with potentially curable esophageal or junctional 
cancer, who underwent neoadjuvant chemoradiotherapy according to 
CROSS2 followed by surgical resection. 
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Patients and Methods
Patients
We included patients treated with nCRT according to CROSS2 fol-
lowed by surgical resection within a previously published single-center 
phase-II trial (February 2001 – January 2004)25, a multi-center rand-
omized controlled phase-III trial (March 2004 – November 2008)2 and 
as standard therapy in the period after completion of the two trials 
(March 2009 - December 2011) at the Erasmus MC – University Med-
ical Center Rotterdam (a tertiary referral hospital in Rotterdam, The 
Netherlands). Patients who did not receive at least 80% of planned 
nCRT or who received a different nCRT regimen were excluded. Also, 
patients with irresectable tumors (cT4b) and/or disseminated disease 
(M1) were excluded. 
Treatment and pathological assessment
The neoadjuvant treatment regimen has been described before in de-
tail2. Esophagectomy was planned 4-6 weeks after completion of nCRT. 
The resection specimens (primary tumor and all resected lymph nodes) 
were processed according to a standardized protocol26. The tumor 
regression grade (TRG) was scored with the modified Mandard scoring 
system as reported by Chirieac et al.3,4. A microscopically radical resec-
tion (R
0
) was defined as a tumor-free resection margin ≥ 1 mm.
Follow-up and data collection
Clinical, surgical and histopathological characteristics were retrieved 
from prospectively maintained institutional databases. TTS was deter-
mined as the interval between the last day of radiotherapy and the day 
of surgery. After surgery, patients were routinely followed; every three 
months during the first postoperative year, every six months during the 
second postoperative year, and yearly until the fifth postoperative year. 
During follow-up, diagnostic investigations were performed only when 
recurrence was suspected clinically. Recurrences were scored at the 
time of first failure. Survival was determined using hospital records and 
municipal registers. 
Surgical outcome 
Surgical outcome was described by duration of operation in minutes, 
intraoperative blood loss in milliliters and length of hospital stay in 
days. Postoperative complications were categorized according to the 
Clavien-Dindo classification27,28, a postoperative complication ranking 
system: grade-0: no complications; grade-I: complications requiring no 
or minimal (non-pharmacological) treatment; grade-II: complications 
requiring pharmacological treatment; grade-III: complications requiring 
surgical, endoscopic or radiological intervention; grade-IV: life-threaten-
ing complications requiring ICU-level care; grade-V: postoperative death. 
Potential delay-related confounders
To correct for the possibility that variations in TTS were not only 
caused by random logistical difficulties, but also by patient-related 
characteristics (i.e. intentionally longer TTS in more vulnerable pa-
tients), effects of TTS on pCR and on surgical outcome were adjusted 
for three potential delay-related confounders. First, this was the Charl-
son comorbidity index29 at diagnosis, an indicator of comorbidity. For 
this index, each condition present at diagnosis is assigned a standard 
score of 1, 2, 3 or 6 (determined by the estimated risk of dying from 
this condition). The total sum per patient is predictive for mortality. 
Second, the Karnofsky performance status30,31 at the end of nCRT, 
an indicator of general well-being. The scale ranges from 100 (normal 
health) to 0 (death). A score of 90 indicates minor signs and/or symp-
toms of disease, 80 indicates mild signs and/or symptoms of disease, 
etc. Third, weight loss during nCRT, defined as the difference in body 
weight (in kilograms) between the start of the first cycle of chemo-
therapy and the start of the fifth cycle of chemotherapy. Weight gains 
were set to zero loss.
Statistical analysis 
Baseline data were described as medians with the interquartile range 
in case of continuous variables and as frequencies with percentages 
in case of categorical variables. Missing baseline data were imputed 
with a single imputation technique based on correlations with relevant 
baseline variables and outcome. TTS was truncated at 5 and 95% to 
reduce leverage effects of outliers. The effect of TTS on pCR and on 
surgical outcome was determined using univariable and multivariable 
logistic regression. Non-linearity of the effect of TTS was assessed with 
restricted cubic splines (three knots)32. To correct for the possibility 
that TTS was intentionally longer in more vulnerable patients, the ef-
fects of TTS on surgical outcome was adjusted in multivariable regres-
sion analysis for the three potential delay-related confounders togeth-
er with surgical approach (=adjusted odds-ratio, aOR). Subsequently, 
the effects of pCR and TTS on disease-free survival and overall surviv-
al were assessed using Cox regression with adjustment for the three 
potential delay-related confounders alone and in combination with 
postoperative complications (=adjusted hazard ratio, aHR). 
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Results
Patient and treatment related characteristics
In total, 325 patients with potentially curable esophageal or junction-
al cancer were included who underwent nCRT according to CROSS2 
followed by resection between February 2001 and December 2011. 
Fifty-one included patients participated in the phase-II trial25, 157 pa-
tients participated in the multimodality arm of the randomized phase-
III trial2 and 117 patients were treated with nCRT followed by resection 
as standard therapy in the period following completion of the phase-III 
trial. In total, 344 patients completed nCRT within the three cohorts. Of 
these, four patients did not undergo surgery (primarily due to patient 
preferences) and fifteen additional patients did not undergo resection 
(due to disease progression). 
Clinical, surgical and histopathological characteristics of included 
patients are summarized in Table 1. Median age at diagnosis was 60 
years. The majority of patients were male (78%), had an adenocarcino-
ma (76%), and were clinically staged as cT3 (77%), cN1 (63%). Before 
truncation, TTS ranged from 18 to 291 days, with a median of 48 days 
(interquartile range 40-60 days), as also shown in figure 1. Median TTS 
in irresectable patients was 46 days (interquartile range 40-61 days), 
which was similar to TTS in resected patients (p=0.99). Surgical resec-
tion was performed regularly via both transhiatal approach (48%) and 
transthoracic approach (50%). Median duration of operation was 368 
minutes, median volume of intraoperative blood loss was 900 ml and 
median length of hospital stay was 14 days. Postoperative complica-
tions requiring pharmacological, interventional or surgical treatment 
(≥ grade-II) were reported in 55% of patients. Postoperative in-hospital 
mortality was 4%. Histopathological staging showed frequent ypT0 and 
ypT3 stages (34% and 32%, respectively), while ypN0 was the most fre-
quent nodal stage (68%). A pCR (=TRG1) was found in 28% of patients. 
The microscopically radical resection rate (R
0
) was 93%. 
The potential delay-related confounders are summarized in Table 2. 
The majority of patients had a pretreatment Charlson comorbidity 
index of 0 (75%) and a Karnofsky performance score at the end of 
nCRT of 90 (64%). Median weight loss during nCRT was one kilogram, 
(p25-p75: 0 – 3). 
Effect of TTS on pCR
Median TTS was 48 days (p25-p75: 40-60 days, p5-p95: 18-83 days). 
The association of TTS with pCR was non-linear (p=0.025). After ap-
proximately 45 days (Supplementary figure 1), additional TTS was as-
sociated with an increased probability of pCR (odds ratio, OR, 1.35 per 
additional week after 45 days, p=0.0004). 
In itself a pathologically complete response was associated with a sig-
nificantly better disease-free survival and overall survival (hazard ratio, 
HR, 0.29, p<0.0001 and 0.44, p<0.0001, respectively). The effect of pCR 
on overall survival was sustained after correction for the three poten-
tial delay-related confounders (adjusted HR, aHR, 0.44, p<0.0001). 
Effect of TTS on short-term surgical outcome 
The effect of TTS on short-term surgical outcome was reasonably 
linear (non-linearity, p=0.920). Increased TTS was associated with 
prolonged duration of operation (12 minutes per additional week of 
TTS, p<0.001), prolonged length of hospital stay (1.55 day per addi-
tional week of TTS, p=0.006) and more severe postoperative compli-
cations (OR 1.20 per additional week of TTS, p<0.001). No association 
was found with intraoperative blood loss (-3 ml per additional week of 
TTS, p=0.898). However, these associations were partly explained by 
the three potential delay-related confounders together with surgical 
approach. After adjustment, the effects were reduced for duration of 
operation (6 minutes per additional week of TTS, p=0.031), length of 
hospital stay (1.03 days per additional week of TTS, p=0.071) and for 
postoperative complications (aOR 1.10 per additional week of TTS, 
p=0.132, Table 3).
Effect of TTS on survival
The effect of TTS on disease-free survival and overall survival was rea-
sonably linear (non-linearity, p=0.566). Increased TTS was not associ-
ated with disease-free survival, (HR 1.00, p=0.976; aHR 0.98, p=0.620), 
nor with overall survival (HR 1.06, p=0.139; aHR 1.03, p=0.465, table 4). 
 
Discussion
Results show that prolonged TTS, beyond 45 days after completion of 
nCRT, significantly increased the probability of pCR. Longer TTS was 
also associated with a small increased risk of postoperative complica-
tions. Furthermore, pCR in the resection specimen was associated with 
significantly improved disease-free survival. However, prolonged TTS 
(with increased probability of pCR) was not associated with improved 
disease-free survival. 
Although prolonged TTS was associated with an increased pCR rate, 
disease-free survival was not accordingly improved. The comparable 
disease-free survival between patients with shorter and longer TTS im-
plies that their disease is biologically similar, despite differences in pCR 
rate. The increase in pCR after prolonged TTS is attributed to patients 
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who presumably would have been non-complete responders at shorter 
TTS. Interestingly, these patients, who become pathologically complete 
responders relatively late after completion of nCRT, do not contrib-
ute to an improved disease-free survival after prolonged TTS. This can 
be explained if ‘late complete responders’ would already behave as 
biologically complete responders at shorter TTS, despite a pathologi-
cally non-complete response in their resection specimens. Therefore, 
the (minimal) residual disease found at histological examination after 
shorter TTS in these late complete responders is presumed to be bi-
ologically non-relevant. We hypothesize that prolonged TTS does not 
truly improve the biological pCR rate, but that prolonged TTS simply 
allows for a more precise histopathological distinction between viable 
residual tumor cells and biologically non-relevant tumor cell debris by 
the pathologist. 
In this cohort, prolonged TTS was significantly associated with a pro-
longed duration of operation, a prolonged length of hospital stay and 
increased postoperative complications. However, these associations 
were partly explained by the three potential delay-related confounders, 
i.e. Charlson comorbidity index29 at diagnosis, Karnofsky performance 
status30,31 at the end of nCRT and weight loss during nCRT (besides 
surgical approach; Table 3). These potential confounding factors were 
chosen to reflect the overall condition of patients at the end of nCRT, 
which might have influenced the surgeons’ decision to delay surgical 
resection after nCRT, independent of logistical planning. Therefore, 
these results indicate that the association of prolonged TTS with nega-
tive short-term surgical outcome and increased postoperative compli-
cations is partly the result of an intentionally prolonged TTS in patients 
with a worse overall condition at the end of nCRT and that prolonged 
TTS has at most a small association with short-term surgical outcome 
and postoperative complications. 
Two previous studies investigated the association between TTS and 
surgical and oncological outcome in patients with esophageal cancer. 
Both studies did not find a correlation with pCR rate23,24. This discrep-
ancy with the present study might be related to the heterogeneity of 
nCRT protocols used in both previous studies. In our cohort, all patients 
completed the same nCRT protocol, and in all patients there was a 
similar initial intention to undergo surgery after 4-6 weeks, possibly 
allowing for a clearer delineation of the effect of TTS on pCR rate. Also, 
the present study investigated the association between TTS and pCR in 
all patients using logistic regression, resulting in more power to detect 
subtle effects as compared to subgroup analyses. Last, the present 
study focused on the association between TTS and disease-free surviv-
al, which was lacking in the study by Kim and colleagues24. 
Currently, controversy exists concerning the management of cancer 
patients with a clinically complete response after neoadjuvant therapy. 
For rectal cancer patients, more conservative strategies have already 
been proposed and tested in clinically complete responders33-36. The 
goal of these wait-and-see approaches is organ preservation and over-
all reduction in treatment-related morbidity and mortality. However, it 
has remained difficult to clinically distinguish truly complete respond-
ers from nearly-complete responders. Patients belonging to the latter 
group might be incorrectly identified as clinically complete responders 
and could thus be exposed to potentially harmful disease progression 
during the wait-and-see period. For esophageal cancer, the challenge 
to distinguish complete from nearly complete responders seems even 
more difficult37-40. However, if surgery can be safely postponed beyond 
the usual 4-6 weeks, without negatively affecting oncological outcome 
as suggested in the present study, more time is allowed to identify 
non-complete responders. Such a strategy would not focus on distin-
guishing complete from non-complete responders at a single instance, 
but would rather use intense surveillance, with targeting of the muco-
sa and submucosa41 during repeated instances, for the detection of 
residual or recurrent disease. Thereby, possibly allowing more time to 
differentiate between truly complete responders and non-complete 
responders. 
Limitations of the study
The first limitation is that the present study was a retrospective analysis. 
However, all parameters in this study were collected prospectively. Fur-
thermore, all three cohorts used the same neoadjuvant CROSS regimen 
and all three cohorts had a similar intention to perform surgery at 4-6 
weeks after completion of nCRT. The second limitation of this study is 
that the number of patients with a TTS beyond 10 weeks was relatively 
small. Therefore, a subtle effect of TTS on disease-free and overall sur-
vival cannot be excluded in patients with a TTS beyond 10 weeks. 
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Conclusions
In patients with potentially curable esophageal or junctional cancer, 
prolonged time to surgery (beyond 45 days) after neoadjuvant chemo-
radiotherapy increases the probability of a pathologically complete 
response, without improving disease-free and overall survival. It might 
also slightly increase the probability of postoperative complications, 
which can be partly explained by intentional postponement of surgery 
in some high-risk patients with worse overall condition. We hypothesize 
that prolonged time to surgery allows for more accurate determination 
of histopathological response due to continued disintegration of nonvi-
able cells in some patients, without affecting actual prognosis after ne-
oadjuvant chemoradiotherapy. We conclude that time to surgery can 
be safely prolonged from the usual 4-6 weeks up to at least 12 weeks, 
which facilitates a more conservative wait-and-see strategy after neo-
adjuvant chemoradiotherapy to be tested.
Table 1 — Clinical, surgical and histopathological characteristics 
of 325 included patients with potentially curable esophageal or 
junctional cancer, treated with neoadjuvant chemoradiotherapy 
according to CROSS2 followed by surgical resection.
Characteristic
Age [years]
median (p25-p75) 
Gender 
Male
Female
Tumor type
Squamous cell carcinoma
Adenocarcinoma
Other
cT-stage§ 
cT1
cT2
cT3
cT4
cN-stage‡ 
cN0
cN1
Time to surgery [days] ₪
median (p25-p75)
Surgical approach
Transhiatal approach
Transthoracic approach
Thoraco-phreno-laparotomy
Duration of operation [min]
median (p25-p75)
Intraoperative blood loss [ml]
median (p25-p75)
Length of hospital stay [days]
median (p25-p75)
Clavien–Dindo  
classification 27, 28 ∆
Grade-0
Grade-I
Grade-II
Grade-III
Grade-IV
Grade-V
%*
78%
22%
23%
76%
2%
3%
19%
77%
1%
37%
63%
48%
50%
2%
22%
23%
25%
13%
12%
4%
n
60 (55 – 67)
253
72
73
247
5
9
60
250
4
120
204
48 (40 – 60)
156
164
5
368 (262 – 388)
900 (550 – 1350)
14 (12 – 23)
72
73
82
43
40
14
n (total)
325
325
325
323
324
325
325
308
281
319
324
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Legend Table 1
*   Percentages may not add up to 100 due to rounding
§   cT-stage: clinical T-stage as defined by endo-ultrasonography and/or CT-scanning 
according to the Union Internationale Contre le Cancer (UICC) TNM Cancer Staging, 
7th edition. 
‡  cN-stage: clinical N-stage as defined by endo-ultrasonography and/or CT-scanning 
and/or FDG-PET-scanning according to UICC TNM Cancer Staging, 6th edition.
₪  Time to surgery was determined as the interval between the last day of radiothera-
py and the day of surgery. 
∆  Clavien-Dindo classification, a postoperative complication ranking system. Grade 
0: no complications, grade I: complications requiring none or minimal (non-pharma-
cological) treatment, grade II: complications requiring pharmacological treatment, 
grade III: complications requiring surgical, endoscopic or radiological intervention, 
grade IV: life-threatening complications requiring ICU-level care, grade V: postoper-
ative death. 
•  ypT and ypN-stage: pathological T-stage and pathological N-stage in the resection 
specimen following neoadjuvant chemoradiotherapy, according to UICC TNM Can-
cer Staging, 7th edition.
¥  Tumor regression grade was defined as: TRG1: no residual tumor cells found (patho-
logically complete response=pCR); TRG2: 1-10% residual tumor cells; TRG3: 11-50% 
residual tumor cells; TRG4: > 50% residual tumor cells. 
◊  R
0
 was defined as a tumor-free resection margin ≥ 1 mm. R
1
 was defined as a mac-
roscopically radical resection, with a microscopically tumor-free resection margin < 
1 mm.
Characteristic
ypT-stage•
ypT0
ypT1
ypT2
ypT3
ypT4
ypN-stage•
ypN0
ypN1
ypN2
ypN3
Tumor regression grade 
(TRG) ¥
1
2
3
4
Radicality◊
R
0
R
1
Characteristic
Charlson comorbidity index29 §
at initial diagnosis
0
1
2
3
4
Karnofsky performance 
status30,31 ‡ at the end of nCRT
100
90
≤80
Weight loss [kg] •
during nCRT
median (p25-p75)
%*
34%
15%
18%
32%
1%
68%
23%
7%
3%
28%
31%
24%
17%
93%
7%
%*
75%
19%
5%
1%
0%
30%
64%
7%
n
110
49
59
103
3
222
74
21
8
90
102
77
56
303
22
n
243
63
15
2
1
80
171
18
1 (0 – 3)
n (total)
324
325
325
325
n (total)
324
269
297
Table 2 — Three potential delay-related confounders in 325 included 
patients with potentially curable esophageal or junctional cancer, 
treated with neoadjuvant chemoradiotherapy according to CROSS2 
followed by surgical resection.
Legend Table 2
*  Percentages may not add up to 100 due to rounding
§  Charlson comorbidity index, an indicator of comorbidity. Each condition present 
at diagnosis is assigned a standard score of 1, 2, 3 or 6 (determined by the esti-
mated risk of dying from this condition). The total sum per patient is predictive for 
 mortality. 
‡  Karnofsky performance status, an indicator of general well-being. The scale ranges 
from 100 (normal health) to 0 (death). A score of 90 indicates minor signs and/or 
symptoms of disease, 80 indicates mild signs and/or symptoms of disease, etc.
•  Weight loss during nCRT was defined as the difference in body weight (in kilograms) 
between the start of the first cycle of chemotherapy and the start of the fifth cycle 
of chemotherapy. Weight gains were set to zero loss.
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Table 3 — Effect of time to surgery on short-term surgical outcome 
and postoperative complications in 325 included patients treated 
with CROSS2 followed by surgical resection, adjusted for the three 
potential delay-related confounders together with surgical approach.
Legend Table 3
*Odds ratio. 
Adjustment for the three delay-related confounders (Charlson comorbidity index29 at 
diagnosis, Karnofsky performance status30,31 during the last week of nCRT and weight 
loss during nCRT) together with surgical approach. 
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Table 4 — Effect of time to surgery on overall survival in 325 included 
patients with potentially curable esophageal or junctional cancer, 
treated with neoadjuvant chemoradiotherapy according to CROSS2 
followed by surgical resection.
Legend Table 4
OS: overall survival; TTS: time to surgery; pCR: pathologically complete response
Delay-related confounders: Charlson comorbidity index29 at diagnosis, Karnofsky per-
formance status30,31 during the last week of nCRT and weight loss during nCRT.
beta
(per additional week)
12
-3
1.55
1.20*
adjusted beta 
(per additional week)
6
-3
1.03
1.10*
Hazard ratio for OS
(per additional week)
1.06 
1.04
1.03
p
<0.001
0.898
0.006
<0.001
p
0.031
0.898
0.071
0.132
p
0.139
0.387
0.465
Outcome
Duration of operation (minutes)
Intraoperative blood loss (ml) 
Length of hospital stay (days) 
Postoperative complications 
(according to the Clavien-Dindo 
classification)
Time to surgery 
Univariate
Adjusted for three potential delay-related confounders
Adjusted for three potential delay-related confounders 
+ postoperative complications (shows effect of TTS on 
overall survival via increased pCR)
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Figure 1 — Distribution of time to surgery (before truncation) in 340 
patients who completed neoadjuvant chemoradiotherapy according 
to CROSS2 and underwent surgery for potentially curable esophageal 
or junctional cancer, 15 of these patients were irresectable due to 
disease progression, while 325 patients underwent resection. 
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Supplementary figure 1 — Effect of time to surgery (after 
truncation) on pCR using a restricted cubic splines model (3 knots) 
for all 325 included patients with potentially curable esophageal 
or junctional cancer, treated with neoadjuvant chemoradiotherapy 
(nCRT) according to the CROSS regimen2 followed by surgical 
resection.
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Legend supplementary figure 1  
Time to surgery is expressed in days. The y-axis represents the relative probability (log 
odds) of reaching pCR. A higher log odds indicates a higher probability of reaching pCR. 
After approximately 45 days the probability of reaching pCR increases.
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Extra discussions
older and more comorbid than those 
with adenocarcinoma. In this study, how 
did the balance of histology in the long 
and short TTS groups? Doesn’t this af-
fect the pCR rate or survival analysis?
3.  In the CROSS trial and this study, TTS 
was planned to be 4 to 6 weeks, but the 
actual median TTS was 7 weeks, that is, 
the surgery was delayed in the majority 
of cases. Was this due to inappropri-
ate trial planning? Or due to lax quality 
control? In the phase II study preceding 
the CROSS trial, the median TTS was 42 
days (6 weeks).What was the standard 
in the clinical practice after the CROSS 
trial?
4.  The follow-up policy (no diagnostic in-
vestigation unless recurrence is suspect-
ed) may not be suitable in clinical studies 
having DFS as an endpoint. 
Response From J. Shapiro, J. van Lanschot 
(Rotterdam, Netherlands):
Thank you for your comments. I will start 
with the first question, which was about 
how survival was calculated. In this study, 
survival was calculated from the start of 
neoadjuvant therapy. We fully agree that 
progression-free survival would have been 
a more appropriate term. 
The second question was about the differ-
ences between squamous cell carcinomas 
and adenocarcinomas. We didn’t perform 
this subanalysis, which I think would have 
been interesting to do. Although, I don’t 
think that time to surgery would have dif-
fered based on the histology. We discussed 
this with the involved surgeons, and there is 
no policy to preferentially treat squamous 
cell carcinomas or adenocarcinomas with 
different delays. So, I think that in this way 
those patients. At the same time, you didn’t 
show any survival benefits or disease-free 
survival benefits in the delayed group. So, 
what are your arguments for waiting longer 
after chemoradiotherapy? Shouldn’t we go 
directly to surgery after 6 weeks?
Response From J. Shapiro, J. van Lanschot 
(Rotterdam, Netherlands):
Thank you for your question. I don’t nec-
essarily propose to wait longer, although 
I think you would obtain a clearer image 
in the resected specimen. I think that this 
study adds to the evidence that if you have 
a reason towait, then you can do this safely 
for up to 12weeks after completion of neo-
adjuvant therapy. It is difficult to test how-
good our correction of the effect of time to 
surgery was using the patients’ condition at 
the end of neoadjuvant therapy, although 
the patients’ condition is considered a valid 
confounder since it confounded both time 
to surgery and our outcome - in this case, 
surgical outcome. We tested for the impact 
of the 3 potential delay-related factors. I 
have to say that weight loss during neoad-
juvant therapy was borderline significant. 
The other 2 were significant in their impact 
on both the time to surgery and on post-
operative outcomes. However, it remains a 
valid point that surgery might become more 
difficult, if you wait longer.
Discussants 1
T. Sano (Tokyo, Japan):
This is an interesting study examining the 
relationship between the time to surgery 
after neoadjuvant CRT and the rate of 
pathological complete response in resecta-
ble esophageal carcinoma. The strong point 
is the large number of patients treated with 
a fixed regimen of CRT. The weak point is 
that TTS was not prospectively determined 
or randomized for analyses, showing a wide 
variation with diverse background differ-
ences. I agreewith the authors’ conclusion 
in the abstract book that prolonged TTS al-
lows for a more accurate determination of 
histopathological response without affect-
ing actual prognosis but am not convinced 
by their conclusions in the manuscript 
that TTS can be safely prolonged for a 
more conservative wait-and-see strategy. 
What is the core clinical message from this 
study? After safely completed nCRT, should 
we wait longer? Or, should we operate on 
the patient with an appropriate TTS like 6 
weeks? 
Some questions:
1.  The definition of DFS or OS is unclear. Is 
it the duration from the start (or end) of 
nCRT or from the date of surgery? In the 
former case, the term ‘disease-free’ is 
inappropriate because the disease does 
exist before surgery. ‘Progression-free’ 
would be suitable. In the latter case, the 
DFS or OS is not appropriate for com-
parison due to lead time bias caused by 
different TTS. 
2.  In the CROSS study, the survival benefit 
of nCRT was definitely larger in squa-
mous cell carcinoma than in adenocar-
cinoma. Patients with SCC are usually 
tumor subtype did not influence the time 
to surgery itself, although I do agree that 
patients with squamous cell carcinoma are 
usually more comorbid. However, this we 
hopefully corrected for with these factors 
that we now included. 
Your third question was about how it’s 
possible that we had longer time to surgery 
intervals than was scheduled in the proto-
col. This is I think largely due to logistical 
problems that were present in The Neth-
erlands during the years of these trials.We 
did do a subgroup analysis for treatment 
center, which did not show an effect. I think 
that these logistical problems were really 
national. 
Your fourth question was a comment about 
how we did our follow-up. I guess that this 
is a local mentality that recurrences are not 
actively looked for. I think the good thing is 
that in The Netherlands, we have very low 
loss to follow-up. So, if a patient does devel-
op a recurrence, we do find out. Although 
it’s true that we might have slightly longer 
disease-free survival intervals than would 
be strictly or formally correct.
Discussants 2
R. van Hillegersberg (Utrecht, 
Netherlands): 
Thank you for this very interesting study.
We know from daily practice that if you 
operate on patients who have had a longer 
interval between chemoradiotherapy and 
surgery, the surgical dissection may be 
more difficult. Indeed, you showed that the 
incidence of complications is also higher in 
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Abstract
Background
Results from the recent CROSS trial showed that neoadjuvant chemo-
radiotherapy (nCRT) significantly increased survival as compared to 
surgery alone in patients with potentially curable esophageal cancer. 
Furthermore, in the nCRT arm 49% of patients with a squamous cell 
carcinoma and 23% of patients with an adenocarcinoma had a patho-
logically complete response in the resection specimen. These results 
provide a rationale to reconsider and study the timing and necessity of 
esophagectomy in (all) patients after application of the CROSS-regi-
men. We propose a surgery as needed approach after completion of 
nCRT. In this approach, patients will undergo active surveillance after 
completion of nCRT. Surgical resection would be offered only to those 
patients in whom residual disease or a locoregional recurrence is highly 
suspected or proven. However, before a Surgery As Needed approach 
in Oesophageal cancer patients (SANO) can be tested in a randomized 
controlled trial, we aim to determine the accuracy of detecting the 
presence or absence of residual disease after nCRT (preSANO trial). 
Methods/Design
This study is set up as a prospective, single arm, multicenter, diagnos-
tic trial. Operable patients with potentially curable squamous cell- or 
adenocarcinoma of the esophagus or esophago-gastric junction will be 
included. Approximately 4-6 weeks after completion of nCRT all includ-
ed patients will undergo a first clinical response evaluation (CRE-I) in-
cluding endoscopy with (random) conventional mucosal biopsies of the 
primary tumor site and of any other suspected lesions in the esopha-
gus and radial endo-ultrasonography (EUS) for measurement of tumor 
thickness and -area. Patients in whom no locoregional or disseminated 
disease can be proven by (cyto)histology will be offered a postponed 
surgical resection, 6-8 weeks after CRE-I (i.e. approximately 12-14 
weeks after completion of nCRT). In the week preceding the postponed 
surgical resection a second clinical response evaluation (CRE-II) will 
be planned, which will include a whole body PET-CT, followed again by 
endoscopy with (random) conventional mucosal biopsies of the prima-
ry tumor site and any other suspected lesions in the esophagus, radial 
EUS for measurement of tumor thickness and –area and linear EUS 
plus fine needle aspiration of PET-positive lesions and/ or suspected 
lymph nodes. The main study parameter is the correlation between 
the clinical response assessment during CRE-I and CRE-II and the final 
pathological response in the resection specimen.
Results
Enrolment began July 23, 2013, results expected January 2016.
Discussion
If this preSANO trial shows that the presence or absence of resid-
ual tumor can be predicted reliably 6 or 12 weeks after completion 
of nCRT, a randomized trial comparing nCRT plus standard surgery 
versus chemoradiotherapy plus surgery as needed will be conducted 
(SANO trial).
Registration
Netherlands Trial Register (NTR4834)
 
Introduction
Cancer of the esophagus remains a highly lethal malignancy, as re-
flected by an average overall five-year survival of 17%1. In the Nether-
lands, the incidence of esophageal cancer resembles the growing trend 
in Western countries, with an estimated incidence of 15/100,000 for 
men and 6/100,000 for women2, and more than 2,500 new cases diag-
nosed nationally each year.
At present, surgical resection is still considered the cornerstone of 
curative treatment for patients eligible with stage cT1b-4aN0-3M0 dis-
ease. The reported five-year survival rate for patients who undergo an 
esophagectomy ranges from 20 to 50%, but rarely exceeds 35%3-7. Es-
ophagectomy is associated with postoperative mortality rates of 1-5% 
in high-volume centers, severe postoperative morbidity and a substan-
tial impact on the quality of life8-13. In order to improve the radicality of 
surgical resection and the long term survival after surgical resection 
many trials have been performed to study the effect of (neo-) adjuvant 
chemo- and/or radiation therapy14-17. One of the largest trials is the re-
cently published CROSS trial. This randomized trial compared neoadju-
vant chemoradiotherapy (nCRT) plus surgery to surgery alone18.
During a five-year period 366 patients from 5 academic and 2 non-ac-
ademic high-volume teaching hospitals in the Netherlands were includ-
ed. This study showed that the addition of nCRT (Carboplatin AUC2, 
Paclitaxel 50 mg/m2 and 41.4 Gy of concurrent radiotherapy) to surgery 
significantly increases long term survival as compared to surgery alone. 
Median overall survival of patients who received nCRT plus surgery was 
49 months, compared to 24 months for those who received surgery 
alone and the 3-year overall survival was superior in the nCRT arm (haz-
ard ratio (HR)=0.66; 95% confidence interval (CI) 0.50-0.87; p=0.003). 
Therefore, nCRT plus surgery is now considered the therapy of choice 
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in the Netherlands and several other countries for potentially curable 
esophageal cancer (cT2-3N0-3M0 and cT1N1-3M0, according to the 
UICC TNM classification, 7th ed.). In subsequent analyses of secondary 
endpoints of the CROSS trial an interesting observation was made. In 
the nCRT arm, 49% of patients with a squamous cell carcinoma (SCC) 
and 23% of patients with an adenocarcinoma (AC) had a pathologically 
complete response (pCR) in the resection specimen (i.e. no viable tumor 
cells were found, neither at the site of the primary tumor nor in the re-
sected regional lymph nodes, as determined by conventional histological 
examination)18. Therefore, these results provide a rationale to reconsider 
and study the timing and necessity of standard esophagectomy in (all) 
patients after application of the CROSS regimen.
We propose a surgery as needed approach after completion of nCRT 
for carcinoma of the esophagus. In this surgery as needed approach, 
patients will undergo active surveillance after completion of nCRT. 
Surgical resection would be offered only to those patients in whom 
a locoregional recurrence is highly suspected or proven, in the ab-
sence of any signs of distant dissemination. Such an organ-preserving 
strategy would clearly have great advantages. Postoperative mor-
tality and severe morbidity (grade ≥3 according to the Clavien-Dindo 
classification19) after esophagectomy in the Netherlands is 5% and 
60%, respectively. Thus, a non-surgical treatment strategy in patients 
with a clinically complete response after nCRT, theoretically saves 5% 
mortality and 60% severe morbidity in this patient group. Moreover, 
this approach might improve quality of life and might lead to a reduc-
tion in health care costs. However, this surgery as needed approach is 
only favorable if long term survival would be comparable to that of the 
trimodality approach comprising nCRT followed by standard surgery. 
Before a surgery as needed approach can be tested in a randomized 
trial, we aim to determine the feasibility of accurate detection of resid-
ual disease after chemoradiotherapy.
Objective
The aim of this present prospective, multicenter, diagnostic study (pre-
SANO study) is to determine the accuracy by which we can detect the 
presence or absence of residual disease after nCRT. The results of this 
trial will inform us about the percentage of patients with a clinically 
complete response after nCRT, and will help to estimate the number 
of patients needed for a subsequent randomized controlled trial. This 
future so called SANO-trial (Surgery As Needed in Oesophageal cancer 
patients) will randomize patients to nCRT plus surgery versus nCRT 
followed by an active surveillance strategy.
 
Methods/Design
Study design
The preSANO trial is a prospective, multicenter, diagnostic trial includ-
ing 120 patients, using a single arm. Five high-volume centers in the 
Netherlands are currently participating in this study (Erasmus Medical 
Center, Rotterdam; Academic Medical Center, Amsterdam; University 
Medical Center, Utrecht; Catharina Cancer Center, Eindhoven; Atrium 
Medical Center, Heerlen). The study has been approved by the medical 
ethics committee of the Erasmus Medical Center (MEC2013-211) and 
has been registered in the Netherlands Trial Register (NTR4834).
Study population
We plan to include individuals from a population of operable patients 
with potentially curable SCC or AC of the esophagus or esophago-gas-
tric junction. All patients who are planned to undergo nCRT according 
to the CROSS regimen18, followed by surgical resection are eligible to 
participate. Patients with dementia or altered mental status prohibit-
ing the understanding and giving of informed consent will be exclud-
ed from participation in this study. Patients will undergo conventional 
pre-treatment selection (including at least a ‘partial body’ F18-FDG 
PET-CT to assess the avidity of the primary tumor process; figure 1 
and Table 1).
Study algorithm
All included patients will receive nCRT according to the CROSS proto-
col (Carboplatin, Paclitaxel and 41.4 Gy of concurrent radiotherapy)18. 
Patients will be re-evaluated either once or twice before undergoing 
surgical resection during clinical response evaluations (CRE). The aim 
of these CREs will be to identify those patients in whom residual and/or 
disseminated disease is present.
CRE-I
The first CRE (CRE-I) will be performed 4-6 weeks after completion of 
chemoradiotherapy (figure 1). During CRE-I, all patients will undergo 
esophagogastroduodenoscopy (EGD) with registration of endoscopic 
images for future reference and biopsies of any suspected lesions, in-
cluding mucosal biopsies at the site of the primary tumor (one regular 
biopsy per centimeter in each of the 4 quadrants), radial endoscopic 
ultrasonography (EUS) for measurement of maximal tumor thickness 
and area and linear EUS. Patients with (cyto)histological evidence of 
locoregional residual disease, but without evidence of disseminated 
disease, will be offered immediate surgical resection. These patients 
have no clear benefit from postponement of surgical resection and 
should therefore have no delay according to current recommendations. 
Patients without (cyto)histological evidence of locoregional residual 
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disease and without disseminated disease will be considered to be 
clinically complete responders and will be offered a postponed surgical 
resection. In these patients a surgical resection will be postponed for 
an additional 6-8 weeks, allowing patients more time to reach a better 
condition for surgery. 
CRE-II
In the week preceding the planned postponed surgical resection a 
second clinical response evaluation (CRE-II) will be scheduled. CRE-II 
will be performed only in patients who were considered to be clinically 
complete responders (i.e. no viable tumor found) at CRE-I. CRE-II will 
consist of a PET-CT (standard for all patients at CRE-II and only for tu-
mor positive patients at CRE-I), an EGD with registration of endoscop-
ic images for future reference and biopsies of any suspected lesions, 
including (random) mucosal biopsies at the site of the primary tumor, 
radial endoscopic ultrasonography (EUS) for measurement of maximal 
tumor thickness and -area and linear EUS plus fine needle aspiration 
(FNA) of PET-positive lesions and/ or suspected lymph nodes. 
An important difference between CRE-I and CRE-II will be that during 
CRE-I clinically complete responders will be offered a postponed surgi-
cal resection, whereas after CRE-II both locoregionally complete- and 
non-complete responders will be advised to undergo a surgical resec-
tion (figure 1). In other words, all patients who are considered clinically 
complete responders at CRE-I and are therefore allowed to postpone 
their surgery by an additional 6-8 weeks, will undergo CRE-II followed 
by the postponed surgical resection, irrespective of the locoregion-
al findings during CRE-II. The diagnostic results from CRE-II will later 
be compared with results from both CRE-I and the final pathological 
analysis of the resection specimen. However, patients with (cyto)histo-
logical evidence of disseminated disease during CRE-I or CRE-II will be 
excluded from further curative therapy and will be referred for pallia-
tive care.
If after CRE-II the planned operation is postponed for more than 4 
weeks (e.g. because the patient has not yet sufficiently recovered from 
the nCRT), a CRE-III (comparable to CRE-II) will be performed one week 
before the (further) postponed operation.
Surgery
Surgical resection will be attempted immediately after CRE-I only in 
those patients who present at CRE-I with (cyto)histologically proven 
residual disease after completion of nCRT, without any signs of dissem-
inated disease. All other patients will undergo surgical resection after 
CRE-II in the absence of distant metastases. 
A transthoracic esophageal resection or a transhiatal approach can be 
performed, depending on both patient characteristics and local expertise 
and preference. Both open and minimally invasive techniques are allowed. 
A wide local excision including the regional lymph nodes is carried out 
in both techniques including a standard dissection of the lymph nodes 
around the coeliac axis. The continuity of the digestive tract will pref-
erably be restored by a gastric tube reconstruction or if required by a 
colonic interposition.
At least 15, but preferably 23 or more lymph nodes should be aimed 
to be removed in every patient. First, because it has been shown 
that long-term survival is maximized with the removal of at least 23 
nodes20. Moreover, the risk of understaging the tumor in these patients 
should be minimized. If an insufficient number of nodes is removed, 
the patient might be erroneously staged as ypN0, while in fact ypNpos 
nodes have been left in-situ (stage migration).
Pathology
All resection specimens will be revised centrally by two independent 
expert pathologists, using a standard protocol. In case of a discordant 
outcome, the specimens will be reviewed by a third independent expert 
pathologist. A final diagnosis will be made only if at least two pathol-
ogists agree. Also, all the CRE-II biopsies of patients who were consid-
ered negative at CRE-II, but who had >10% residual tumor in their re-
section specimen will be revised centrally following the same strategy. 
In these specimens special attention will be given to the effects of the 
preoperative chemoradiation, i.e. tumor reduction and therapy effects. 
The lymph node dissection should contain at least 15, but preferably 
23 or more nodes derived from both mediastinum and upper abdomen 
which are essential for correct ypTNM staging. The resection margins, 
especially the circumferential margin, will be evaluated with a 1mm 
cut-off point for vital tumor. This implies that the tumor-free margin 
should be >1mm in order to be classified as R
0
. If vital tumor is present 
at ≤1mm from the surgical resection margin it is considered microscop-
ically positive (R
1
).
Interim analysis
An interim analysis will be performed by an independent safety com-
mittee after a total inclusion of 60 patients in order to carefully mon-
itor serious complications during CRE-I and CRE-II and to assess the 
achieved radicality of the performed operations.
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Main study parameter/endpoint
The main study parameter in this study is the correlation between the 
clinical response assessment during CRE-I and CRE-II and the final 
pathological response in the resection specimen, as measured by the 
modified tumor regression grading (TRG) system of Chirieac; no residu-
al carcinoma (TRG1), 1-10% residual carcinoma (TRG2), 11-50% resid-
ual carcinoma (TRG3), 51-100% residual carcinoma (TRG4) [21]. 
We propose that in this study TRG2 residual tumors may be missed as 
long as we expect them to be detectable reliably as soon as they have 
outgrown from TRG2 to TRG3-4 during follow up. The risk that TRG2 
residual tumors will lead to irresectability in the short-term is likely 
to be small/negligible. However, we do propose that TRG3 and TRG4 
residual tumors should be detected without further delay in order to 
prevent short-term loss of resectability and to minimize the risk of 
long-term distant disease dissemination. The validity of these assump-
tions can only be determined in a future SANO trial, in which an active 
surveillance strategy will be compared with standard surgery in all 
patients after nCRT.
Statistical analysis
Sample size calculation
As was seen in the previous CROSS trial approximately 40% of the 
included patients will have TRG3 or TRG4 residual tumor in the resec-
tion specimen18. With a total inclusion of 120 patients, approximately 
45 patients will have TRG3 or TRG4 residual tumor. We consider 45 
patients a sufficiently large sample for determining the accuracy of 
individual and/or combined diagnostic tests. In order to estimate the 
distribution of 120 patients planned to be included, data were used 
from the CROSS trial as indicated in figure 2. Furthermore, several as-
sumptions were made:
-  We assume that during the first clinical response evaluation (CRE-I), 
clinically complete responders will comprise patients with TRG1 or 
TRG2 (as taken from the pathological response data of the CROSS 
trial), whereas clinically non-complete responders will be patients 
with TRG3 or TRG4.
-  The percentage of patients with SCC and AC with TRG1 or TRG2 
in the CROSS trial was 78% and 57%, respectively. This means that 
approximately 60% of included patients are expected to have nega-
tive (cyto)histology at CRE-I. 
-  In a trial by Blom et al.22 approximately 10% of patients who were 
re-evaluated by PET-CT after completion of nCRT had newly discov-
ered disseminated disease. We assume less newly found disseminat-
ed disease with positive (cyto)histology at CRE-II, because a number 
of these patients are expected to be discovered during CRE-I.
-  We assume that approximately 25% of clinically complete respond-
ers will refuse to undergo the postponed resection and choose to 
undergo an active surveillance strategy if no alarming results are 
found during CRE-II.
These calculations indicate that approximately 60 patients will show 
a clinically complete response after combined diagnostic investiga-
tions, during CRE-I and CRE-II (including EUS-FNA with tumor thick-
ness measurements and PET-CT). Of these, approximately 15 patients 
will refuse to undergo surgery and will undergo active surveillance and 
approximately 30 patients will have a pathologically complete response 
(TRG1). The 15 remaining patients are expected to have residual 
disease, of whom approximately 12 patients will have TRG2 residual 
tumor and approximately 3 patients will have TRG3 or TRG4 residual 
tumor. As we proposed above, TRG2 residual tumors may be missed. 
Therefore, we expect that approximately 3 patients with clinically rele-
vant residual disease (TRG3 or TRG4) will be missed.
In case of unexpected aberrant distribution of patients in the preSA-
NO-trial that leads to decreased TRG3 and TRG4 rates, results of the 
first 120 patients will be analyzed following the present protocol. If 
these results are promising but do not reach statistical significance, 
possibly due to a lack of power, inclusion of extra patients will be con-
sidered. If inclusion of extra patients is desirable, the protocol will be 
amended and assessed by the medical ethics committee.
Data analysis
The clinical response evaluation will consist of different diagnostic 
modalities. Results of each diagnostic modality will be presented as 
categorical or continuous data, depending on the outcome measure of 
each diagnostic modality. These results will be correlated to the (cat-
egorical) tumor regression grading in the resection specimen, using a 
chi-square based test (categorical-categorical) or a one-way ANOVA 
test (continuous-categorical) with post-hoc testing. 
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Results
The first patient has been enrolled on July 23, 2013 and results are 
 expected in January 2016.
 
Discussion
The uniqueness of this study lies in the prospective evaluation of a 
sufficiently large number of patients, using multiple diagnostic modali-
ties on different time points. Although (cyto)histological assessment of 
biopsies and / or FNAs is the most objective parameter, several studies 
have shown that the response to nCRT is reflected by tumor size or 
volume as assessed by EUS23-26. The rationale to include a second clin-
ical response evaluation before a planned surgical resection is to allow 
for a comparison between multiple measurements and to increase the 
chance of detecting residual- and/or disseminated disease. It is expect-
ed that during CRE-II (due to an extended time period from the end of 
nCRT) the F18-FDG PET-CT signal will have a more favorable signal-
to-noise ratio than has been described previously27-32, because after 12 
weeks the artefacts due to radiation-induced inflammation are expect-
ed to have largely dissolved. This allows for identification of suspected 
lymph nodes to be targeted by FNA during CRE-II. 
The reason to include patients with SCC as well as patients with AC in 
the preSANO trial, is that the CROSS regimen has been shown to be 
effective in both groups of patients. The pCR rate of 49% in patients 
with SCC and 23% in patients with AC in the CROSS trial, provide a 
rationale for a SANO approach in both histological subtypes . Further-
more, together with the low frequency of toxic effects of the CROSS 
regimen (91% received the full treatment regimen of nCRT), these 
high pCR rates advocate the use of the relatively low dose of 41.4 Gy 
radiotherapy18.
Although we have not yet clearly shown that we are able to detect a 
clinically threatening residual cancer 4-6 weeks after nCRT, there are 
several arguments why it is not deemed necessary to do so before we 
can further delay the planned surgical resection with an additional 6-8 
weeks. Recently, it was shown that prolonged time to surgery after 
nCRT up to at least 12 weeks had no effect on disease-free- and over-
all survival (HR=1.00 and HR=1.06 per additional week, p=0.976 and 
p=0.139, respectively). Moreover, prolonged time to surgery increased 
the probability of pCR in the resection specimen (odds ratio, OR=1.35 
per additional week of time to surgery, p=0.0004)33. Comparable re-
sults have been published by other groups34, 35.
Postoperative mortality and severe morbidity (grade ≥3 according 
to the Clavien-Dindo classification [19]) after esophagectomy in the 
Netherlands is 5% and 60%, respectively. Thus, a non-surgical treat-
ment strategy in patients with a clinically complete response after 
nCRT, theoretically saves up to 5% mortality and 60% severe morbidity 
in this patient group. Moreover, this approach might improve quality of 
life and might lead to a reduction in health care costs. Therefore, we 
will consider this study as successful when the results of the com-
bined diagnostic modalities lead to a maximum percentage of clinical-
ly false-negative TRG3 and TRG4 tumors of twice the postoperative 
mortality, i.e. 10%. If more than 10% of TRG3 or TRG4 tumors will be 
missed, the SANO trial will be reconsidered.
If the preSANO trial shows that TRG3 and TRG4 residual tumor can be 
predicted reliably, a randomized trial comparing nCRT plus standard 
surgery versus chemoradiotherapy plus Surgery As Needed in Oesoph-
ageal cancer patients (the SANO trial) will be conducted. Hopefully, 
this SANO trial will result in an organ-preserving treatment strategy for 
a selected group of patients and therefore reduce treatment related 
morbidity and mortality, improve quality of life and lead to a reduction 
in health care costs.
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Figure 1 — Study algorithm
Legend figure 1  
Pretreatment work-up and clinical response evaluations include:
-  ‘partial body’ or ‘whole-body’ F18-FDG PET-CT1 
-  OGD (with biopsies) 
-  EUS (with FNA)2
-  Dedicated CT of neck, thorax, abdomen and pelvis (in pretreatment work-up and on 
indication)
-  External US of the neck (in pretreatment work-up and on indication).
1 During the pretreatment work-up, it suffices when a ‘partial body’ F18-FDG PET-CT 
of the esophagus will be performed (to test for avidity of the primary lesion); if it is 
preferred to make a ‘whole-body’ PET-CT not only after, but also before the neoadju-
vant chemoradiotherapy in order to detect distant metastases at an earlier stage, the 
indication for performing an external US with FNA of the neck can be limited to those 
patients who have a suspected lymph node on the PET-CT [22]. In the period after neo-
adjuvant therapy one whole-body F18-FDG PET-CT will be performed either at CRE-I 
(for the clinically non-complete responders) or at CRE-II (for the clinically complete 
responders at CRE-I). 
2 EUS with FNA of suspected lymph nodes only during CRE-II, not during CRE-I.
 
CRE: clinical response evaluation; CT: computed tomography; EUS: endoscopic 
ultrasonography; FNA: fine-needle aspiration; nCRT: neoadjuvant chemoradiother-
apy; EGD: esophagogastroduodenoscopy; PET: positron-emission tomography; US: 
 ultrasonography. 
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Figure 2 — Expected distribution of patients (based partly 
on CROSS-trial data).
Legend figure 2 
All numbers are based on an inclusion of 120 patients. CI: confidence interval; CRE: clin-
ical response evaluation; nCRT: neoadjuvant chemoradiotherapy; N: number of patients; 
TRG: tumor regression grade, as measured by the modified TRG system of Chirieac21. Of 
the 45 patients who will undergo a postponed resection following CRE-II, 15 patients are 
expected to have a pathologically incomplete response (at least TRG2).
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12-15
0-3 
15
95% CI
(22- 38)
(6- 23)
(0- 8)
(9- 23)
TRG 1
TRG 2 
≥ TRG3
Refusal
207206 Part II - Chapter 9
Table 1 — Study algorithm
Legend table 1
1  Hematology: CBC, differential 
2  Biochemistry: serum protein, albumin, magnesium, electrolytes, serum creatinin, biliru-
bin, alkaline phosphatase, AST, and pregnancy test if indicated at baseline only
3 Radial EUS: with measurement of maximum tumor thickness and –area
4  Linear EUS: with fine-needle aspiration (FNA) of any suspected lymph nodes 
5  Bronchoscopy: when tumor is located above the carina and when there is suspicion for 
invasion of the tracheo-bronchial tree
6  Toxicity: to be evaluated after each cycle (incidence and grade according to CTC 
toxicity scale)
7  PET-CT: during CRE-I, after EGD and EUS, only for clinically non-complete responders, 
to exclude disseminated disease
8  PET-CT: during CRE-II, prior to EGD and EUS, for all patients (all were clinically com-
plete responders during CRE-I) to guide EGD and EUS in targeting suspected locore-
gional lesions and to exclude disseminated disease.
Pretreatment
X
X
X
X
X
X
X
X
X
X ‘partial body’
X
X
X
Baseline
First clinical response 
evaluation (CRE-I)
X
X
X
X
X7 ‘whole body’
Second clinical response 
evaluation (CRE-II)
X
X
X
X
X
X8 ‘whole body’
Parameter
History, Physical Examination
Performance status
Haematology1
eGFR
Biochemistry2
Endoscopy + (random) biopsies
Radial EUS3
Linear EUS (+FNA)4
CT of neck, thorax, abdomen and pelvis
PET-CT
Pulmonary function tests
Bronchoscopy5
ECG
Toxicity6
Inclusion
120
-
-
CRE-I
36
72
12
CRE-II
6
60
6
Histology
15
30
-
15
Positive
Negative
Disseminated
Positive
Negative
Disseminated
Positive
Negative
Disseminated
Positive
Negative
Disseminated
Refuses 
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Chapter 10 Future perspectives
Survival of patients undergoing primary surgical resection for eso-
phageal cancer has steadily increased over the last decades, from a 
five-year overall survival rate of approximately 12% in the 1960s and 
1970s1 and approximately 20% in the 1980s and 1990s2,3 to approx-
imately 35% in the last two decades.4,5 Survival improved during this 
period mainly due to improved preoperative diagnostic modalities, 
more restrictive patient selection, intensified perioperative patient 
management and improved surgical technique, thus lowering peri-op-
erative mortality and increasing locoregional control. New multimodali-
ty treatment regimens, such as the Dutch CROSS neoadjuvant chemo-
radiotherapy (nCRT) regimen, have further increased the five-year 
overall survival rate of patients undergoing esophagectomy for eso-
phageal or junctional cancer to approximately 47%.5,6 However, when 
considering the entire group of esophageal cancer patients (including 
patients with disseminated disease at presentation) the five-year over-
all survival rate still remains sobering at approximately 10%.7 
Therefore, the current challenge in esophageal cancer treatment is 
to further improve survival (at an acceptable loss in quality of life) for 
those selected patients who have locally advanced esophageal cancer 
and are planned to undergo nCRT plus surgery with curative intent. 
Should we extend the surgical resection?
The main goal of surgical therapy with curative intent for oncological 
disease is maximization of locoregional control. However, with many 
tumor types and especially with esophageal cancer, achieving maxi-
mum locoregional control with surgery alone has proven difficult. Many 
factors add to this, such as the frequent deep invasion of the primary 
tumor at presentation, the early regional (lymphatic) dissemination and 
the surrounding critical structures which do not allow for wide excision. 
Therefore, current neoadjuvant chemo(radio)therapy strategies have 
focused on achieving tumor downstaging, thus allowing for a more rad-
ical surgical resection. This was clearly shown in the CROSS trial, where 
radical resection percentages increased from 69% in the surgery alone 
group to 92% in the nCRT plus surgery group.5 These percentages have 
increased even further in recent years due to increasing experience with 
post chemoradiotherapy resections. Therefore, in the current era of 
multimodality treatment, radicality of resection has reached acceptable 
percentages and is thereby no longer a major determinant of survival.
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Should we perform an extended lymphadenectomy?
Talsma et al.8 have shown that in the surgery alone group of the 
CROSS trial the number of resected nodes was significantly associ-
ated with survival, while in the nCRT plus surgery group that associa-
tion was no longer present. Also, the positive association between the 
number of nodes resected and the number of positive nodes identified, 
which was significant in the surgery alone group was absent in the 
nCRT plus surgery group. These results indicate that in patients treated 
with nCRT plus surgery, there is no clear survival benefit of maximizing 
the number of lymph nodes resected. However, to adequately quanti-
fy the potential therapeutic impact of extended lymphadenectomy for 
patients treated with nCRT plus surgery, a new randomized controlled 
trial is needed in which patients are randomized after nCRT between a 
limited (transhiatal) lymphadenectomy and a more extended (transtho-
racic) lymphadenectomy. 
Should we intensify the neoadjuvant chemoradiotherapy regimen? 
Oppedijk et al.9 have shown that after nCRT (according to CROSS) plus 
surgery only 5% of patients develop infield recurrences, while only 1% 
of patients develop infield recurrences without synchronous distant 
failure. Some 2% of patients develop borderline recurrences and 6% 
develop regional outfield recurrences. These results indicate that inten-
sifying the nCRT regimen might improve survival in approximately 1% 
of patients and extending the radiation field might improve survival in 
approximately 2% of patients. However, the marginal survival benefit 
that could possibly be achieved by intensification of chemotherapy and 
radiotherapy or by the extension of the radiation field would be offset 
by a significant increase in nCRT related morbidity. Therefore, it does 
not seem beneficial to routinely increase the nCRT dose or to routinely 
extend the radiation field. However, it should be of interest for future 
research to try and identify those patients, pretreatment, who stand 
to benefit from intensification of chemotherapy and/or radiotherapy or 
from the extension of the radiation field.
Can we minimize iatrogenic morbidity and mortality?
Results from the initial phase II feasibility trial10 and the subsequent 
randomized phase III CROSS trial5 have shown that the nCRT treat-
ment regimen according to CROSS is generally well tolerated, with 
100% and 94% of patients, respectively, completing neoadjuvant ther-
apy without delay or dose-reduction. Furthermore, the nCRT treatment 
regimen is associated with a relatively low frequency of high-grade 
toxic effects. These results suggest that morbidity and mortality from 
nCRT is already low and might therefore not be reduced much further.
Standard esophagectomy, which is associated with severe postopera-
tive morbidity and a substantial impact on the quality of life11-14, might 
be reconsidered as a necessity for all patients following nCRT. In the 
nCRT group of the CROSS trial5 49% of patients with a squamous cell 
carcinoma and 23% of patients with an adenocarcinoma had a patho-
logically complete response in the resection specimen (i.e. no viable 
tumor cells were found at the site of the primary tumor or in the resect-
ed regional lymph nodes, as determined by conventional histological 
examination). Therefore, these results provide a rationale to reconsider 
and study the timing and necessity of esophagectomy in (all) patients 
after application of the CROSS regimen. Under analogous conditions, 
a non-operative management in rectal cancer patients with a clinically 
complete response after nCRT has been shown feasible and safe, lead-
ing to organ-sparing treatment with low morbidity and mortality rates 
and favorable long-term survival in a subset of these rectal cancer 
patients.15-17 Currently a single arm diagnostic feasibility trial (preSANO, 
Dutch Trial Register NTR4834)18 is underway in several Dutch high vol-
ume centers, which aims to determine the accuracy of clinically detect-
ing or predicting the presence of residual disease after nCRT. If indeed 
results from the preSANO trial will be encouraging, a new randomized 
trial comparing nCRT plus standard surgery versus chemoradiother-
apy plus surgery as needed in esophageal cancer patients (the SANO 
trial) will be conducted. Results from the future SANO trial will show 
whether an organ-preserving treatment strategy (for a selected group 
of patients) is safe and whether such a treatment strategy also reduces 
treatment related morbidity and improves quality of life.
Can we improve distant disease control?
Most patients with locally advanced esophageal cancer, who undergo 
nCRT plus surgery with curative intent, will die due to distant dis-
ease recurrence. In the nCRT plus surgery group of the CROSS trial, 
49% (87/178) of patients showed disease recurrence, of whom 22% 
(39/178) showed locoregional disease recurrence and 39% (70/178) 
showed distant disease recurrence (22 patients showed both locore-
gional and distant disease recurrence).6 These results emphasize the 
importance of distant disease recurrence as one of the major deter-
mining factors in overall survival.
Perhaps adding adjuvant treatment, either as chemotherapy or as 
targeted therapy19 (or a combination of both), in a selected (high-risk) 
group of patients might reduce the number of distant disease recur-
rences, thereby increasing overall survival in these patients. However, 
the addition of adjuvant treatment should always be balanced with its 
cost in quality-of-life. It is to be expected that the addition of adjuvant 
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treatment, after neoadjuvant treatment and surgical resection, will 
carry a heavy burden for patients, especially for those patients with 
significant comorbidities. 
In conclusion, five-year overall survival for patients with locally ad-
vanced esophageal cancer, who undergo nCRT plus surgery with 
curative intent has improved in recent decades to approximately 47%. 
The neoadjuvant CROSS regimen has proven to be effective for tumor 
downstaging yet well tolerable for patients. In-field and borderline 
recurrences are rare and therefore do not justify intensifying the nCRT 
regimen. Perhaps, in the near future, an organ-preserving treatment 
strategy (for a selected group of patients) will prove to be safe, with 
hopefully an associated reduction in treatment-related morbidity and 
improvement in quality-of-life. However, what continues to endanger 
our patients is distant disease recurrence, as approximately 40% of 
patients with locally advanced esophageal cancer, treated with nCRT 
plus surgery will develop distant disease recurrence during follow-up. 
Therefore, we should focus our research efforts on effective yet mild 
chemotherapy and/or targeted therapy treatment regimens, specif-
ically geared towards increasing our distant disease control rate. Fi-
nally, although not the topic of this dissertation, patients with dissem-
inated esophageal cancer at presentation, who do not get the benefit 
of potentially curative treatment should also be the benefactors of 
continued research in order to maximize their survival and minimize 
their suffering.
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The research described in this thesis addresses prediction of survival 
and new treatment strategies for patients with esophageal or junc-
tional cancer. Results will be discussed in two parts, Part I focusses on 
the prediction of survival using conventional and more novel prognostic 
factors in patients with esophageal or junctional cancer. While Part II 
focusses on the long-term survival benefit of neoadjuvant (i.e.preoper-
ative) chemoradiotherapy plus surgery, as compared to surgery alone 
and on the feasibility of a new treatment strategy for a subset of pa-
tients with potentially curable esophageal or junctional cancer. 
Part I
Prognostication for esophageal and junctional cancer
In patients with cancer of the esophagus or esophagogastric junction, 
several prognostic factors for survival have been identified and pre-
diction models have been developed to predict survival in individual 
patients, based on these prognostic factors.1,2 However, most of these 
prognostic factors have been identified and validated in the era of 
primary surgical resection. In chapter 1 we show that most of these 
conventional prognostic factors lose their prognostic importance in 
patients treated with neoadjuvant chemoradiotherapy (nCRT) plus sur-
gery. Only the pretreatment number of suspected tumor positive lymph 
nodes and the posttreatment number of resected tumor positive lymph 
nodes remain as independent prognostic factors. Interestingly, the 
pretreatment number of suspected tumor positive lymph nodes was an 
independent prognostic factor, despite its relative inaccuracy.3 There-
fore, to further study the possible relevance of pretreatment tumor 
extent we describe and validate a novel method of determining pre-
treatment tumor extent in chapter 2. In this chapter we show that the 
pretreatment tumor extent could be reproducibly determined based 
on the location of tumor scarring (i.e. fibrosis) and on the location of 
residual tumor cells in the resection specimen after surgery. Especially 
the number of pretreatment tumor positive lymph nodes carries much 
prognostic information. For example, patients who had pretreatment 
nodal involvement and became node-negative due to nCRT had a 
worse survival compared to patients without any pretreatment nod-
al involvement. Resecting more lymph nodes was previously shown to 
improve prediction of survival4,5 and even survival itself6,7 in patients 
with esophageal cancer. However, it is unclear whether after nCRT re-
secting more lymph nodes is still indicated. Therefore, we compared the 
prognostic impact of total number of resected lymph nodes and the 
number of resected tumor positive lymph nodes between patients who 
underwent nCRT plus surgery and surgery alone in chapter 3. Results 
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been mostly disappointing. Before we can consider a watchful waiting 
policy (instead of a standard surgical removal of the esophagus) in a 
subgroup of patients with esophageal cancer, a better insight into the 
location of residual tumor is needed. Therefore, in chapter 6 we describe 
the exact location of residual tumor in the esophageal wall and resected 
lymph nodes after nCRT and we describe the tumor regression pattern 
of esophageal cancer as induced by nCRT. A possible determinant of 
the complete response rate might be the waiting time between the end 
of nCRT and the day of surgery. Theoretically, a prolonged waiting time 
might increase the complete response rate and possibly improve sur-
vival because of a prolonged effect of nCRT. Conversely, a prolonged 
waiting time might lead to residual tumor outgrowth, increased diffi-
culty of surgical resection due to inceased tissue scarring with a higher 
postoperative complication rate and possibly a worse overall survival. 
Therefore, we investigate the impact of waiting time on the complete 
response rate, short-term surgical outcome and survival in chapter 7. In 
this chapter we show that a prolonged waiting time (beyond 45 days) 
increases the probability of a complete response, slightly increases the 
probability of postoperative complications and does not impact survival. 
Finally, in chapter 8, we describe the study protocol of a single arm diag-
nostic feasibility trial (preSANO, Dutch Trial Register NTR4834)15 which 
is currently running in several Dutch high volume centers and aims to 
determine the accuracy of clinically detecting or predicting the presence 
of residual disease after nCRT.
show that tumor involvement of lymph nodes, especially if persistent 
after nCRT, is a strong negative predictor of survival, confirming our 
results from chapters 1 and 2. Also, the number of resected nodes 
(irrespective of tumor positivity) was shown to be an independent 
prognostic factor for survival in patients treated with surgery alone, 
but not in patients treated with nCRT plus surgery. Therefore, these 
data question the benefit of maximization of lymph node removal after 
nCRT. In order to better predict survival for patients after primary sur-
gery, we studied activation of certain genes in patients’ tumor tissue as 
biomarkers for survival. Activation of these genes was demonstrated 
using a labelling technique (immunohistochemistry) which can be visu-
alized using a microscope, as described in chapter 4. In this chapter we 
confirm that a simple panel of three biomarkers can predict survival in 
patients with esophageal adenocarcinoma, independently from other 
patient and tumor related variables and that this panel of three bio-
markers also predicted survival in patients from other continents. 
Part II
New treatment strategies for esophageal and junctional 
cancer
The CROSS trial compared nCRT plus surgery to surgery alone in 
patients with esophageal or junctional cancer. Initial results showed 
that 13% more patients were alive after five years in the nCRT plus 
surgery group as compared to the surgery alone group. These results 
made nCRT plus surgery the new treatment of choice for esophageal 
and junctional cancer in many countries, including The Netherlands. 
In chapter 5 we confirm the initial results of the CROSS trial using 
longer patient follow-up and we also show that patients in the nCRT 
plus surgery group develop less disease recurrence at the site of the 
original tumor and also less recurrence in other organs (i.e. metas-
tases). Still today surgical removal of the esophagus carries a risk of 
death between 2% and 5%. Even at highly specialized centers this type 
of surgery is associated with severe and frequent complications, with 
a substantial impact on the quality of life. Interestingly, after nCRT ap-
proximately 30% of patients have no residual tumor in their esophagus 
(i.e. complete response). Therefore, it is questionable whether patients 
with a complete response in the resection specimen after nCRT have 
sufficient additional benefit to justify subsequent standard surgical re-
moval of the esophagus. Several studies have tried to identify patients 
with a complete response after nCRT using different diagnostic modal-
ities, such as endoscopy.8-14 However, results from these studies have 
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Het onderzoek dat in dit proefschrift beschreven is, behandelt de voor-
spelling van overleving en nieuwe behandelstrategieën voor patiënten 
met een slokdarm- of junctiecarcinoom. De resultaten worden bespro-
ken in twee delen. Deel I richt zich op de voorspelling van overleving, 
waarbij gebruik wordt gemaakt van conventionele en nieuwe prog-
nostische factoren bij patiënten met een slokdarm- of junctiecarci-
noom. Deel II richt zich op het lange-termijn overlevingsvoordeel van 
neoadjuvante (i.e. preoperatieve) chemoradiotherapie gevolgd door 
een chirurgische resectie, in vergelijking met alleen een chirurgische 
resectie. Tevens richt dit deel zich op de haalbaarheid van een nieuwe 
behandelstrategie voor (een deel van de) patiënten met een slokdarm- 
of junctiecarcinoom. 
Deel I
Voorspelling van overleving bij patiënten met een slokdarm- of 
junctiecarcinoom
Bij patiënten met kanker van de slokdarm en slokdarm-maag overgang 
zijn verschillende prognostische factoren geïdentificeerd om overleving 
te voorspellen voor individuele patiënten na voltooiing van behandeling 
en zijn modellen ontwikkeld op basis van deze prognostische factoren.1,2 
Echter, het merendeel van deze conventionele prognostische factoren 
werden geïdentificeerd in een tijdperk van primaire chirurgische resectie 
(dus zonder additionele chemo- of radiotherapie). In hoofdstuk 1 tonen 
wij dat het merendeel van de conventionele prognostische factoren hun 
voorspellende waarde verliezen bij patiënten die behandeld worden met 
neoadjuvante chemoradiotherapie (nCRT) gevolgd door een chirurgi-
sche resectie. Alleen het aantal verdachte tumor positieve lymfeklieren 
bij start van de behandeling en het aantal tumor positieve lymfeklieren 
in het resectiepreparaat bij voltooiing van behandeling blijven waar-
devolle prognostische factoren in het tijdperk van nCRT gevolgd door 
resectie. Opvallend is dat het aantal verdachte tumor positieve lym-
feklieren bij start van de behandeling een waardevolle prognostische 
factor bleek te zijn, ondanks de relatieve onnauwkeurigheid waarmee 
dit kan worden bepaald.3 Om de potentiële waarde te bestuderen van 
de initiële uitgebreidheid van de tumor, lokaal en in naburige lymfeklie-
ren, beschrijven wij in hoofdstuk 2 een nieuwe methode om de initiële 
uitgebreidheid van de tumor nauwkeurig te bepalen. In dit hoofdstuk to-
nen wij dat de initiële uitgebreidheid van de tumor nauwkeurig bepaald 
kan worden in het resectiepreparaat op basis van tumorrestanten en op 
basis van verlittekening van de tumor (i.e. fibose). Vooral het aantal ver-
dachte tumor positieve lymfeklieren bij start van de behandeling bevat 
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veel prognostische informatie. Bijvoorbeeld, patiënten die bij start van 
de behandeling tumor positieve lymfeklieren hebben, maar na afloop 
van de behandeling géén tumor positieve lymfeklieren meer hebben, 
houden toch een slechtere overleving dan patiënten die nooit tumor 
positieve lymfeklieren hebben gehad. Eerder onderzoek toonde dat 
het verwijderen van meer lymfeklieren het voorspellen van overleving 
verbetert4,5 en zelfs de overleving zelf verbetert6,7 bij patiënten met 
slokdarmkanker. Echter, het is onduidelijk wat het nut is van lymfeklier 
verwijdering na nCRT. Daarom vergeleken wij in hoofdstuk 3 de prog-
nostische waarde van het aantal verwijderde lymfeklieren en het aantal 
verwijderde tumor positieve lymfeklieren tussen patiënten die behan-
deld werden met nCRT gevolgd door chirurgische resectie en patiënten 
die behandeld werden met alleen een chirurgische resectie. Resultaten 
tonen dat tumor positiviteit in lymfeklieren, met name aanhoudende 
positiviteit na nCRT, sterke negatieve voorspellers zijn van overleving. 
Dit bevestigde onder andere de resultaten uit hoofdstukken 1 en 2. Het 
aantal verwijderde lymfeklieren (onafhankelijk van het aantal tumor 
positieve lymfeklieren) was een waardevolle voorspeller van overleving 
bij patiënten die behandeld werden met alleen een chirurgische resec-
tie, maar niet bij patiënten die behandeld werden met nCRT gevolgd 
door chirurgische resectie. Derhalve dient men zich op basis van deze 
resultaten af te vragen wat de waarde is van uitgebreide lymfeklier-
verwijdering na nCRT. Om beter de overleving van patiënten een met 
slokdarm- of junctiecarcinoom te kunnen voorspellen na een chirurgi-
sche resectie, bestudeerden wij de activatie van bepaalde genen in het 
tumorweefsel van patiënten als biomarkers voor overleving. Activatie 
van deze genen werd bepaald middels een labeltechniek (immunohisto-
chemie), waarmee de activatie zichtbaar wordt onder een microscoop, 
zoals beschreven in hoofdstuk 4. In dit hoofdstuk bevestigen wij dat een 
eenvoudig panel van drie biomarkers de overleving van patiënten met 
een slokdarm- of junctie adenocarcinoom kan voorspellen, onafhanke-
lijk van andere patiënt- en tumor gerelateerde factoren. 
Deel II
Nieuwe behandelstrategieën voor patiënten met een 
slokdarm- of junctiecarcinoom
De CROSS trial vergeleek nCRT gevolgd door chirurgische resectie met 
alleen een chirurgische resectie bij patiënten met een slokdarm- of 
junctiecarcinoom. De initiële resultaten toonden dat bij patiënten die 
behandeld werden met nCRT gevolgd door chirurgische resectie, na 
vijf jaar 13% meer patiënten in leven waren. Door deze resultaten werd 
nCRT gevolgd door chirurgische resectie in Nederland en veel andere 
landen de standaardbehandeling voor patiënten met een slokdarm- of 
junctiecarcinoom. In hoofdstuk 5 bevestigen wij deze initiële resultaten 
van de CROSS trial bij een langere follow-up. Ook laten wij zien dat er 
bij patiënten die behandeld worden met nCRT gevolgd door chirurgi-
sche resectie minder recidieven optreden in het gebied van de originele 
tumor en ook minder afstandsmetastasen ontstaan. Vandaag de dag 
is het risico op overlijden bij een chirurgische resectie van de slokdarm 
nog steeds twee tot vijf procent. Zelfs in hoog gespecialiseerde centra 
zijn dit soort ingrepen geassocieerd met ernstige en frequente com-
plicaties met een significante impact op de kwaliteit van leven. Opval-
lend is dat bij ongeveer 30% van de patiënten die een slokdarmresec-
tie ondergaan na nCRT geen tumorresidu meer gevonden wordt in de 
verwijderde slokdarm (i.e. complete respons). Het is daarom de vraag 
of patiënten met dergelijke complete respons nog wel genoeg voordeel 
hebben van een slokdarmresectie, om deze ingreep standaard bij alle 
patiënten uit te voeren. Verscheidene onderzoeken hebben geprobeerd 
om deze patiënten met een complete respons te identificeren na vol-
tooiing van de nCRT, voorafgaand aan een resectie.8-14 Resultaten van 
deze onderzoeken waren voornamelijk teleurstellend. Voordat men een 
meer selectieve strategie kan overwegen (in plaats van een slokdarm-
resectie bij iedere patiënt) is een beter inzicht nodig in de locatie van 
tumorresidu na nCRT. In hoofdstuk 6 beschrijven wij de exacte locatie 
van tumorresidu in de slokdarmwand en in de omliggende lymfeklieren. 
Tevens beschrijven wij in dit hoofdstuk het tumorregressiepatroon na 
blootstelling aan nCRT. Een mogelijke factor die van invloed is op het 
complete respons percentage in het resectiepreparaat is de wachttijd 
tussen voltooiing van de nCRT en de chirurgische resectie. Theoretisch 
zou een langere wachttijd door een langer effect van de nCRT het 
complete respons percentage en mogelijk zelfs de overleving positief 
kunnen beïnvloeden. Daarentegen, zou een langere wachttijd ook kun-
nen leiden tot hernieuwde tumor uitgroei, een bemoeilijkte chirurgische 
resectie (door toegenomen tumorverlittekening) en mogelijk zelfs een 
verminderde overleving. Daarom onderzoeken wij in hoofdstuk 7 de 
invloed van de wachttijd op het complete respons percentage, op de 
korte-termijn chirurgische uitkomsten en op de overleving. In dit hoofd-
stuk tonen wij dat een wachttijd langer dan 45 dagen de kans op een 
complete respons verhoogt, de kans op postoperatieve complicaties 
minimaal verhoogt, maar er geen effect is op de overleving. Tot slot, 
beschrijven wij in hoofdstuk 8 een nieuw onderzoek (preSANO, Dutch 
Trial Register NTR4834)15 dat op dit moment in enkele Nederlandse 
hoog volume centra wordt uitgevoerd, waarbij wordt bepaald wat de 
nauwkeurigheid is waarmee met behulp van diagnostiek kan worden 
voorspeld of er bij een patiënt na voltooiing van de nCRT nog tumor-
residu aanwezig is in de slokdarm. 
227226 Samenvatting
Referenties
1.  Lagarde SM, Reitsma JB, de Castro SM, Ten Kate FJ, Busch 
OR, van Lanschot JJ. Prognostic nomogram for patients 
undergoing oesophagectomy for adenocarcinoma of the 
oesophagus or gastro-oesophageal junction. Br J Surg 
2007;94:1361-8.
2.  Lagarde SM, Reitsma JB, Ten Kate FJ, et al. Predicting 
individual survival after potentially curative esophagectomy 
for adenocarcinoma of the esophagus or gastroesophageal 
junction. Ann Surg 2008;248:1006-13.
3.  van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, 
Siersema PD. Staging investigations for oesophageal cancer: a 
meta-analysis. Br J Cancer 2008;98:547-57.
4.  Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node 
dissection for squamous cell and adenocarcinoma of the 
esophagus. Ann Surg 2002;236:177-83.
5.  Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenec-
tomy for carcinoma of the esophagus and gastroesophageal 
junction in 174 R
0
 resections: impact on staging, disease-free 
survival, and outcome: a plea for adaptation of TNM clas-
sification in upper-half esophageal carcinoma. Ann Surg 
2004;240:962-72.
6.  Jamieson GG, Lamb PJ, Thompson SK. The role of lymph-
adenectomy in esophageal cancer. Ann Surg 2009;250:206-9.
7.  Tong D, Law S. Extended lymphadenectomy in esophageal 
cancer is crucial. World J Surg 2013;37:1751-6.
8.  Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT, and 
EUS to identify pathologic responders in esophageal cancer. 
Ann Thorac Surg 2004;78:1152-60; discussion -60.
9.  Westerterp M, van Westreenen HL, Reitsma JB, et al. Esopha-
geal cancer: CT, endoscopic US, and FDG PET for assessment 
of response to neoadjuvant therapy--systematic review. 
Radiology 2005;236:841-51.
10.  Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. 
The accuracy of endoscopic ultrasonography with fine-needle 
aspiration, integrated positron emission tomography with com-
puted tomography, and computed tomography in restaging 
patients with esophageal cancer after neoadjuvant chemora-
diotherapy. J Thorac Cardiovasc Surg 2005;129:1232-41.
11.  Schneider PM, Metzger R, Schaefer H, et al. Response eval-
uation by endoscopy, rebiopsy, and endoscopic ultrasound 
does not accurately predict histopathologic regression after 
neoadjuvant chemoradiation for esophageal cancer. Ann Surg 
2008;248:902-8.
12.  Peng H-Q, Halsey K, Sun C-CJ, et al. Clinical utility of 
postchemoradiation endoscopic brush cytology and biopsy 
in predicting residual esophageal adenocarcinoma. Cancer 
2009;117:463-72.
13.  Jost C, Binek J, Schuller JC, et al. Endosonographic radial 
tumor thickness after neoadjuvant chemoradiation therapy to 
predict response and survival in patients with locally advanced 
esophageal cancer: a prospective multicenter phase ll study by 
the Swiss Group for Clinical Cancer Research (SAKK 75/02). 
Gastrointestinal endoscopy 2010;71:1114-21.
14.  Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C. 
Ineffectiveness of (1)(8)F-fluorodeoxyglucose positron emission 
tomography in the evaluation of tumor response after comple-
tion of neoadjuvant chemoradiation in esophageal cancer. Ann 
Surg 2013;258:66-76.
15.  Noordman BJ, Shapiro J, Spaander MC, et al. Accuracy of 
Detecting Residual Disease After Cross Neoadjuvant Chemora-
diotherapy for Esophageal Cancer (preSANO Trial): Rationale 
and Protocol. JMIR research protocols 2015;4:e79.
229
Dankwoord Geachte promotor prof. dr. J.J.B. van Lanschot, beste professor, dank voor de kans die u mij gaf om dit proefschrift te schrijven. De jaren van 
dit promotietraject waren soms erg stormachtig en ik heb diep respect 
voor hoe u mij ook in die perioden bent blijven begeleiden. Bij bespre-
kingen kregen de projecten telkens weer uw volle aandacht en werden 
plannen opnieuw getoetst en verder uitgediept. De samenwerking ver-
liep goed, waarbij u mij de vrijheid gaf om zelf onderzoeksplannen uit te 
werken, terwijl u waakte over het grotere geheel (en de tijdsplanning!). 
Dank voor uw betrokkenheid, uw scherpe analyses en uw nauwkeurig-
heid, ik leerde er veel van en het werk werd er veel beter door. Het was 
een voorrecht uw promovendus te zijn.
Geachte co-promotor dr. B.P.L. Wijnhoven, beste Bas, je enthousias-
me en creativiteit in het onderzoek zijn aanstekelijk en absoluut een 
voorbeeld voor me. Je hebt het steeds drukker gekregen in de afgelo-
pen jaren, maar je had (of maakte) altijd tijd voor me vrij. Ons contact 
bestaat de laatste tijd vooral uit voortgangsgesprekken, maar dat mag 
de pret niet drukken. Dank voor de goede tijd!
Geachte prof. dr. C. Verhoef, beste Kees, veel dank dat jij dit proef-
schrift hebt willen beoordelen. Wat lijkt inmiddels het begin toch op het 
einde! (althans in de tractus digestivus…) Hoop dat je het leuk vond om 
weer eens wat over de slokdarm te lezen...
Prof. dr. C. Mariette, dear professor, it is an honor that you have 
agreed to be a member of the evaluation committee and that you are 
willing to come to Rotterdam for my thesis defense. À bientôt!
Prof. dr. J.P. Pignol, thank you that you have agreed to be a member of 
the evaluation committee. 
Leden van de kleine commissie, hartelijk dank voor uw bereidwilligheid 
om de inhoud van dit proefschrift te beoordelen. 
Geachte dr. A. van der Gaast, beste Ate, jouw idee om patiënten met 
slokdarmkanker voor te behandelen met chemotherapie en bestra-
ling bleek een schot in de roos, waar wij bij de Chirurgie nog steeds de 
vruchten van plukken, zowel in de kliniek, als in het onderzoek. Dank 
voor de goede samenwerking.
Geachte prof. dr. E.W. Steyerberg, beste Ewout, jij hield onze plannen 
moeiteloos op het methodologisch rechte pad en wist alles eenvoudiger 
te maken, waarvoor dank! 
Geachte dr. K. Biermann, beste Katharina, ondanks je vele klinische 
verplichtingen maakte je altijd tijd voor mij en mijn onderzoeksplanne-
tjes vrij. Dank voor de fijne samenwerking.
228
231230 Dankwoord
Beste prof. dr. R. Fodde, beste Riccardo, dank voor alle tijd en moei-
te die je in mij en in ons project stak. Helaas heeft onze samenwerking 
geen publicaties opgeleverd, maar ik leerde wel bij jou de basis van het 
experimentele onderzoek en van de fundamentele oncologie, heel veel 
dank hiervoor. Patrick, Rosalie, Andrea, Yaser, Joana, Katia, Matthias, 
Martin and Ulrike, thank you for your patience with me!
Beste dr. W.N.M. Dinjens, beste Winand, wat ben jij een bijzonder 
mens! Dank voor de fijne samenwerking.
David van Klaveren, je bent briljant. Dank dat ik met je samen mocht 
werken.
Beste professor dr. F.J.W. ten Kate, u waakte ervoor dat ik mij niet in 
het Rotterdamse nachtleven zou verliezen door alleen om 7.00 ’s och-
tends tijd voor mij te hebben. Het werden al snel de meest productieve 
uren van de dag en met die metingen schreven we een paar fantas-
tische publicaties! Dank voor uw betrokkenheid en enthousiasme. Zo 
dank ik ook prof. dr. G.J.A. Offerhaus en dr. S.L. Meijer. 
Leden van de CROSS studie groep, in het bijzonder dr. M.I. van  Berge 
Henegouwen, dr. M.C.C.M. Hulshof, dr. G.A.P. Nieuwenhuijzen, dr. 
M.J.C. van der Sangen, drs. C.M. van Rij, prof. dr. M.A. Cuesta en last 
but not least prof. dr. H.W. Tilanus, dank voor jullie betrokkenheid 
en goede samenwerking. Hopelijk gaan er nog vele mooie projecten 
volgen.
Pieter, nog nooit iemand zó weinig zin zien hebben… tegelijkertijd 
legde jij wel de basis voor veel van het werk in dit proefschrift, waar-
voor dank. We hebben de afgelopen jaren heel wat zaaltjes afgelopen 
samen, maar het absolute hoogtepunt was je voordracht op de ISDE in 
Venetië: het cabaret kwam dichterbij en je moest nog het een en ander 
op een echt publiek uitproberen... het werd een weergaloos succes, 
met name op de achterste rij. Op 3 juni nog één keer samen een zaaltje 
aflopen, daarna alleen nog maar operatiekamers, het wordt briljant! 
Gefeliciteerd (alvast) met jouw promotie! 
Koen, chirurg én epidemioloog! Wat was het lymfeklier stuk toch een 
mooi avontuur: gepassioneerde (of was het gefrustreerde?) besprekin-
gen met Caspar over ‘stage migration’, discussies met Ewout tot in de 
lift (‘toen begreep ie het pas…’) en als uitsmijter een bulderende prof. 
dr. T.R. DeMeester in Athene. Maar het stuk was steengoed en jij hield 
stand. Zo eindigden wij die avond met een goed gevoel (en goed ge-
zelschap!) op de Nederlandse ambassade voor een ouderwets Oranje-
feestje. Eind goed al goed! 
Robert (volhouden, komt goed!), Victorien, Bo, Kirstin, Mirelle, Niels, 
Zarina, Joost&Steef en Barry, maatjes van het onderzoek! Borrels, 
cursussen, Chirurgencup, skireizen (niets mis met langlaufen…) en het 
cabaret. Het waren fantastische tijden, dank voor de goede tijd en lol 
samen! 
Beste dr. Dawson, dank voor dat ene telefoontje! 
IJsvogels, groot en klein, door jullie werd het de Chirurgie. Dank voor de 
kans het vak bij (en van) jullie te leren, tot snel!
Beste Adri, Carola, Conny en Vanessa, bedankt voor al jullie 
inspanningen.
Lieve vrienden, bij jullie vielen de zwaarste klappen, maar ik ga het 
goed maken, beloofd! Paul, Rutger, John, Yannick, Steven, Ismael (De-
cathlon Donny), Çiğdem en Sven: dank voor de nodige ontspanning en 
gezelligheid tussendoor. Jullie zijn me erg dierbaar.
Mijn paranimfen, Eelke en Karel, vrienden voor het leven! Wat ont-
zettend leuk dat jullie mijn paranimfen kunnen zijn. Met jullie werd de 
onderzoekstijd (bijna) een feest! Hotel de Oude Pastorie in Veldho-
ven, zwemmen in de Westersingel, café Fout, het Kralings zwembad, 
limoncello in Venetië, sushi in Vancouver, de vele koffiebreaks en nog zó 
veel meer. Kareltje, ik zie je snel in het IJsselland, dan ga ik eindelijk ‘ns 
wat van je leren! Eel, je bent er ook bijna, de laatste lootjes! Er kwam 
nog even een paleisje tussendoor, maar daarna gaan we ook snel jouw 
feestje vieren! 
Lieve schoonfamilie: Janka, Artur, Anaelle, Michaël, Noémie, Victor en 
Bella, het is heel fijn jullie erbij te hebben. Dank voor al jullie hulp. 
Lieve mam, jij deed het altijd allemaal in je eentje, wat vind ik dat knap! 
Ook nu nog sta je altijd voor ons klaar en dat waardeer ik echt enorm. 
Dit waren voorlopig de laatste lootjes. Nu kan ook jij dus echt gaan ont-
spannen, echt! Op naar Sevilla! 
Lieve Clara, mijn beste maatje. Wat hebben we toch een fantastisch 
avontuur samen! Zonder jou had ik dit nooit kunnen doen. Je gaf me 
liefde, ruimte, begrip en steun. Je ving op wat ik liet liggen, je was sterk 
waar ik zwak was, je gaf me een thuis. Dank je voor alles! 
Allerliefste Adam en Hannah, hoe betrekkelijk zijn al deze volgeschre-
ven bladzijden als ik naar jullie kijk… ik hou van jullie met heel mijn hart.
233
PhD portfolio
PhD Training 
Oral presentations (0.5 points each)  
Wnt signaling and cancer stemness in esophageal adenocar-
cinoma: friends or foes? United European Gastroenterology 
Week, Vienna
Impact of neoadjuvant chemoradiotherapy on conventional 
prognostic factors and on individual prediction of survival in 
patients with esophageal or junctional cancer. International 
Society for Disease of the Esophagus, Vancouver
Prolonged time to surgery after neoadjuvant chemoradiother-
apy in patients with esophageal or junctional cancer. Interna-
tional Society for Disease of the Esophagus, Vancouver
Lymph node retrieval during esophagectomy with and without 
neoadjuvant chemoradiotherapy; prognostic and therapeutic 
impact on survival. International Society for Disease of the 
Esophagus, Vancouver
Prolonged time to surgery after neoadjuvant chemoradiother-
apy in patients with esophageal or junctional cancer. NVvH 
Chirurgendagen, Veldhoven
Prolonged time to surgery after neoadjuvant chemoradiother-
apy in patients with esophageal or junctional cancer. Europe-
an Surgical Association, Athens
Impact of neoadjuvant chemoradiotherapy on prognostic 
factors for survival in patients with esophageal or junctional 
cancer. Voorjaarsvergadering NVGE, Veldhoven
'Surgery as needed' after neoadjuvant chemoradiotherapy for 
esophageal or junctional cancer. Stafdag Heelkunde Erasmus 
MC, Rotterdam
Accuracy of detecting residual disease after neoadjuvant 
chemoradiotherapy for oesophageal cancer (preSANO). Dutch 
Oesophagogastric Cancer Group Meeting, Utrecht
Year
2014
2014
2014
2014
2014
2014
2014
2013
2013
ECTS
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
Name PhD student: J. Shapiro
Erasmus MC department:  Surgery
PhD period: October 2010 - September 2014
Title thesis:  Prognostication and new treatment strategies 
for esophageal and junctional cancer
Promotors: Prof.dr. J.J.B. van Lanschot
Date defense thesis:  June 1, 2016
232
235234 PhD Portfolio
Teaching
Supervising MSc students at the Erasmus MC
International conferences (0.3 points/day)
-  United European Gastroenterology Week, Vienna
-  International Society for Disease of the Esophagus, Vancouver
- European Surgical Association, Athens
- European Cancer Congress, Amsterdam
- European Society for Disease of the Esophagus, Rotterdam
- European Surgical Association, Beaune
- International Society for Disease of the Esophagus, Venice
-  European Society for Disease of the Esophagus, Newcastle 
upon Tyne
Scientific meetings (0.3 points/meeting)
-  Dutch Oesophagogastric Cancer Group Meeting
-  NVvH Chirurgendagen
-  Voorjaarsvergadering NVGE
Residual esophageal cancer after neoadjuvant chemoradio-
therapy mainly involves the (sub)mucosa. European Surgical 
Association, Beaune
Timing of surgery and location of residual tumor after neo-
adjuvant chemoradiotherapy (nCRT) for esophageal cancer. 
Voorjaarsvergadering NVGE, Veldhoven
Neoadjuvant chemoradiation plus ‘surgery as needed’ for 
squamous cell carcinoma of the oesophagus. Dutch Oesoph-
agogastric Cancer Group Meeting, Rotterdam
Search for cancer stem cells in ESO26, an esophageal 
adenocarcinoma cell line. Stafdag Heelkunde Erasmus MC, 
Rotterdam
Poster presentations (0.5 points each)
Residual esophageal cancer after neoadjuvant chemora-
diotherapy frequently involves the (sub)mucosa. European 
Society for Disease of the Esophagus, Rotterdam
More pathologically complete responders after a longer inter-
val between chemoradiotherapy and surgery for esophageal 
cancer. European Cancer Congress, Amsterdam
Search for cancer stem cells in ESO26, an oesophageal 
adenocarcinoma cell line. European Society of Esophagology, 
Newcastle upon Tyne
In-depth courses (0.3 points/day)
Basiscursus regelgeving en organisatie klinisch onderzoekers 
(BROK), Erasmus MC, Rotterdam
Integriteit in wetenschappelijk onderzoek, Erasmus MC, 
 Rotterdam
Systematisch literatuuronderzoek, Erasmus MC, Rotterdam
Epigenetics in health and disease, LUMC, Leiden
Methodologie van patiëntgebonden onderzoek en voor-
bereiding van subsidieaanvragen, Erasmus MC, Rotterdam
PhD Training 
Oral presentations (0.5 points each) Year
2013
2013
2012
2011
2013
2013
2011
2014
2013
2013
2012
2012
Year
2011-2014
2014
2014
2014
2013
2013
2013
2012
2011
2012-2014
2010-2014
2011-2014
ECTS
0.5
0.5
0.5
0.5
0.5
0.5
0.5
1.0
0.6
0.6
1.0
0.3
ECTS
3.0
1.5
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
237
List of publications 1.  Bosman LW, Koekkoek SKE, Shapiro J, Rijken BF, Zandstra F, van der Ende B, et al. Encoding of whisker input by cerebellar 
Purkinje cells. J Physiol. 2010; 588(19): 3757-83.
2.  Jongen JL, Pederzani T, Koekkoek SKE, Shapiro J, van der 
Burg, J, De Zeeuw CI, et al. Autofluorescent flavoprotein 
imaging of spinal nociceptive activity. J Neurosci. 2010; 30(11): 
4081-7.
3.  Shapiro J, van Lanschot JJB. Definitive chemoradiation ther-
apy. In 'Innovation in Esophageal Surgery', editor L. Bonavina; 
Springer International Publishing 2012: 85-94.
4.  Ong CA, Shapiro J, Nason KS, Davison JM, Liu X, Ross-Innes C, 
et al. Three-gene immunohistochemical panel adds to clinical 
staging algorithms to predict prognosis for patients with 
esophageal adenocarcinoma. 
 J Clin Oncol. 2013; 31(12): 1576-82.
5.  Shapiro J, ten Kate FJW, van Hagen P, Biermann K, Wijnhoven 
BPL, van Lanschot JJB. Residual esophageal cancer after neo-
adjuvant chemoradiotherapy frequently involves the mucosa 
and submucosa. 
 Ann Surg. 2013; 258(5): 678-88.
6.  Shapiro J, van Hagen P, Lingsma HF, Wijnhoven BPL, Bier-
mann K, ten Kate FJW, et al. Prolonged time to surgery after 
neoadjuvant chemoradiotherapy increases histopathological 
response without affecting survival in patients with esophageal 
or junctional cancer. 
 Ann Surg. 2014; 260(5): 807-13.
7.  Talsma AK, Shapiro J, Looman CW, van Hagen P, Steyerberg 
EW, van der Gaast A, et al. Lymph node retrieval during 
esophagectomy with and without neoadjuvant chemoradio-
therapy: prognostic and therapeutic impact on survival. 
 Ann Surg. 2014; 260(5): 786-92.
8.  Shapiro J, Wijnhoven BPL, van Lanschot JJB. 
  Reply to letter: "Residual esophageal cancer after neoadju-
vant chemoradiotherapy frequently involves the mucosa and 
submucosa". 
 Ann Surg. 2015; 262(2): e84-e85.
9.  De Bruijn K, Biermann K, Shapiro J, Dogan F, Spaander M, 
Janssen J, et al. Absence or low IGF-1R-expression in esoph-
ageal adenocarcinoma is associated with tumor invasiveness 
and radicality of surgical resection. 
 J Surg Oncol. 2015; 111(8): 1047-53.
10.  Noordman BJ, Shapiro J, Spaander MC, Krishnadath KK, van 
Laarhoven HW, van Berge Henegouwen MI, et al. Accuracy of 
detecting residual disease after cross neoadjuvant chemora-
diotherapy for esophageal cancer (preSANO Trial): rationale 
and protocol. 
 JMIR Research Protocols. 2015; 4(2): e79.
11.  Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van 
Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant 
chemoradiotherapy plus surgery versus surgery alone for 
oesophageal or junctional cancer (CROSS): long-term results 
of a randomised controlled trial. 
 Lancet Oncol. 2015;16(9):1090-8.
12.  Shapiro J, van Lanschot JJB, Hulshof MCCM, van der Gaast 
A. Effectiveness of neoadjuvant chemoradiotherapy for ear-
ly-stage esophageal cancer. 
 J Clin Oncol. 2015; 33(3): 288-9.
13.  Talsma AK, Shapiro J, Wijnhoven BPL, van Lanschot JJB. Goals 
of surgical therapy for esophageal cancer. 
  In 'Minimally invasive foregut surgery for malignancy', editors 
SN Hochwald and M Kukar; Springer International Publishing 
2015: 35-49.
14.  Toxopeus EL, Nieboer D, Shapiro J, Biermann K, van der Gaast 
A, van Rij CM, et al. 
  Nomogram for predicting pathologically complete response 
after neoadjuvant chemoradiotherapy for oesophageal cancer. 
Radiother Oncol. 2015; 115(3): 392-8.
15.  Shapiro J, Biermann K, van Klaveren D, Meijer SL, Offerhaus 
GJA, ten Kate FJW, et al. Prognostic value of pretreatment 
tumor extent in patients treated with neoadjuvant chemora-
diotherapy plus surgery for esophageal or junctional cancer. 
 Ann Surg. 2016; [epub ahead-of-print].
16.  van Olphen SH, Biermann K, Shapiro J, Wijnhoven BP, Toxopeus 
EL, van der Gaast A, et al. P53 and SOX2 protein expression 
predicts esophageal adenocarcinoma in response to neoadju-
vant chemoradiotherapy. 
 Ann Surg. 2016; [epub ahead-of-print].
17.  Shapiro J, van Klaveren D, Lagarde SM, Toxopeus ELA, van der 
Gaast A, Wijnhoven BPL, et al. Prediction of survival in patients 
with esophageal or junctional cancer: impact of neoadjuvant 
chemoradiotherapy on conventional prognostic factors. 
 Accepted for publication.
236
239
About the author Joël Shapiro was born on December 2, 1983 in Rotterdam, the Neth-erlands. After obtaining his high school degree at the Erasmiaans 
Gymnasium, Rotterdam in 2002, he worked and travelled for one year, 
spending a summer studying epidemiological methods at the Univer-
sity of California, Berkeley.
In 2003 he started Medical school at the Erasmus University Rot-
terdam, during which he successfully obtained his Master in Neuro-
science degree (supervisors dr. S.K.E. Koekkoek and prof. dr. C.I. de 
Zeeuw). As part of his research he spent two months at the Depart-
ment of Neuroscience, University of Minnesota, Minneapolis, studying 
cerebellar cortical activity using autofluorescent flavoprotein imaging 
(supervisor: prof. dr. T.J. Ebner).
He spent his final clinical rotation at the Department of Surgery of 
the IJsselland Hospital, Capelle aan den IJssel and two elective rota-
tions in the USA, one at the Department of Surgery, Memorial-Sloan 
Kettering Cancer Center, New York and one at the Department of 
Surgery, Mayo Clinic, Rochester. He obtained his Medical degree in 
2010 (cum laude). In that same year he started his PhD training with 
prof. dr. J.J.B. van Lanschot and prof. dr. R. Fodde, investigating the 
role of prognostication and exploring new treatment strategies in the 
era of neoadjuvant chemoradiotherapy, while experimentally study-
ing the role of cancer stem cells in esophageal cancer. In 2014, after 
four years of full-time research, with his PhD work nearly complete, he 
returned to the IJsselland Hospital to work as a surgical resident ‘not 
in training’ (ANIOS). On July 1, 2015, Joël started his surgical training 
(AIOS) at the Erasmus MC (residency coordinator: dr. B.P.L. Wijn-
hoven) and from July 1, 2016 he will continue his surgical training at 
the IJsselland Hospital (residency coordinator: dr. I. Dawson). 
He is happily married to Clara Shapiro-Koss, a psychiatrist-in-training, 
with whom he has two beautiful monsters, Adam (6) and Hannah (3).
238
240
ISBN: 978-94-6169-877-3
